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TRADEMARK LAW & CONSUMER SAFETY
David A. Simon*
Abstract
Trademark law protects consumers and mark owners against
economic harm. When consumers are confused about the source of a
good or service, this increases consumer search costs or imposes
reputational costs on trademark owners. But what happens when a
pharmacist, confused by two similar drug names, accidentally prescribes
estrogen instead of an antidepressant? Trademark law, in such cases, has
adapted its core doctrine—likelihood of confusion—to protect the public
from another kind of injury: physical harm. By lowering the standard
required for confusion when physical harm could result, courts
recognized that standard trademark analysis did not always capture the
harms posed by various kinds of confusion. This Article argues that
courts should, for similar reasons, adjust the standard for deceptiveness.
When a mark’s potential to mislead consumers about the nature of the
product poses a risk to the consumers’ physical safety, courts should
lower the standard for finding the mark deceptive.
Current law bars registration of “deceptive” trademarks—trademarks
that influence consumer purchasing decisions by misdescribing the
nature, quality, or characteristics of the good on which the mark appears.
The test for determining whether a mark is deceptive, however, is too
rigid. To make matters worse, under current doctrine all deceptive marks
are treated as equally harmful. Yet not all deceptive marks pose the same
potential for harm. Sometimes the risk of harm is only economic or has
only economic effects. A customer who receives SPUNOUT ICE
CREAM may erroneously think that the ice cream was produced by a
special spinning process, and she may buy it for that reason. In other
cases, however, the risk of harm may implicate more serious
considerations, such as physical safety. A consumer who buys the dietary
supplement BRAINSTRONG because it suggests, without evidence, that
it will improve brain function faces a variety of potential physical
effects—effects not experienced by the patron of ice cream. Risks posed
by misleading marks, in other words, vary by the type of good on which
they appear. Where a good or service implicates serious concern of
physical harm, courts should, as they have in the confusion context, pay
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closer attention. This requires three modest changes. First, courts should
evaluate as potentially deceptive marks that suggest, but do not describe,
a product’s qualities, characteristics, functions, features, or effects.
Second, courts should be willing to find marks deceptive even when the
deception is material to the purchasing decisions of only a small number
of consumers. Finally, courts should bar deceptive marks from trademark
protection. These changes would discourage the use of misleading marks,
increase the quality of consumer information, and reduce the risk of
physical harm.
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INTRODUCTION
Customers who are confused when making purchasing decisions
suffer economic harm. Or at least that is what trademark law tells us. Just
how this harm is characterized depends on one’s view of trademark
theory. Despite this economic framework, disputes over trademarks can
implicate noneconomic concerns.1 When they do, courts have been
willing to shape trademark doctrine to accommodate them. When, for
1. RUDOLF CALLMANN, CALLMANN ON UNFAIR COMPETITION, TRADEMARKS &
MONOPOLIES § 21:05, Westlaw (database updated Nov. 2019) (noting the “Doctrine of Greater
Care”); see also 4 J. THOMAS MCCARTHY, MCCARTHY ON TRADEMARKS AND UNFAIR
COMPETITION § 23:103 (5th ed. 2017) (noting product confusion). One set of authors went so far
as to claim: “Courts exercise greater care in their finding of a likelihood of confusion whenever
confusion of the trademarks would entail serious consequences. The harmful consequences must
be physical, or perhaps psychological, but no court activates the doctrine solely upon a showing
of economic injury.” Comment, Trademarks and the Concept of Greater Care, 14 WM. & MARY
L. REV. 441 (1972) (emphasis added), reprinted in David Johnson et al., Trademarks and the
Concept of Greater Care, 64 TRADEMARK REP. 26, 33 (1974).
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example, pharmaceuticals share similar names, courts recognize that
pharmacists may mistakenly dispense PREMARIN (an antidepressant)
when intending to dispense PRESAMINE (estrogen).2 Confusion here
can mean more than just lost sales or poor reputation.3 A patient who
ingests estrogen instead of an antidepressant might experience a wide
range of unpleasant side effects, physiological changes, and if the
patient’s depression remains untreated, a heightened risk of suicide.4 The
stakes are high. And yet the causal connection between confusion and
physical harm is a function of trademark law. Courts understand this,
which is why they use confusion—by consumers and nonconsumers
alike—to help manage the risk.5
This Article is a story of how trademark law has managed this risk,
why it has done so, and when it might consider doing so in the future.
This Article argues that trademark law should extend its riskmanagement role to cases where trademarks pose a risk of physical harm
because they are deceptive. To better protect the public, trademark law
should make two changes to the way it evaluates deceptive trademarks.
First, when the product on which the mark appears poses a higher risk to
public safety, courts should lower the standard of deceptiveness. Doing
so means expanding the kinds of marks that can be found deceptive:
suggestive, as well as descriptive, marks should be subject to the
deceptiveness test. The higher the risk of harm, the more likely courts
should be willing to move along the Abercrombie spectrum.6 But this
change alone will not increase the probability of a deceptiveness finding.
Courts must also adjust downward the standard of materiality—the
requirement that the mark’s deception “affect a significant portion of the
relevant consumers’ decision to purchase” the product on which the mark
appears.7 The quantity and kind of consumers’ decisions affected by the
2. Am. Home Prods. Corp. v. USV Pharm. Corp., 190 U.S.P.Q. (BNA) 357 (T.T.A.B.
1976), 1976 WL 20937.
3. Even if the patient ingests the wrong medication, the drug would not suffer any
reputational harm because the patient would eventually discover she had taken the wrong
medication. So, wrongly ingesting a product could not affect the reputation of a drug that the
consumer knows is different.
4. See, e.g., J. John Mann et al., Suicide Prevention Strategies: A Systematic Review, 294
JAMA 2064, 2067 (2005) (noting that antidepressant effects are unclear but that studies show
declining suicide rates in countries where antidepressant prescriptions increased).
5. See Section II.B.
6. See Abercrombie & Fitch Co. v. Hunting World, Inc., 537 F.2d 4, 10–11 (2d Cir. 1976)
(explaining the difference between generic and “merely descriptive” terms for purposes of
establishing registration).
7. U.S. PATENT & TRADEMARK OFFICE, TRADEMARK MANUAL OF EXAMINING PROCEDURE
§ 1203.02(b) (Catherine P. Cain ed., 2016); see In re Budge Mfg. Co., 857 F.2d 773, 775 (Fed.
Cir. 1988).
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deception should be related to the risk posed by the product. The higher
the risk, the lower the number.
Second, courts should ban deceptive marks from protection, in
addition to registration. Currently, case law has not definitively answered
the question of whether deceptive marks barred from registration under
the Lanham Act8 are also barred from protection at common law. This
Article argues that the equitable doctrine of “unclean hands” renders
deceptive marks unenforceable. Not only that, but decisions by the U.S.
Patent and Trademark Office (PTO) finding marks deceptive should be
conclusive bars to enforcement. Courts should also be free to apply the
doctrine of unclean hands, and findings of deceptiveness by the PTO, to
bar trademark infringement claims by plaintiffs whose trademarks are
deceptive.9
To reach this conclusion, we first need to follow the case law back to
the 1940s, when courts confronted disputes involving products that, if
confused, might pose a risk of physical harm to consumers. Often, but not
always, these involved prescription medications. In many of these cases,
courts used a central concept in trademark law—the “consumer”—to
account for these risks. In some cases, confusion posed a risk when it
occurred among doctors, pharmacists, or store clerks, and not with the
ultimate consumer. Other times confusion occurred among the ultimate
consumer but well after they purchased the product. Capturing these risks
often meant defining the consumer to include “intermediaries” who may
interact with the product.
In general, this was nothing new. Intermediaries, such as distributors,
had been the subject of trademark law’s confusion analysis for years.10
But at least prior to the Lanham Act’s amendment in 1962, in those cases
intermediaries were actual consumers of the product, even if they were
not the ultimate consumer.11 Even more recent expansions of the concept
8. Ch. 540, 60 Stat. 427 (1946) (codified as amended at 15 U.S.C. §§ 1051–1072, 1091–
1096, 1111–1127, 1141, 1141a–1141n (2018)).
9. Barring deceptively suggestive marks from registration and protection will not, of
course, bar their use. But, for reasons explained in Section II.D, it is likely to provide a sufficient
disincentive for producers to adopt them.
10. See infra notes 121 & 129. Courts often assess confusion with respect to these different
purchasers and may find only certain uses, in certain markets, infringing. E.g., Lindy Pen Co. v.
Bic Pen Corp., 725 F.2d 1240, 1247 (9th Cir. 1984) (affirming likelihood of confusion for the
“telephone sales market” but not for “over-the-counter sales, mail order sales and sales by the
manufacturer to intermediaries,” and remanding to the district court to make additional findings
of fact).
11. See Checkpoint Sys., Inc. v. Check Point Software Techs., Inc., 269 F.3d 270, 295–96
(3d Cir. 2001) (discussing elimination of the term “purchasers” from the Lanham Act in 1962 and
courts’ subsequent inference that nonpurchaser confusion could be actionable and holding that
the amendment made initial interest confusion actionable).
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of confusion—such as initial interest confusion—focused on
“consumers” who ultimately bought a product, even if they were not
confused when they did so.12
In cases where confusion might cause physical harm, by contrast,
courts sometimes considered nonconsumer intermediaries as the relevant
consumers. Actionable confusion might occur, courts found, among
“consumers” who neither bought nor used the product, at least not in the
conventional sense. In other cases, physical risks posed by confusion
occurred after the consumer bought the product. In the latter cases,
trademark law did not need any novel doctrinal maneuvers to
accommodate the confusion; post-sale confusion was actionable.13 But it
did repurpose the doctrine from one that protected the producer’s brand14
to one that protected the consumer’s body. Even before the 1962
amendment to the Lanham Act, confusion was large enough to digest
risks posed by physical harm, especially because often the case for an
economic injury was colorable. Courts used the concept’s capaciousness
to manage risks to consumers.
Not all courts, however, swallowed the role of risk manager. At first,
reluctance stemmed from a fear of opining on matters outside the judicial
ken. Later, as the Food and Drug Administration (FDA) developed more
concrete policies regarding drug names, some judges who confronted
these risks deferred to the agency they felt had better institutional
competence to evaluate them.15 This position of deference, however, was
not the majority view. And even those courts that abdicated their role as
risk managers could do so only in cases where the FDA had begun to
exercise authority: those involving prescription and (to a lesser extent)
over-the-counter drugs.16 In general, they left unregulated other products
12. Initial interest confusion occurs when a mark’s similarity draws the consumer’s initial
interest, which is dispelled by the time the consumer decides to purchase the product with the
confusingly similar name. See, e.g., Brookfield Comms., Inc. v. W. Coast Entm’t Corp., 174 F.3d
1036, 1062 (9th Cir. 1999); Grotrian, Helfferich, Schulz, Th. Steinweg Nachf. v. Steinway &
Sons, 523 F.2d 1331, 1341 (2d Cir. 1975). This was not true for post-sale confusion, which did
not require any potential purchaser of the product to be confused. See infra notes 13–14.
13. Post-sale confusion occurs among individuals—some of whom may not be potential
purchasers—after the sale of the product in question. E.g., Ferrari SPA Esercizio Fabriche
Automobili E Corse v. Roberts, 944 F.2d 1235, 1243 (6th Cir. 1991); Rolex Watch USA, Inc. v.
Canner, 645 F. Supp. 484, 492 (S.D. Fla. 1986). Consumers who buy fake ROLEX watches on
the street corner are not confused about whether their watches came from or are sponsored by
ROLEX. But other individuals who encounter the fake ROLEX think it is the real thing.
14. See Jeremy N. Sheff, Veblen Brands, 96 MINN. L. REV. 769, 776–94 (2012) (discussing
three theories of post-sale confusion and settling on “status confusion” as the origin of the
doctrine).
15. See infra Section I.C.
16. See infra notes 206, 214 and accompanying text.
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that might implicate the risk of physical harm, such as dietary
supplements, car fuses, and financial products.17
The result, I suggest, is twofold. On the one hand, trademark law
developed a jurisprudence finely attuned to cases where confusion could
cause physical harm. Courts used trademark law’s concepts of
“confusion” and “consumer” to address this risk, which, in part,
trademark law helped to create. On the other hand, the law left
unaddressed similar risks posed not by confusion, but by a mark’s
suggestion that the product on which it appears has particular features,
characteristics, functions, compositions, qualities, effects, or uses. There
are reasons why the PTO and courts have chosen to offload or overlook
these risks while recognizing others. These have to do with concerns
about the role of trademark law as regulation, the PTO’s institutional
competence, and trademark law’s interaction with other areas of law,
such as tort, contract, false advertising, and First Amendment
jurisprudence.
Although these concerns are well-founded, this Article argues they are
not sufficient to ignore what has become a problem, in part, of trademark
law’s own making. Trademark law incentivizes companies to use
trademarks that suggest, imply, or insinuate particular features,
characteristics, functions, compositions, qualities, effects, or uses. Marks
of this kind are entitled to automatic and “strong” protection—
entitlements not enjoyed by marks that merely describe the product.18
Ordinarily, these suggestions, while perhaps persuasive, are mostly
benign. And even when their misleading character influences consumer
purchasing decisions, the risk is largely economic. Consumers may
purchase CHERRYBURST ice cream thinking it contains cherries when
it does not. Here consumers lose money, but not much else. In some
cases, however, the misleading character of the product name poses a
threat to the physical safety of the consumer. Consumers who purchase
the dietary supplement BRAINSTRONG19 may not know that the
product could pose a serious risk of bleeding or that it may interact with
other drugs or herbs they consume. The same is true for MEGA MEN

17. See infra notes 206, 214 and accompanying text.
18. “Arrayed in an ascending order which roughly reflects their eligibility to trademark
status and the degree of protection accorded, these classes are (1) generic, (2) descriptive, (3)
suggestive, and (4) arbitrary or fanciful.” Abercrombie & Fitch Co. v. Hunting World, Inc., 537
F.2d 4, 9 (2d Cir. 1976). Generic marks are entitled to no protection. Id. Descriptive marks are
eligible for trademark protection upon acquiring “secondary meaning”—an association between
the mark and source in the mind of the consumer. Id. Suggestive, arbitrary, and fanciful marks are
entitled to automatic protection as inherently “distinctive.” Id. at 11.
19. BRAINSTRONG, Registration No. 4,352,302.

https://scholarship.law.ufl.edu/flr/vol72/iss5/5

6

Simon: Trademark Law & Consumer Safety

TRADEMARK LAW & CONSUMER SAFETY

2020]

679

multivitamins,20 NERVEFIX supplements,21 and BABY SAFE pool
fencing.22 Here trademark law can learn a lesson from itself and, like it
does in the confusion context, lower the standard for deceptiveness. The
deception scale, if we can call it that, will slide. Products that pose a
greater risk to physical harm will require less proof of deceptiveness than
products unlikely to affect, or are only tangentially related to, physical
health. Deceptive marks will be barred not only from registration but also
from protection.
Within this scheme, trademark law is, in effect, both an initial line of
defense and a law of last resort. Trademark law acts first as a
prophylactic, attempting to quash potential harm before it arises. But it
also is doing, in some small measure, work that other areas of law may
have difficulty adequately addressing in many cases. Tort law, for
example, is the muse for personal injury claims. Perhaps it might capture
some of the harms that product names pose to consumers? Tort law is
both a natural and uncomfortable fit for the kinds of harm that might
arise.23 Fraud, negligent misrepresentation, and even negligence may
present theoretical legal options to the consumer who is harmed as a result
of using a product with a deceptively suggestive name.24 Yet the practical
limitations of these claims invite a greater role for trademark law. Many
of the potential tort claims arising from suggestive names might not entail
sufficient damages to warrant litigation—at least from the perspective of
plaintiffs’ attorneys.25 Additionally, tort law may be a clumsy fit for
harms that current causes of action have difficulty conceptualizing.26 That
20.
21.
22.
23.

MEGA MEN, Registration No. 2,163,971.
NERVEFIX, Registration No. 4,803,507.
BABY SAFE, Registration No. 1,455,741.
Passing off and unfair competition have been, historically, conceptualized as torts.
RESTATEMENT (THIRD) OF UNFAIR COMPETITION foreword (AM. LAW INST. 2019) (“The subject of
unfair competition was to have been addressed in the Restatement, Second, of Torts, as it had
been in the original Restatement of Torts. However, it was eventually decided that the law of
unfair competition had evolved to the point that it was no longer appropriate to treat it as a
subcategory of the law of Torts.”). See generally RESTATEMENT (FIRST) OF TORTS §§ 711–743
(AM. LAW INST. 1938) (explaining various causes of action for “fraudulent marketing” and “trademark” and “trade-name” infringement).
24. RESTATEMENT (SECOND) OF TORTS §§ 310–311 (AM. LAW INST. 1965) (explaining the
actions for misrepresentation); id. § 281 (explaining the elements of negligence).
25. The Restatement (Third) of Unfair Competition states it this way: “A seller’s
misrepresentations may be actionable by deceived purchasers under traditional rules of tort and
contract law and also under the various state and federal consumer protection statutes. In many
instances, however, the cost of obtaining relief may exceed the purchaser’s potential remedy.”
RESTATEMENT (THIRD) OF UNFAIR COMPETITION § 2 cmt. a (AM. LAW INST. 1995).
26. Tort law, for example, may protect against fraudulent misrepresentation, but it requires
a variety of elements that might be difficult to prove from a trademark alone. The Restatement
(Second) of Torts provides that an action for negligent misrepresentation involving physical harm
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does not mean it is incapable of doing so, only that tort law may not be
the best means of remedying the harm that results in every case. This also
is not to downplay the role tort law can play in remedying these risks.
There is an important position for tort claims, particularly with products
whose names and advertising invite reliance on fabricated or misleading
claims, which lead to injury or monetary loss.27 Indeed, one hope is that
this proposal will force producers to make more explicit product claims
in their advertising which may, in turn, subject them to greater liability in
tort and false advertising law.28
Similar issues confound the FDA’s29 role in policing dietary
supplements. In principle, there is no reason why the FDA should refrain
from regulating dietary supplement names. Changes would, at the very
least, require federal rulemaking, as the FDA’s current authority to do so
under the Dietary Supplement Health and Education Act of 199430 is
requires:
(1) One who negligently gives false information to another is subject to liability
for physical harm caused by action taken by the other in reasonable reliance upon
such information, where such harm results
(a) to the other, or
(b) to such third persons as the actor should expect to be put in
peril by the action taken.
(2) Such negligence may consist of failure to exercise reasonable care
(a) in ascertaining the accuracy of the information, or
(b) in the manner in which it is communicated.
RESTATEMENT (SECOND) OF TORTS § 311 (AM. LAW INST. 1965); see id. § 310 (stating a stricter
standard for “Conscious Misrepresentation Involving Risk of Physical Harm”); see also infra Part
II (discussing ways in which the deceptive marks doctrine can protect consumers).
27. See RESTATEMENT (SECOND) OF TORTS § 311 (AM. LAW INST. 1965).
28. False advertising law is a natural fit for product claims and deceptive advertising. This
Article, however, is concerned only with how trademark law can, within its existing framework,
work to combat the problem of deceptive marks that pose a risk to public safety.
29. Ironically, the origins of the FDA began in the PTO. History of FDA’s Internal
Organization, FDA, https://www.fda.gov/about-fda/history-fdas-fight-consumer-protection-andpublic-health/history-fdas-internal-organization [https://perma.cc/U43S-KAVG] (last updated
Jan. 31, 2018). Concerns over drug labeling dated back to the 1800s and served as motivation for
the 1906 Pure Food and Drugs Act. See The Pure Food and Drug Act, U.S. CAPITOL VISITOR CTR.,
https://www.visitthecapitol.gov/exhibitions/congress-and-progressive-era/pure-food-and-drugact [https://perma.cc/9SHE-KRA9]; see also Laws Enforced by FDA, FOOD & DRUG ADMIN.
(Mar. 29, 2018), https://www.fda.gov/regulatory-information/laws-enforced-fda [https://perma.cc
/SV2B-86PU] (explaining that the 1906 Act provided over 200 laws for public health and
consumer protection). As drugs became big business, the 1906 Act was replaced and updated. See
id. The FDA’s authority, not to mention its place within the federal government bureaucracy, has
been updated and modified throughout its history. For example, “[t]he Federal Food, Drug, and
Cosmetic Act of 1938 was passed after a legally marketed toxic elixir killed 107 people, including
many children.” Id.
30. Pub. L. No. 103-417, 108 Stat. 4325 (1994) (codified as amended in scattered sections
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questionable. But perhaps the larger obstacle is that the FDA does not
regulate all products that pose a risk to consumers. It has a specific focus:
food, drugs, medical devices, and cosmetics.31 Trademark law,
meanwhile, has no determinate content.32 Almost any product category
can qualify for trademark protection. What’s more, the Lanham Act has
some explicit provisions that expressly attempt to regulate consumer
safety.33
Trademark law, of course, is not the only answer to a problem that has
roots in the health sector. Whatever disincentive trademark law can
provide, there is no reason to ignore other solutions that could potentially
mitigate the risks when they arise. But the use of existing doctrines in
trademark law to tamp down the existing risk comes at a relatively low
political and legal cost. Courts can make these changes, when
appropriate, without disrupting whole areas of law. And, in the process,
they may spark a larger discussion about how to reform advertising for
products that affect human health. If, as a result, the FDA or other
regulatory agencies like the Federal Trade Commission (FTC) pick up
the slack, I consider the proposal a success.
Indeed, trademark law might learn a few lessons from federal
regulatory agencies. FDA regulations, for example, clearly explain that
drug names cannot suggest that they have “some unique effectiveness or
composition” when they have common properties34—a rule that protects
against suggesting to consumers that a drug might make them smarter,
happier, or healthier when in reality it may only make them as alert as a
cup of coffee. Trademark law might adopt a similar rule for the same
reasons.
of 21 and 42 U.S.C.).
31. Federal Food, Drug, and Cosmetic Act, ch. 675, 52 Stat. 1040 (1938) (codified as
amended in scattered sections of 21 U.S.C.).
32. 15 U.S.C. §§ 1052, 1127 (2018) (allowing for the registration of “any word, name,
symbol, or device, or any combination thereof” with limited exceptions). But see id. § 1125
(providing a federal cause of action for trademark infringement or dilution actions, or false
advertising claims, against “[a]ny person who, on or in connection with any goods or services, or
any container for goods, uses in commerce any word, term, name, symbol, or device, or any
combination thereof, or any false designation of origin, false or misleading description of fact, or
false or misleading representation of fact, which . . . is likely to cause confusion,” or constitutes
false advertising), invalidated by Coll. Sav. Bank v. Fla. Prepaid Postsecondary Educ. Expense
Bd., 527 U.S. 666 (1999); Iancu v. Brunetti, 139 S. Ct. 2294, 2302 (2019) (holding that the
Lanham Act’s prohibition on “immoral or scandalous” trademarks infringes on the First
Amendment); Matal v. Tam, 137 S. Ct. 1744, 1765 (2017) (holding that the disparagement clause
of the Lanham Act violated the Free Speech Clause of the First Amendment).
33. See Fastener Quality Act Amendments Act of 1999, Pub. L. No. 106-34, 113 Stat. 118
(1999) (codified at 15 U.S.C. §§ 5511a, 5411b).
34. 21 C.F.R. § 201.10(c)(3) (2019).
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And, again, the proposal does not seek to employ trademark law to
solve the entire problem of deceptive advertising. Trademark law, after
all, is not the entire source of the problem. It is, however, at least a silent
partner in funding a problematic enterprise. By providing registration
and protection of names that suggest or allude to product features, the
law encourages such names.35 By barring them from registration and
protection, trademark law can provide a disincentive for producers to
choose deceptive names. None of this is meant to banish, once and for
all, each and every risk posed by product names or packaging.
Unscrupulous producers might still use deceptive names despite the lack
of protection. But that is not a reason to allow trademark law to perpetuate
the problem. If it was, then the deceptiveness doctrine would be
superfluous. More than that, however, other areas of law—food and drug
regulation, state regulation of deceptive trade practices, tort law, etc.—
work to combat problems that trademark law cannot. In fact, barring
deceptive names from registration and protection would actually
encourage other legal regimes to play a greater role. And it would do so
while discouraging producers from using deceptive names in the first
place. By doing so, trademark law can help protect the public from
physical harm.
Perhaps some of these suggestions will not materialize, or the case for
them is thinner than I have argued. Even if true, this Article makes two
unique contributions. First, it supplements the existing history of
trademark law, providing cases where there were good reasons for
lowering the threshold for actionable confusion. Many contemporary
criticisms of trademark law focus on its historical expansion relative to
its original economic purpose(s). Trademark law’s traditional role has
been as a regulatory mechanism for the use of names in a market
economy—in trade. If harm occurred, economic theory conceptualized it
in one of three ways. Consumers might be confused about where the
product came from (perhaps purchasing one intending to purchase
another)36 or develop a mistaken negative association with a producer
because the confusing product is of lesser quality. In the former case,
consumers’ search costs increase. The more time consumers spent
35. The U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court both
have made quite a stink about the importance of federal trademark registration. See Matal, 137 S.
Ct. at 1753; In re Tam, 808 F.3d 1321, 1327–28 (Fed. Cir. 2015), as corrected (Feb. 11, 2016),
aff’d sub nom. Matal, 137 S. Ct. 1744.
36. In the example above, the consumer does not buy the wrong product. She buys exactly
the product that she meant to buy. She is not confused about whether she is getting PREMARIN
or PRESAMINE, and the names do not influence her purchasing decision. Her physician or
possibly her pharmacists are confused or have made a mistake. Are they “consumers”? See infra
notes 150–56 and accompanying text.
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looking for similar marks, the less efficient trademark law became. In the
latter case, confusion undermines the incentive to invest in product
quality. Producers would be reluctant to invest in a product if competitors
used confusingly similar names to trade off its goodwill. Finally, thanks
to Frank Schechter, harm can impair not merely goodwill but the selling
power, the brand, of the mark itself.37
Yet, as this Article shows, within this economic story is another. One
where courts used the concept of confusion to refuse registration or to
find liability because they felt doing so might protect consumers from
physical, as well as economic, harm. At least in these cases, trademark
law provided a reasonable rationale for expanding the scope of
protection. Here trademark law has acted as a secondary backstop to legal
regimes that might seem like a natural fit for the harm the law protected
against—including products liability, false advertising, tort, licensing
laws, and food and drug laws. Although economic concerns did animate
many of these cases, we also see in these decisions trademark law acting
as guardian of the public’s safety and not merely its pocketbook.38
The second contribution is to draw attention to how courts have
answered, or started to answer, the following question: are deceptive
marks that are refused registration unenforceable? When the PTO denies
a registration on deceptiveness grounds, that does not, by itself,
necessarily bar the mark from trademark protection at common law. This
Article shows, however, that courts have been willing to apply the
equitable doctrine of “unclean hands” to bar plaintiffs from enforcing
unregistered deceptive marks. Courts’ reasoning, this Article argues,
applies equally to all deceptive marks, including marks found deceptive
by the PTO. The result is that a finding of deceptiveness by the PTO, or
by a court, should bar the owner of that mark from both registration and
protection.
The rest of this Article presents these cases in historical context and
argues for changes to how courts evaluate whether a mark is deceptive.
Because the changes themselves concern a central concept in trademark
law—harm—Part I explores this concept. In particular, Section I.A
examines the reemergence of harm as a central focus of commentators in
the past two decades. Section I.B then shows how courts used the
concepts of “confusion” and “consumer” to protect the public from
physical, as well as economic, harm. Section I.C then shows why this
37. Frank Schechter, The Rational Basis of Trademark Protection, 40 HARV. L. REV. 813,
818–19, 822–23, 825–27, 831 (1927).
38. None of this is to suggest that trademark law should discard economic harm when the
risk of physical harm arises or that economic harm is never relevant to physical harm. Trademark
infringement lawsuits are motivated by money, not safety. And economic harm is often the trigger
that sets off trademark law’s alarm bells. But once rung, the law should pay close attention to
other risks that amplify, or displace, the economic risks.
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doctrine has, in some limited cases, begun to fall out of favor for reasons
external to trademark law.
Part II explains how courts’ concern for consumers’ physical safety
should be extended to deceptive marks. Here we see that trademark law
routinely polices the market for falsehoods, but only when they are
descriptive. This reveals a paradox in the deceptive marks doctrine: the
more a mark suggests a product will work or has certain qualities, even if
it does not, the more trademark protection the mark will receive. That is,
the more likely a mark is designed to deceive indirectly or subliminally,
the more protection the law provides. Without an adequate emphasis on
suggestive marks, particularly in markets with higher risk profiles (such
as dietary supplements), trademark law encourages marks that mislead
consumers. Not only does this undermine trademark law’s economic
function, it actively increases the risk of physical harm. As a corrective,
courts should adjust the deceptiveness doctrine in two ways when a mark
presents a heightened risk of physical harm. First, courts should expand
the notion of “deceptiveness” to include marks that falsely suggest or
imply a quality, characteristic, or function of a product related to health
or safety, even when there is no outright misdescription or express
deception. Second, the threshold for materiality should be lowered. This
means broadening the kinds of marks that can be classified as deceptive
and reducing the number of consumers required for deception to be
material. Finally, to provide teeth to this proposal, all deceptive marks,
whether refused registration or unregistered, should be unenforceable.
I. TRADEMARK LAW AND THE RISK OF HARM
Despite the fact that “confusion isn’t everything,”39 in current
trademark law confusion counts for quite a lot. Rightly or wrongly, courts
often are concerned only with whether the defendant’s mark is likely to
cause confusion as to the source or sponsorship of the product or service
to which it is affixed. What counts as confusion is determined by a
familiar, factor-based analysis.40 Each factor is probative of liability (i.e.,
“likelihood of confusion”), but context determines whether the probative
39. William McGeveran & Mark P. McKenna, Confusion Isn’t Everything, 89 NOTRE
DAME L. REV. 253, 253 (2013).
40. The factors tend to vary by circuit, but in general they are the similarity between the
plaintiff’s and the defendant’s marks; the proximity of the plaintiff’s and the defendant’s products;
the likelihood that the plaintiff will “bridge the gap” from its current product(s) to the product line
of the defendant; evidence of actual confusion; the defendant’s good faith (or lack thereof) in
adopting the mark; the quality of the defendant’s product or service; and the sophistication of the
consumers of the plaintiff’s products. E.g., Polaroid Corp. v. Polarad Elecs. Corp., 287 F.2d 492,
495 (2d Cir. 1961). For a comprehensive list of factors by circuit, see GRAEME B. DINWOODIE &
MARK D. JANIS, TRADEMARKS AND UNFAIR COMPETITION: LAW AND POLICY 470–71 fig.7.1
(2004).
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value favors the plaintiff or defendant. Because courts can “weigh”
factors depending on the facts of the case, they can shape the factors to
the context in which confusion is likely to arise. When parodies are
involved, for example, courts are willing to find that a well-known
mark—a factor that normally favors the plaintiff—is at least neutral.41
The rationale is that for a parody to be successful, it must be wellknown.42 As a result, courts are more likely to find justified the parodist’s
use of a well-known mark, or no mark at all, to convey her message.43
Limber doctrine makes for nuanced analysis but also significant
contortions. Confusion can be stretched to cover a wide variety of cases
where other values play a dominant role. Or it can become hopelessly
elastic at the expense of other values, including those central to the
purpose of trademark law itself.44 Worst of all, it does not even address
the right questions.45 Most scholars, in fact, have engaged in detailed
arguments about how confusion has swallowed other values and why it
should be corrected.46 Nearly all of these arguments center on how this
expansion has come at the expense of trademark law’s historical,
economic origins.47
41. David A. Simon, The Confusion Trap: Rethinking Parody in Trademark Law, 88 WASH.
L. REV. 1021, 1029–42 (2013) (explaining how courts interpret the parody principle).
42. Id. at 1032.
43. Id. at 1032 & n.45.
44. See Robert G. Bone, Taking the Confusion Out of ‘Likelihood of Confusion’: Toward a
More Sensible Approach to Trademark Infringement, 106 NW. U. L. REV. 1307, 1310 (2012)
(“[T]he open-ended and protean nature of the test produces bad results by chilling socially
valuable uses and supporting excessively broad interpretations.”); Michael Grynberg, Trademark
Litigation as Consumer Conflict, 83 N.Y.U. L. REV. 60, 68–69 (2008).
45. See Bone, supra note 44, at 1307, 1311, 1336–48 (arguing that the likelihood of
confusion standard “is a mess” and that the test itself has nothing to do with the “information
transmission function” of trademark law).
46. See, e.g., Lisa P. Ramsey, First Amendment Limitations on Trademark Rights, in
INTELLECTUAL PROPERTY AND INFORMATION WEALTH: ISSUES AND PRACTICES IN THE DIGITAL AGE
155 (Peter K. Yu ed., 2007) [hereinafter Ramsey, First Amendment]; Jennifer E. Rothman, Initial
Interest Confusion: Standing at the Crossroads of Trademark Law, 27 CARDOZO L. REV. 105,
140–49 (2005). See generally Lisa P. Ramsey, A Free Speech Right to Trademark Protection?,
106 TRADEMARK REP. 797 (2016) [hereinafter Ramsey, Trademark Protection] (framing the issue
in the context of First Amendment rights).
47. To the extent that some theories develop “speech” rationales, they are exceptions to this
statement. Most commentators, however, seek to make room within trademark law for other
values. Internal trademark values are economic; external values intrude into the internal values of
trademark law. See Chandrakanth Seethamraju, The Value Relevance of Trademarks, in
INTANGIBLE ASSETS 228 (John R. M. Hand & Baruch Lev eds., 2004) (examining whether
trademarks are internally generated and externally acquired). When they conflict, many scholars
argue that trademark law should step aside. See William McGeveran, Rethinking Trademark Fair
Use, 94 IOWA L. REV. 49, 115–21 (2008) [hereinafter McGeveran, Rethinking Trademark];
William McGeveran, The Trademark Fair Use Reform Act, 90 B.U. L. REV. 2267, 2296–98 (2010)
[hereinafter McGeveran, Trademark Fair Use]; Ramsey, Trademark Protection, supra note 46,
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This Part argues that scholars’ focus on economic harm, while
accurate, has partially concealed trademark law’s role in protecting the
public from physical harm. Economic theory has made it unnecessary to
suggest that trademark law might protect the public’s noneconomic,
corporeal interests.48 Perhaps this is because some economic or moral
theories subsume physical harm.49 Even if this is true, it is useful to
examine when noneconomic harms might implicate trademark law and
how trademark law should respond. It is a point reinforced by a scholarly
consensus that the law has become bloated and could benefit from a diet
of less protection and more judicial exercise.50 It is worth asking, in other
words, when some of trademark’s added weight might come in handy.
Drawing on scholarship, case law, and government directives, I string
these threads together. First, Section I.A explores how courts and
commentators have conceived of trademark law and criticized its
expansion. Section I.B shows how courts used the concept of confusion
to reduce the risk of physical harm to consumers. Finally, Section I.C
explains how these concerns culminated in reforms at the FDA and why
this change enabled some courts to ignore the anxiety they had once
experienced about consumer safety.
A. Harm in Trademark Law and Doctrinal Bloat
Trademark law is designed to shield producers or consumers from
economic harm. Just what kind of economic harm is worth trademark
law’s time? It is an open question. Depending on one’s philosophical
leanings, trademark law can be seen as advancing the economic interests
of the consumer, the producer, or perhaps both.51 Whichever one chooses,
she finds a comfortable home in the “dominant”52 theory of trademark
law: economics. For economists, trademark law encourages economic
efficiency by reducing consumer search costs and, in the process,
increasing investment in product quality.53 Preventing confusingly
at 798; Simon, supra note 41, at 1083–84.
48. This is not to suggest that trademark scholars have not considered how other interests
should limit trademark law. Only that these “other interests”—free speech, etc.—are
conceptualized typically as external to trademark law—something that trademark law must adjust
to rather than something it might help promote.
49. Some have offered moral theoretical grounds for trademark law, which I address below.
50. See infra Section I.A.
51. One prominent commentator suggests that “to select as paramount either protection of
trademark property or protection of consumers” is an oversimplification of the “dual goals of
trademark law.” 1 MCCARTHY, supra note 1, § 2:2.
52. Mark P. McKenna, The Normative Foundations of Trademark Law, 82 NOTRE DAME
L. REV. 1839, 1841 (2007) (evaluating criticism of the modern deviation from the traditional
consumer-protection focus of trademark law).
53. William M. Landes & Richard A. Posner, The Economics of Trademark Law, 78
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similar trademarks decreases search costs and prevents free riding that
would undermine the quality of the producer’s mark.54 Jennifer Rothman
also has suggested that, as part of this economic picture, trademark law’s
role is to ensure a competitive marketplace.55
Robert Bone, who has called this dominant line of thought the
“information transmission model,”56 has suggested another reason for
having trademark law: to prevent firms from misleading consumers into
buying products they do not want.57 Bone’s conception of trademark law
purposefully leaves out “goodwill,” which he views as a byproduct of
historical and legal factors that converged and hemorrhaged in the late
nineteenth and early twentieth centuries.58 The resulting conceptual
TRADEMARK REP. 267, 271 (1988) [hereinafter Landes & Posner, Economics] (“The benefits of
trademarks in reducing consumer search costs require that the producer of a trademarked good
maintain a consistent quality over time and across consumers. Hence trademark protection
encourages expenditures on quality.”); William M. Landes & Richard A. Posner, Trademark Law:
An Economic Perspective, 30 J.L. & ECON. 265, 275 (1987) [hereinafter Landes & Posner,
Perspective] (noting that trademark law’s primary function is to provide a means for promoting
economic efficiency; on this view, trademark law’s “essential economic function” is to “reduc[e]
consumer search costs”). To engage in a law-and-economics analysis simply is to provide a
normative account. See David A. Simon, Problems in Theory: Intellectual Property (unpublished
manuscript) (on file with author). See generally Edward S. Rogers, The Lanham Act and the Social
Function of Trade-Marks, 14 LAW & CONTEMP. PROBS. 173 (1949) (discussing the Lanham Act
by providing a normative account). Scholar Edward Rogers was one of the chief architects of the
Lanham Act and is partly responsible for its passage. See id. at 177. He endorses this rationale, if
in a slightly modified form. See id. at 180–81. But he also suggests that trademarks make
producers responsible to the public for their goods. See id. at 175–76. It is a subtle irony that
trademark owners are often not liable in tort to the public. See Lynn M. LoPucki, Toward a
Trademark-Based Liability System, 49 UCLA L. REV. 1099, 1102 (2002).
54. Landes & Posner, Economics, supra note 53, at 272; Landes & Posner, Perspective,
supra note 53, at 270. Robert Bone suggests that “[m]isleading consumers undermines efficiency,
and when it is intentional, can offend moral norms against lying.” Robert G. Bone, Hunting
Goodwill: A History of the Concept of Goodwill in Trademark Law, 86 B.U. L. REV. 547, 556
(2006). Some scholars, such as Jennifer Rothman, find room for a third economic goal: the
“promotion of ‘fair competition’ by leaving ample room for businesses to compete.” Rothman,
supra note 46, at 127 (quoting S. REP. NO. 79-1333, at 1274−75 (1946)). Whether this is a separate
goal or one subsumed within the economic account is immaterial to this Article.
55. Rothman, supra note 46, at 127. This is not, traditionally, part of the economic
justification for trademark law. But see Versa Prods. Co. v. Bifold Co. (Mfg.), 50 F.3d 189, 207
(3d Cir. 1995) (“One primary purpose of the Lanham Act is to foster fair competition.”).
56. Bone, supra note 54, at 549. It is indeed a dominant approach. See, e.g., Rothman, supra
note 46, at 124–30 (arguing that the “justifications” for trademark law follow an economic line of
thinking).
57. Bone, supra note 54, at 556.
58. See id. at 567–68, 574 (explaining how trademark law originally protected consumers
from deception but the merger of law and equity jurisdictions and the adoption of trademark
ownership as a property right have forced courts to reconcile in rem rights and the law’s purpose
of preventing consumer deception through various means, including adopting the concept of
goodwill, which “unhook[ed] trademark law from its traditional anchor in fraud” and which
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coagulation produced a kind of judicial stroke, and courts began
expanding the kinds of harms they were willing to protect against.
At least that is what Bone claims. Mark McKenna reads the case law
differently.59 To him, legal history suggests that trademark law had
narrow beginnings concerned primarily with trade diversion.60 Since
trade diversion occurred only when marks deceived consumers,
trademark law and unfair competition naturally focused on deception in
these cases.61 Deception was, in other words, what rendered something
unfair—but it was unfair to producers, not consumers.62 So rather than a
consumer-focused enterprise designed to improve decision-making,
American trademark law was designed (or eventually has become
designed) to protect producers.63 Consumer protection was just a knockon effect of the primary goal of protecting producers.64
subsequent courts used to develop new theories of trademark infringement “without regard to
consumer deception”). See generally id. at 576–82 (explaining social and economic factors
throughout different time periods).
59. William Landes and Richard Posner, rather unconvincingly, seek to provide a
descriptive “rather than normative” account of trademark law. Landes & Posner, Perspective,
supra note 53, at 265. They want “to explain the structure of trademark law rather than to change”
it. Id.
60. McKenna, supra note 52, at 1840–41; see also Bone, supra note 54, at 564–65
(describing early trademark rights as sounding in property); Glynn S. Lunney, Jr., Trademark
Monopolies, 48 EMORY L.J. 367, 367 (1999); cf. Bone, supra note 54, at 560, 567, 572 (arguing
that early trademark cases were concerned with protecting sellers from losses due to deceptive
practices and consumers from deception) (“The goal of trademark law was to protect consumers
from deception and confusion and to safeguard a seller’s ability to use its hard-earned reputation
to sell its products.”). Bone argues that the shift to “goodwill” from traditional theories of
preventing consumer deception and trade diversion was a result of a move toward a property
framework. Bone, supra note 54, at 567. This move required courts to import property concepts
into trademark law (such as in rem rights), which created tensions in trademark theory and
doctrine. Id. Courts resolved these tensions by expanding the concept of goodwill and using it to
unify discrete areas of tort law and unfair competition. Id. at 572–74; cf. id. at 550 (“[T]he
information transmission model aims to prevent misleading representations . . . the
misappropriation model aims to prevent unauthorized appropriations.”).
61. McKenna, supra note 52, at 1841, 1853–54 (explaining how courts focused on producer
harms, including fraud against the mark owner in early English cases); id. at 1857–58 (“Courts
intermingled talk of fraud and property, not because they were unclear about the basis of
protection, but because in all these cases their real concern was that the defendant improperly
diverted the plaintiff’s trade. The defendant’s fraud or deception was what made some attempts
to divert improper.” (footnote omitted)). See generally id. at 1858–60 (reviewing early American
cases).
62. McKenna’s account does not agree that the law/equity distinction that Bone highlights
played a meaningful role in forcing a reconciliation of inconsistent theories. See generally id. at
1855–58 (discussing English case law).
63. Id. at 1847–48. See generally id. at 1858–87 (reviewing cases).
64. See id. at 1866 (showing how confusion was not dispositive without a specific showing
of economic harm to the plaintiff).
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Trademark originalism aside, some scholars have sought an opening
for approaches that emphasize the moral dimension of trademark wrongs.
Bone, for example, suggests that an intent to deceive consumers indicates
moral culpability that should be punished.65 Jeremy Sheff wants to take,
in his words, a “contractualist” approach to trademark law.66 By focusing
on consumer–producer relationships, he thinks contractualism can
“justify” certain trademark law doctrines67 and help resolve various
conflicts.68 Where contractualism cannot provide concrete answers, data
must be gathered.69 Where data is not likely to be gathered,
contractualism “frees us from the fool’s game of arguing . . . empirical
questions in the absence of relevant data” without forcing us to accept a
Lockean one in the data’s absence.70 What’s more, the contractualist
approach provides a setting in which “reasons supporting [normative]
visions” can be “fully aired and tested.”71
Whatever approach one takes, there is no shortage of criticism to levy
at the current state of trademark law. Much of this critique centers on the
expansion of trademark law beyond its (original) “purpose.” Economic
approaches criticize expansion because it does not promote economic
efficiency.72 Expanded protections—such as dilution, initial interest
confusion, and post-sale confusion—do nothing (or very little) to
decrease search costs or increase producer investment in product
quality.73 Trademark originalist approaches criticize expansion of
65. Bone, supra note 44, at 1350–51.
66. Jeremy N. Sheff, Marks, Morals, and Markets, 65 STAN. L. REV. 761, 763 (2013). Sheff
views philosopher Immanuel Kant as a “contractualist.” Id. This is a view shared by, among
others, philosopher John Rawls. JOHN RAWLS, A THEORY OF JUSTICE 10 n.4 (rev. ed. 1999). But
this is not the ordinary conception of a contractualist.
67. It is not clear what commentators mean when they purport to “justify” a doctrine of law-a question to which I devote attention elsewhere. David A. Simon, How to “Justify” Intellectual
Property? (unpublished manuscript) (on file with author).
68. See Sheff, supra note 66, at 801–06 (discussing post-sale confusion). It is somewhat
ironic that Sheff’s moral account of trademark law never addresses the glaring question posed by
the internal structure of trademark law: does the trademark itself influence consumers and
undermine their autonomy? The backdrop for trademarks is advertising, an industry devoted to
generating “unfelt” needs and persuading people they need things they do not. Can trademark law,
given the current state of advertising and functions of marks, ever work in Kantian or
contractualist terms?
69. Id. at 810.
70. Id.
71. Id. at 812.
72. See, e.g., Lunney, supra note 60, at 389 (explaining how trademark law expansion
threatens an efficient and competitive market). But see Irene Calboli, The Case for a Limited
Protection of Trademark Merchandising, 2011 U. ILL. L. REV. 865, 903 (arguing for a limited
merchandising right).
73. Of course, the economic model itself does nothing to encourage investment in product
quality. Instead, it encourages investment in advertising the trademark. The incentive is for
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producer-based rules for at least two reasons. One originalist points out
that such expansion is not justified given trademark’s natural law
foundation and limited purpose of curbing trade diversion. 74 Another
thinks that the property model itself is what uprooted trademark law from
its origins of consumer protection.75 In either case, it is a small step to
criticize doctrines—initial interest confusion,76 post-sale confusion,77
trade dress protection,78 liberalization of licensing rules,79
merchandizing,80 confusion as to noncompeting goods,81 dilution,82 and
protection of domain names83—that have nothing to do with either trade
diversion or consumer protection.
Recent proposals have sought to rein in trademark law’s excess by
requiring trademark law to focus more directly on why confusion is
producers to create a solid brand, and this may, but frequently does not, provide an incentive to
make a higher quality product. Some brands, in fact, are based explicitly on not providing a quality
product. See, e.g., Amanda Cochran, Spirit Airlines CEO: We’re the McDonald’s of Airlines, CBS
NEWS (May 22, 2013, 12:46 PM), https://www.cbsnews.com/news/spirit-airlines-ceo-were-themcdonalds-of-airlines/ [https://perma.cc/5J8Z-YF5G] (comparing Spirit Airlines to McDonald’s
and Walmart and noting that everyone hates these companies but that they make money because
people continue to purchase their goods and services). But see Jake Linford, Placebo Marks, 47
PEPP. L. REV. 45, 90–96 (2019) (arguing, in light of benefits consumers can draw from a markrelated placebo effect, that consumers may benefit from preserving post-sale confusion and antidilution protection at least for marks with a reputation for improving consumer performance).
74. McKenna, supra note 52, at 1887–904.
75. Bone, supra note 54, at 567; Bone, supra note 44, at 1322–23, 1325.
76. Bone, supra note 54, at 612–15 (arguing that initial interest confusion “can produce
core information-related harms if the inferior quality of defendant’s product deters an initially
interested consumer from completing the transaction before his confusion dissipates” but noting
that this is not usually a serious problem and that “[i]t is extremely difficult to square initial
interest confusion on the internet with the information transmission policies of trademark law”
and explaining that courts typically “rely almost exclusively on misappropriation” rationales to
justify this expansion); McKenna, supra note 52, at 1905–07.
77. Bone, supra note 54, at 607–12 (arguing that post-sale confusion liability can be
justified on an information transmission function of trademark law but not in “the broadest postsale confusion decisions,” where courts typically justified such confusion on appropriation
grounds); McKenna, supra note 52, at 1907–09.
78. McKenna, supra note 52, at 1907, 1909–10.
79. Id. at 1907, 1910–11.
80. Id. at 1907, 1911–12; see Bone, supra note 54, at 614–15 (explaining how the “seminal
case” involving merchandising “rested its holding on a misappropriation rationale” (citing Bos.
Prof’l Hockey Ass’n v. Dall. Cap & Emblem Mfg., Inc., 510 F.2d 1004, 1008, 1011–12 (5th Cir.
1975)).
81. Bone, supra note 54, at 593–99 (explaining how courts used the concept of goodwill to
expand protection to unrelated products bearing a similar mark to the producer’s); id. at 599–602
(explaining a “[r]etrenchment” of the previous expansion); id. at 602–604 (explaining the modern
expansion).
82. McKenna, supra note 52, at 1912–14.
83. Id. at 1914–15.

https://scholarship.law.ufl.edu/flr/vol72/iss5/5

18

Simon: Trademark Law & Consumer Safety

2020]

TRADEMARK LAW & CONSUMER SAFETY

691

harmful. Their suggestions differ in scope but fundamentally rely on the
same solution: require proof that confusion causes harm. For Mark
Lemley and Mark McKenna, this means tying confusion to direct
competition and product quality and otherwise incorporating a
materiality requirement.84 Confusion as to the source of a competing
product is sufficient to justify judicial intervention.85 Where products do
not compete, actionable confusion hinges on materiality—consumer
confusion must make a real difference to purchasing decisions.86
Materiality can be presumed, however, when confusion hinges on
product quality.87 In all other cases—such as in cases of confusion as to
sponsorship or endorsement—the plaintiff would have to demonstrate
this materiality.88
Rebecca Tushnet has argued, in a similar vein, that trademark law
should import false advertising law’s materiality requirement.89 She
argues that trademark law should demand more evidence in endorsement
84. Mark A. Lemley & Mark McKenna, Irrelevant Confusion, 62 STAN. L. REV. 413, 415–
16, 428, 433, 448, 453–54 (2010) (defining “the category of trademark infringement” as including
“uses of a mark that cause confusion about responsibility for quality” of particular goods or
services and that are very likely to materially affect consumers’ decision-making; those uses
should, therefore, be actionable, even if they are for goods that do not compete directly with the
mark owner’s); see also Mark P. McKenna, Testing Modern Trademark Law’s Theory of Harm,
95 IOWA L. REV. 63, 67–68 (2010) (disaggregating “harms” posed by consumer confusion and
evaluating them against findings from marketing literature).
85. This is true provided that the “confusion arises before purchase and is not dispelled” by
the time of purchase. Lemley & McKenna, supra note 84, at 450. They also make allowances for
famous marks, the owners of which can sue for dilution. Id.
86. Id. at 451 (defining materiality as “likely to affect the purchasing decisions of a
substantial number of consumers”).
87. Id. at 429–30, 433–34 (“In other words, confusion regarding responsibility for quality
ought to be presumed material.”). One odd feature of this proposal—perhaps of trademark law in
general—is that it proposes liability for confusion based on perceptions that the consumer herself
cannot rely on. Consumers assume that the local Baskin Robbins is the Baskin Robbins, not a
franchisee. Id. at 428. But it is not, and it bears no responsibility for the products. Id. Yet Lemley
and McKenna argue that nontrademark owners should be held liable for infringement when they
use the Baskin Robbins mark on, say, milk. Id. The upshot here is that Baskin Robbins can sue
for the unauthorized use of its mark on milk, but the patron of a Baskin Robbins cannot sue Baskin
Robbins if an employee beat her senseless or, possibly, poisoned her with tainted ice cream.
Where is the consumer protection? See LoPucki, supra note 53, at 1121.
88. Lemley & McKenna, supra note 84, at 434, 436–39, 446–48 (arguing that “consumers
get no quality-related information from the defendant’s use of a mark in cases that involve
confusion about other types of relationships that might exist between the plaintiff and defendant”
and that in such cases materiality must be demonstrated because “consumers generally do not
impute responsibility based solely on the fact of association,” and proposing a false advertising
framework to evaluate them). Here materiality is a sliding-scale determination that allows “courts
to tailor relief even when they find some remediable confusion.” Id. at 447.
89. Rebecca Tushnet, Running the Gamut from A to B: Federal Trademark and False
Advertising Law, 159 U. PA. L. REV. 1305, 1305 (2011).
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claims90 and in implied claims where the “trademark is not the primary
identifier of the defendant’s product or service.”91 Tossing out implicit
claims of false endorsement on motions to dismiss will, she hopes, reduce
litigation costs and discourage overzealous trademark owners. 92 A rule
that allows courts to adjudicate implicit claims risks producing high error
rates, which, in turn, negatively impact the “overall level of truth in the
system.”93 “A restored materiality requirement,” Tushnet argues, “would
require courts to consider why (or when) confusion is harmful.”94
Like Tushnet, Lemley, and McKenna, Bone agrees that trademark law
has become overweight by consuming all aspects of confusion and,
hence, increasing liability.95 To shrink the excess, he too thinks that
“there must be a good reason why the law should prevent confusion when
it involves consumers responding to marks.”96 Bone differs from
Tushnet, Lemley, and McKenna, however, in conceiving of what this
limiting reason should be. In particular, he thinks that “liability should
depend on the moral character of the defendant’s conduct or the expected
trademark-related harm from confusion.”97 If the defendant intends to
deceive the public, the law should presume harm conclusively.98 Where
there is no moral failing, Bone permits economic analysis to move
forward.99 His liability test would limit the relevant factors courts should
90. Id. at 1329–30 (arguing for requiring evidence of actual confusion and showing that at
least one court has created a contradiction that requires “plaintiffs alleging any . . . false implicit
message [other than implicit false endorsement to] . . . show evidence demonstrating that
consumers received that message”).
91. Id. at 1329; see id. at 1318 (“The presence of the name itself, in a distinctive font in the
most prominent position on the label, necessarily implies the source claim to a culturally
competent modern consumer.”); id. at 1318–27 (noting that the standard for the false advertising
explicit/implicit distinction and differing evidentiary standards do not make theoretical or
practical sense); id. at 1327 (discussing the doctrine of “necessary implication”).
92. Id. at 1331–32.
93. Id. at 1334–35 (analogizing the rule to HIV tests, which have a sensitivity of 98% and
a specificity of 99.8% but could yield an extremely high number of false positives because only
one in 3,000 individuals are affected with HIV, i.e., an incidence rate or “base rate” of .0003̅).
94. Id. at 1360.
95. Bone, supra note 44, at 1308–09.
96. Id. at 1309.
97. Id. at 1348. Much of Bone’s critique is directed at the likelihood of confusion factors,
which according to him, developed “as an ad hoc compromise without a guiding policy rationale.”
Id. at 1335.
98. Bone seems to think that this will reduce litigation costs because it is “a much simpler
test for granting injunctive relief than the multifactor likelihood of confusion test.” Id. at 1351.
But this rests on the false assumption that discovery related only to the issue of deception will be
adequately developed by the time the plaintiff files a motion for a preliminary injunction. This is
unlikely given that motions for preliminary injunctions typically issue well before the parties have
conducted enough discovery to determine the motivations of the defendant.
99. Id. at 1361 (asserting that the economic analysis includes “expected cost,” which
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consider and focus the inquiry on whether confusion “impair[s] . . . [the
trademark’s] information transmission function.”100 Harm occurs, in
other words, when confusion prevents consumers from relying on a mark
to “retrieve information about the product they wish to buy” or when it
prevents firms from “communicat[ing] high quality to consumers.”101
Bone’s policy prescriptions differ in specifics, but in each case he wants
courts to “consider both the probability of confusion and the magnitude
of [economic] harm that confusion is likely to generate.”102 All three of
these approaches, and others like them,103 follow the same general
thought: likelihood of confusion standard has become divorced from the
very principles of harm that animate trademark law. These approaches
are sensible. If confusion has become unhinged, then tightening the
screws promises to constrict the doctrine and make a lasting repair. But
what if having a screw loose can actually prevent significant consumer
harm?
This Article argues that, at least in one line of cases, an expansive
concept of confusion made quite good sense. This does not mean one has
to deny that “a confusion-only infringement analysis and a vague and
open-ended test [afford] judges . . . wide latitude to impose liability on
questionable grounds—such as anti-free riding—as long as they can find

considers “(1) the probability that a cost-generating event will occur and (2) the magnitude of
the social cost when it does occur”).
100. Id. at 1363. Here, the harms are of the traditional kind. Id. (explaining that traditional
economic harms are important only to the extent they impair the information transmission function
of the mark).
101. Id. at 1312.
102. Id. at 1370; see id. at 1362–70.
103. There is a robust literature on how to rein in the excesses of trademark law. One
approach is to focus on values exogenous to trademark law and use them to craft defenses to
infringement. See, e.g., Graeme B. Dinwoodie & Mark D. Janis, Confusion Over Use:
Contextualism in Trademark Law, 92 IOWA L. REV. 1597, 1602 (2007) (rejecting trademark use
theory); Graeme B. Dinwoodie, Developing Defenses in Trademark Law, 13 LEWIS & CLARK L.
REV. 99, 112 (2009) (arguing trademark law should accommodate values with real defenses and
not merely adjustments to the likelihood of confusion analysis); McGeveran, Rethinking
Trademark, supra note 47, at 53 (arguing that a more limited conception of confusion and more
uniform, less fact-intensive defenses would better cabin trademark law and free it from excessive
litigation costs); McGeveran, Trademark Fair Use, supra note 47, at 2304–17 (arguing for fairuse safe harbors in trademark law). Others have proposed trademark “use” as a means for doing
so. See, e.g., Stacey L. Dogan & Mark A. Lemley, Grounding Trademark Law Through
Trademark Use, 92 IOWA L. REV. 1669, 1670 (2007) (urging courts to resist “a radical departure
from [the] . . . traditional model without specific instruction from Congress”); Stacey L. Dogan &
Mark A. Lemley, Trademark and Consumer Search Costs on the Internet, 41 HOUS. L. REV. 777,
784 (2004) (“While the view of trademark enforcement as reducing consumer search costs is well
known in the economic literature, we extend that work by showing how many of the limitations
and defenses in trademark doctrine also serve that goal.”).
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a plausible confusion risk.”104 But it does mean we should recognize that
the same flexibility enables courts to protect the public on other grounds,
including “moral” grounds of a different kind than the one Bone suggests.
The next Section shows how.
B. The Risk of Physical Harm, or the Doctrine of Greater Care
Despite its economic focus, trademark law sometimes must confront
risks to consumer safety. Where confusingly similar trademarks might
pose physical harm to the consumer, courts have been willing to lower
the standard of liability to prevent the risk from materializing.105 Usually,
courts accomplished this task using the concept of “consumer.”
Sometimes they included as consumers intermediaries who do not buy
the product but have control over who does. Other times courts used the
concept of “confusion” to help diagnose and treat the risk. In at least two
cases,106 for example, courts focused on post-sale confusion among actual
purchasers of the product.107 This Section explains how and why courts
did so.
Trademark disputes involving confusion that posed a risk to physical
safety arose in only specific contexts. By far the most common situation
was two similarly named prescription drugs.108 It was in this context that
the U.S. Court of Customs and Patent Appeals (CCPA),109 in Campbell
104. Bone, supra note 44, at 1335.
105. One prominent commentator calls this “confusion of products.” MCCARTHY, supra note
1, § 23:5. He proclaims that “[t]here is no doubt that trademark law does protect against” it. Id.;
see also Kos Pharm., Inc. v. Andrx Corp., 369 F.3d 700, 704, 732 (3d Cir. 2004) (issuing a
preliminary injunction for infringement where two cholesterol-altering drugs with similar
names—ADVICOR and ALTOCOR—but different dosages, active ingredients, and side effects
were found to be confusingly similar for prescribing physicians); Am. Cyanamid Co. v. U.S.
Rubber Co., 356 F.2d 1008, 1009 (C.C.P.A. 1966) (“[T]he similarity in sound and spelling,
particularly the former, is sufficient, we think, to create a likelihood of various kinds of confusion
and mistake, considering the close relationship of the goods in use.”).
106. Byk-Gulden, Inc. v. Trimen Labs., Inc., 211 U.S.P.Q. (BNA) 364 (T.T.A.B. 1981),
1981 WL 40488 (Kera, Member, concurring in part and dissenting in part); Am. Home Prods.
Corp. v. USV Pharm. Corp., 190 U.S.P.Q (BNA) 357 (T.T.A.B. 1976), 1976 WL 20937.
107. This is not the ordinary definition of post-sale confusion. Sheff, for example, argues
that post-sale confusion regulates “socially expressive consumption.” Sheff, supra note 14, at 773.
It is true that traditionally and commonly this is how post-sale confusion has been conceptualized.
But in at least two cases discussed here, concern over post-sale confusion was rooted in physical
harm. See, e.g., Glenwood Labs., Inc. v. Am. Home Prods. Corp., 455 F.3d 1384, 1386–87 (Fed.
Cir. 1972); Campbell Prods., Inc. v. John Wyeth & Bro., Inc., 143 F.2d 977, 979 (C.C.P.A. 1944).
108. Trademark law also explicitly recognizes safety concerns in the Fastener Quality Act,
15 U.S.C. § 5401 (2018), and its implementing regulations. See 15 C.F.R. § 280.1 (2019).
109. The CCPA was the predecessor of the Federal Circuit. Court Jurisdiction, U.S. CT.
APPEALS FOR FED. CIR., http://www.cafc.uscourts.gov/the-court/court-jurisdiction [https://perma
.cc/28M7-V45W].
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Products, Inc. v. John Wyeth & Bro., Inc.110 adopted what has been
called, somewhat inaptly, the Doctrine of Greater Care.111 The trademark
applicant had sought to register ALUTROPIN for an oral medication,
dispensed in a clear glass bottle, to treat ulcers and gastric acidity.112 The
opposer—which owned the registered mark ALULOTION for a
“poisonous” lotion, sold in a “3-ounce blue bottle,” applied to treat
impetigo—contested the registration on grounds of confusing
similarity.113 The products appeared in different color bottles with
different shapes.114 A prescription was required for either medication.115
FDA labeling requirements made clear one product was not the other.116
And neither product competed with the other for market share—one
treated stomach upset, the other skin infection.117
The CCPA refused registration on grounds that the names were
confusingly similar.118 Of particular importance was the potential risk of
physical harm posed by confusion among products: “[I]t seems to us that
where ethical goods are sold and careless use is dangerous, greater care
should be taken in the use and registration of trade-marks to assure that
no harmful confusion results.”119 This reasoning would prove important
110. 143 F.2d 977 (C.C.P.A. 1944).
111. Id. at 979; see Schering Corp. v. Thompson Med. Co., 209 U.S.P.Q. 72 (S.D.N.Y. May
14, 1979), 1979 WL 24976, at *4–5; CALLMANN, supra note 1, § 21:5; Johnson, supra note 1, at
444. The name is inapt because invoking the doctrine requires courts to find that highly
sophisticated consumers actually exercise less care in choosing products. U.S. PATENT &
TRADEMARK OFFICE, supra note 7, § 1207.01(d)(xii).
112. Campbell, 143 F.2d at 977–78.
113. Id.
114. Id. at 978.
115. Id.
116. Id. at 978, 979.
117. Id. at 977–78.
118. Id. at 978, 980. It affirmed the findings of the First Assistant Commissioner of Patents,
who had reversed the decision of the Examiner of Trademark Interferences. Id. at 978.
119. Id. at 979 (noting that the products had the same “descriptive properties”). This case
was decided under the Trademark Act of 1905. Ch. 592, 33 Stat. 724 (1905) (current version at
15 U.S.C. §§ 81–134 (2018)), repealed by Act of July 5, 1946, ch. 540, § 46(a), 60 Stat. 427, 444.
The “descriptive properties” of the goods are now called classes. Moore v. Procter & Gamble Co.,
193 F.2d 194, 197 (C.C.P.A. 1951) (“The Court of Customs and Patent Appeals has held that the
terms ‘same class’ and ‘same descriptive properties’ . . . are synonymous in their meaning.” (citing
Cheek-Neal Coffee Co. v. Hal Dick Mfg. Co., 40 F.2d 106 (C.C.P.A. 1930))). Under the 1905
Act, no trademark registration could issue if the “identical” mark or one that was “likely to cause
confusion” had been registered previously by another party on goods of the “same descriptive
properties.” 33 Stat. at 725–26. “Ethical goods” was the term used to refer to medicinal products
sold by druggists, usually on prescription. See 15 MEDICAL CENTURY 412 (Willis A. Dewey & J.
Richey Horner eds., 1907) (illustrating a flyer which referenced a druggist’s dedication to “ethical
goods,” which included a promise to “never inclose [sic] any printed prescriptions or medical
suggestions with our goods”). Druggists, however, could dispense medications (except narcotics)
without prescriptions until 1938. Peter Temin, The Origin of Compulsory Drug Prescriptions, 22
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in future cases for two reasons. First, it presaged the use of a different
confusion standard, in the eighty years that followed, when physical harm
could result. Although this standard would vary slightly from case to
case, its principle would remain constant: when physical harm might
result from confusion, lower the threshold for confusing similarity in both
registration and infringement.
After Campbell, a number of courts confronted cases with similar
problems. Some cases, such as Moore v. Procter & Gamble Co.,120 noted
that risks posed by confusion could arise from the actions of
nonconsumer intermediaries, such as store clerks.121 When the consumer
asked to buy detergent for personal use (DUZ DOES MORE), the clerk
might walk him to a similarly named louse powder (DUZ MORE) by
mistake.122 “[I]n view of the poison contained in appellant’s product,” the
court declared it would “protect[] . . . the public interest” by “resolving
any existent doubt against the registration of the newcomer’s mark.”123
Not all of the decision, of course, hinged on this risk. Perhaps there was
enough similarity between the marks, product lines, and channels of trade
to sustain a traditional trademark action.124 And, certainly, consumers’
J.L. & ECON. 91, 91 (1979).
120. 193 F.2d 194 (C.C.P.A. 1951).
121. Id. at 197 (“Under such circumstances, this court is interested in seeing not only that
the purchaser makes no mistake himself, but also that he is not led into confusion or mistake by
error of the clerk or grocer involved in the transaction.”). Intermediary consumers, such as
professional buyers, have been the subject of confusion inquiries for a long time. Edward Hilker
Mop Co. v. U.S. Mop Co., 191 F. 613, 618 (6th Cir. 1911) (“Both parties, however, advertised
prominently in their own names; their respective advertisements sometimes appearing upon a
given page of the same journal. Such advertisements were not primarily intended to make sales
to the ultimate purchaser, but to obtain agents, to whom other literature was sent in case of
response to advertisements.”). But in many of the early cases, the intermediary consumer was
targeted directly for sale of the products. E.g., id. This made it easier to call the professional buyer
the intermediary consumer since the offending advertisements did not implicate the ultimate
consumer. See, e.g., Best Foods, Inc. v. Hemphill Packing Co., 5 F.2d 355, 358 (D. Del. 1925)
(refusing to find unfair competition because the items bearing similar marks were sold to
professional dealers and not consumers and “the dealers . . . know the names of the persons with
whom they deal and the trade-marks of the goods which they sell or desire to sell, and are not so
apt to be confused”).
122. This was an appeal from the decision of the Examiner of Trademark Interferences
dismissing the notice of opposition of the opposer to an application under the Trademark Act of
1905 for registration of a trademark for “louse powder for poultry, livestock, and dogs.” Proctor
& Gamble Co. v. Moore, 85 U.S.P.Q. (BNA) 176 (Comm’r Pat. & Trademarks 1950), 1950 WL
4187, at *1, aff’d, 193 F.2d 194 (C.C.P.A. 1951) (“The mark sought to be registered consists of
the notation ‘DUZ MOR.’ The opposer relies upon its ownership and prior use of ‘Duz,’ as a trade
mark for soap, alleging that applicant’s mark so nearly resembles that mark as to be likely to cause
confusion or mistake.”).
123. Moore, 193 F.2d at 197.
124. At the time of this decision, however, the modern likelihood of confusion test had not
yet developed. Bone, supra note 44, at 1317 (noting that the creation of the modern multifactor
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unsophisticated status did not hurt the chances of infringement.125 But
these findings, perhaps even this latter finding, buttressed the court’s
rationale. What happens if an elderly man, perhaps one old enough to sit
on the CCPA in 1951,126 goes looking for soap and ends up washing his
clothes with animal-grade louse powder—maybe even on a daily
basis?127 Maybe the actual consumer was not confused about the source
of the product. But the “mistaken purchase” did seem to fit within the
traditional trademark law framework. In this case, at least, the court
viewed the risk of physical harm as one of many factors to consider.128 It
is impossible to know whether this consideration was decisive, but it
certainly influenced the court’s decision to deny registration.
All of this left unsaid another issue that would appear in 1954 and
again just a year later in R.J. Strasenburgh Co. v. Kenwood Laboratories,
Inc.129: who was the consumer? The issue was of critical importance. If
patients were consumers of prescription medication, no consumers would
be confused when they purchased the wrong one. Consumers, it was true,
bought the drugs—in this case TRISED (the applicant’s mark for a
sedative tablet) and TRICID (the opposer’s mark for an antacid tablet).130
But physicians and pharmacists prescribed and dispensed the drugs.131
Patients with insomnia whose doctors mistakenly prescribed TRICID
might become unpleasantly irregular, but their own confusion did not
cause the backup. Consumers—those who actually purchased the drugs
at retail locations—were no more confused about the source of the drug
test was in the early 1960s).
125. See Moore, 193 F.2d at 197.
126. The average age of the sitting judges on the CCPA in 1951 was 65.6 years old. They
were Judges Finis James Garret (seventy-six years old), Joseph Raymond Jackson (seventy-one
years old), Ambrose O’Connell (seventy years old), Noble Jacob Johnson (sixty-four years old),
and Francis Eugene Worley (forty-seven years old). See U.S. Court of Customs and Patent
Appeals: Judges, FED. JUD. CTR., https://www.fjc.gov/history/courts/u.s.-court-customs-andpatent-appeals-judges [https://perma.cc/LY52-EYLT].
127. Large-scale use of soap instead of louse powder might result in a public health crisis of
its own. Maybe it is less concerning when a dog is washed with soap instead of louse powder. But
perhaps the concern should not be laughed off too quickly.
128. See Moore, 193 F.2d at 197–98.
129. 106 U.S.P.Q. (BNA) 379 (Comm’r Pat. & Trademarks 1955), 1955 WL 6473. In 1954,
one district court had no trouble finding relevant confusion among intermediaries. Cole Chem.
Co. v. Cole Labs., Inc., 118 F. Supp. 612, 616–17 (E.D. Mo. 1954). Since both companies in Cole
engaged in the sale of medical products that would be used on or consumed by individuals, a mixup of marks could “have serious consequences for the patient.” Id. at 616. To that end,
“[p]revention of confusion and mistakes in medicine [was] . . . too vital to be trifled with.” Id. at
617. The actual dispute in Cole was not a trademark dispute but an action to enforce a settlement
agreement. Id. at 613–14.
130. Strasenburgh, 106 U.S.P.Q. (BNA) 379, 1955 WL 6473, at *1.
131. Id.
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than the name of the drug itself.132 At a time when direct-to-consumer
(DTC) drug advertising was nonexistent, consumers probably had little
knowledge of any drug names.133
If consumers were not confused, on what grounds could the court find
confusing similarity? One solution, the one adopted by the Commissioner
of Patents, was to define consumers as physicians and dispensing
pharmacists.134 This solved the problem of how to protect the public from
physical harm but created a new one. Doctors and pharmacists were
highly trained and experienced in pharmaceutical preparations. Now the
court had to explain how, in the contexts of hundreds of prescription
drugs, a mere two names could confuse these skilled consumers. Because
the CCPA did not confront the issue of consumer sophistication,135 the
court simply found confusion among the relevant consumers—doctors
and pharmacists—likely.136
132. Courts would build upon such ideas in expanding trademark law to cover “confusion,
mistake, or deception occurring at some future point in time.” Rolex Watch USA, Inc. v. Canner,
645 F. Supp. 484, 493 (S.D. Fla. 1986) (“The fact that an immediate buyer of a $25 counterfeit
watch does not entertain any notions that it is the real thing has no place in this analysis.”).
133. DTC advertising began tepidly at first in the 1980s. Francis B. Palumbo & C. Daniel
Mullins, The Development of Direct-to-Consumer Prescription Drug Advertising Regulation, 57
FOOD & DRUG L.J. 423, 424–27 (2002) (reviewing the history of DTC advertising). After more
than a decade of practice, the FDA issued draft industry guidance on the practice in 1997 and
finalized it in 1999. Id. at 427–30 (noting that the FTC had authority over all drug advertisements
until 1962, when Congress transferred this authority to the FDA, and the FDA had authority to
regulate only drug labeling until that time); see id. at 430 (explaining guidance issuance and
finalization). Thereafter DTC drug advertising ballooned. See Meredith B. Rosenthal et al.,
Promotion of Prescription Drugs to Consumers, 346 NEW ENG. J. MED. 498, 500–01 (2002).
134. See Strasenburgh, 106 U.S.P.Q. (BNA) 379, 1955 WL 6473, at *1. Courts did this in at
least one other context but in the reverse direction. Am. Cyanamid Co. v. U.S. Rubber Co., 356
F.2d 1008, 1009 (C.C.P.A. 1966) (including farmworkers in the definition of consumers because
confusion among them might damage crops even though the individuals who bought the product
were the farm directors and operators).
135. The term “sophistication” relating to “purchasers” appears in the case law in 1961,
though the idea that courts should evaluate confusion based on the purchaser’s attention to detail
goes back much farther. Compare Polaroid Corp. v. Polarad Elecs. Corp., 287 F.2d 492, 495 (2d
Cir. 1961) (noting that among the variables courts consider is “the sophistication of the buyers”),
with RESTATEMENT OF TORTS § 729 cmt. g (AM. LAW INST. 1938) (“The buying habits of the
purchasers of the particular goods in question are also significant. If the goods are bought by
purchasers who exercise considerable attention and inspect fairly closely, the likelihood of
confusion is smaller than when the goods are bought by purchasers who make little or no
inspection.”), and Wirtz v. Eagle Bottling Co., 24 A. 658, 659 (N.J. Ch. 1892) (“[T]he court must
take into consideration the degree of care which buyers usually exercise in buying such an article
as that which is the subject of the distinguishing mark; for it is a matter of common knowledge
that the ordinary buyer does not, as a general rule, exercise as much caution in buying an article
for which he pays a few pennies as he does in purchasing a more valuable thing.”).
136. Strasenburgh, 106 U.S.P.Q. (BNA) 379, 1955 WL 6473, at *1 (noting that doctors and
pharmacists are likely to be confused because of the fanciful character and phonetics of the
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This is not, it should be noted, an irregular practice in the context of
trademark law generally.137 Intermediaries who purchase a product
bearing the trademark are considered consumers—that is as true today as
it was in 1940. And, currently, when products are marketed to both
professional and nonprofessional buyers, common practice is to use as
the baseline the least sophisticated consumer class to which the product
is marketed.138 It is unclear if this particular practice was common139 in
the 1940s and 1950s.140 Even if it was, it is also uncertain whether doctors
marks).
137. See Edward Hilker Mop Co. v. U.S. Mop Co., 191 F. 613, 618 (6th Cir. 1911) (assessing
confusion among professional buyers and not the ultimate consumer).
138. E.g., Sabinsa Corp. v. Creative Compounds, LLC, 609 F.3d 175, 186 (3d Cir. 2010)
(“However, where the group of buyers is a combination of professionals and ordinary consumers,
the class as a whole is not held to the higher standard of care.”); MCCARTHY, supra note 1,
§ 23:100.
139. But what was clear is that different advertisements and uses to different classes of
purchasers were often assessed separately. See supra note 121 and accompanying text.
140. Brookfield Communications v. West Coast Entertainment Corp., 174 F.3d 1036 (9th
Cir. 1999), for example, states this proposition, cited favorably by scholar Thomas McCarthy. See
id. at 1060. But that decision is traced back to a case in the U.S. District Court for the Southern
District of Ohio in 1990, which asserted this conclusion and cited as support a decision that does
not make the same assertion. Worthington Foods, Inc. v. Kellogg Co., 732 F. Supp. 1417, 1448
(S.D. Ohio 1990) (“The normal consumer is the ‘reasonably prudent buyer.’ Such consumers are
not necessarily ‘very cautious’ or experts, but they are also not ‘indifferent’ or ‘careless.’ Instead,
they are those consumers of ‘reasonable intelligence and discrimination.’” (citations omitted)
(first quoting Little Caesar Enters., Inc. v. Pizza Caesar, Inc., 834 F.2d 568, 571 (6th Cir. 1987);
then quoting 2 J. MCCARTHY, TRADEMARKS AND UNFAIR COMPETITION § 27:29 (2d ed. 1984)));
see Little Caesar Enters., 834 F.2d at 572 (“With regard to the sixth factor, likely degree of
purchaser care, the district court thought it unlikely that the public would conduct much
preprandial product research. We agree, but note that it probably makes little difference on the
facts before us.”). The Worthington court, interestingly, also cited the 1984 version of McCarthy’s
treatise for this proposition. See Worthington, 732 F. Supp. at 1448 & n.87; see also MCCARTHY,
supra note 1, § 23:29 (providing an updated version of the sections that the Worthington court
cited). Another case in McCarthy’s recent treatise cites a decision by the CCPA that does not
support the proposition. See Country Floors, Inc. v. Gepner, 930 F.2d 1056, 1066 (3d Cir. 1991)
(“Furthermore, even if most of the customers are professionals, the trademark law protects the
entire gamut of purchasers, including retail consumers and members of the trade.”). The Kroger
court stated:
The marks of both parties are applied to canned vegetables, goods that are cheap
in price and of every day use. In [an earlier case], we said of the goods there
involved: “It must be remembered that the goods to which the marks are applied
are of common everyday use in the household. They are very inexpensive and
are consumed in their use. Purchasers therefore would not be expected to exercise
such degree of care in their purchase as would be exercised in more expensive
and rarely purchased articles.
Kroger Grocery & Baking Co. v. Blue Earth Canning Co., 88 F.2d 725, 726 (C.C.P.A. 1937)
(citation omitted) (quoting Lever Bros. v. Riodela Chem. Co., 41 F.2d 408, 410 (C.C.P.A. 1930));
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and pharmacists would have been classified as intermediaries because
they were not, strictly speaking, intermediary purchasers.
But what is clear is that, over time, courts had no trouble holding that
intermediaries of all kinds—purchasers or not—could give rise to
relevant confusion.141 So the court may have been on firm—or perhaps
fertile—legal ground in characterizing doctors and pharmacists as
“consumers.” And most likely this move was part of a more general
response to two phenomena: first, the increasing possibility of nationwide
federal registration, and second, the demands foisted upon trademark law
in regulating a booming market economy.142 But it was important, in this
case and those that followed, that the court did so by referencing the
potential risk to the ultimate consumer that confusion caused. And it is
this kind of confusion that implicated public safety.143

see also Omega Importing Corp. v. Petri-Kine Camera Co., 451 F.2d 1190, 1195 (2d Cir. 1971)
(declining to hold that as between sophisticated and unsophisticated consumers the latter should
take precedence). The Omega court ruled, rather, that the relevant audience is the ordinary
purchaser, not the expert. See Omega, 451 F.2d at 1195. Another case, which also does not stand
for this proposition, cites for support scholar Rudolf Callmann’s treatise—and lifts language from
Florence, below. Feathercombs, Inc. v. Solo Prods. Corp., 306 F.2d 251, 256–58 (2d Cir. 1962).
So, it may be that at least by the 1970s this trend had become noticeable to commentators.
Florence Manufacturing Co. v. J.C. Dowd & Co., 178 F. 73 (2d Cir. 1910), provides an example.
See id. at 75. But one strains to see, especially in light of the facts of the case, the idea that lower
consumer sophistication counts in a mixed market from a rather general statement about the
consuming public. See id. (“The law is not made for the protection of experts, but for the public—
that vast multitude which includes the ignorant, the unthinking and the credulous, who, in making
purchases, do not stop to analyze, but are governed by appearances and general impressions.”).
141. See supra notes 121, 128 and accompanying text; infra note 174. Tort law has made
similar adjustments. See Nabors Well Servs., Ltd. v. Romero, 456 S.W.3d 553, 564 (Tex. 2015)
(noting that the “the driver” is responsible for exercising reasonable care to retrain minors
traveling in her vehicle, but also explaining that the child may be liable if the child failed to
exercise the degree of care that an “ordinarily prudent child of [the same] age, intelligence,
experience and capacity . . . under the same or similar circumstances” would exercise (alteration
in original) (quoting Rudes v. Gottschalk, 324 S.W.2d 201, 204 (Tex. 1959))).
142. For an interesting account of trademarks from a historical perspective, see Sidney A.
Diamond, The Historical Development of Trademarks, 65 TRADEMARK REP. 265 (1975).
143. By doing so, the court enabled private enforcement of public safety concerns, which
had the added benefit of reducing litigation and liability costs. See Am. Cyanamid Co. v. U.S.
Rubber Co., 356 F.2d 1008, 1009 (C.C.P.A. 1966) (“While a farm manager planning a spraying
program would no doubt exercise such a degree of care in selecting and compounding his spray
as to preclude mistake on his part, we see merit in appellee’s argument that the sale, purchase,
and handling of CYGON and PHYGON products at the verbal level, possibly under noisy
conditions, might result in confusion or mistake and even damage to crops through a confused
worker applying the wrong material.”); Cole Chem. Co. v. Cole Labs., Inc. 118 F. Supp. 612, 618
(E.D. Mo. 1954) (“Must plaintiff stand by helpless until harm has resulted to some human being.
Then the search will be for the negligent party and the cause of the confusion will end with
everyone pleading innocent. Why not end it now?”).
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Regardless of who was confused, risks to public safety arose in
contexts other than prescription medications. Just a few weeks before
Strasenburgh, the U.S. Court of Appeals for the Eighth Circuit in Dietene
Co. v. Dietrim Co.144 used the public safety rationale in a case involving
“fortified dietary food supplement[s]” available without a prescription
(and sold145 to both pharmacies and retail customers).146 In reversing the
lower court’s conclusion that the plaintiff’s mark was descriptive and its
finding of infringement, the Eighth Circuit declared “vitally important”
the “avoidance of confus[ion]” where “products . . . may affect human
health and which ordinarily should be taken upon the advice or
recommendation of a physician.”147 While the harm now expanded to
include “human health,”148 discussion of the relevant consumer was
limited. The court underscored the nature of the injury to the public,
rather than to the plaintiff, by granting an injunction but finding that the
plaintiff had suffered no “substantial damages” despite the concurrent use
of the infringing mark for over a decade.149 Without any damage to the
plaintiff, the grounds for the injunction, though premised on “confusion,”
can be best explained by a concern for potential harm to the public, rather
than to the plaintiff.
Although cases, like Dietene, involving confusion over nonprescription products exist, they are not plentiful. More common were
cases involving prescription drugs. But, as noted above, they typically
involved sophisticated “consumers”: doctors and dispensing pharmacists.
Sophisticated consumers are assumed to be more discerning and,
therefore, less likely to be confused. When the stakes were high enough,
however, courts have tended to downplay the importance of consumer
sophistication. In Morgenstern Chemical Co. v. G.D. Searle & Co.,150 for
144. 225 F.2d 239 (8th Cir. 1955).
145. The plaintiff sold its product in capsules, and the defendant sold its product in powder
form. Id. at 241–42. But see Morgenstern Chem. Co. v. G.D. Searle & Co., 150 F. Supp. 726, 728,
730 (D.N.J. 1957), rev’d, 253 F.2d 390 (3d Cir. 1958) (noting that the plaintiff and the defendant
both manufactured circular pink tablets).
146. Dietene, 225 F.2d at 241–42.
147. Id. at 243.
148. Id.
149. Id. at 243, 244 (“Since the record indicates that the plaintiff suffered no substantial
damages or loss of profits from the defendant’s competition and that an accounting would be
futile, we think that none need be had.”). The plaintiff had been using DIETINE since 1934 and
the defendant since 1943 or 1944. Id. at 241, 242. This was also the case in Morgenstern. See
Morgenstern, 253 F.2d at 394 (holding that an injunction should issue but that there should not
be a reference to an accounting or award of damages). Injunctions in trademark cases, at least
prior to eBay Inc. v. MercExchange, LLC, 547 U.S. 388 (2006), were routine even without a
demonstrable showing of damages. So the result itself was not extraordinary except that the
finding came after ten years of use with no documented damages whatsoever. See id. at 391.
150. 253 F.2d 390 (3d Cir. 1958).
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example, the U.S. Court of Appeals for the Third Circuit noted that
although doctors and pharmacists were highly trained, they were not
“infallible.”151 And they could, just like anyone else, mix up
MICTURIN152 (the plaintiff’s common law mark for urinary tract
infections) and MICTINE (the defendant’s claimed mark for diuretic
therapy) even though the drugs treated different conditions.153 Yet
because the products did not compete, there could be no unfair
competition.154 Nevertheless, the nature of the risk involved was too
much for the Third Circuit. The court could not afford to “speculate as to
whether there is a probability of confusion between similar names.”155 As
a result, “[i]f there is any possibility of such confusion in the case of
medicines public policy requires that the use of the confusingly similar
name be enjoined.”156

151. Id. at 393.
152. Morgenstern Chem. Co. v. G.D. Searle & Co., 150 F. Supp. 726, 731 (D.N.J. 1957),
rev’d, 253 F.2d 390 (3d Cir. 1958) (“The name ‘Micturin’ or ‘Micturin Tablets,’ though not a
registered trade-mark or trade name, is a valid common-law trade name.”).
153. Id. at 730–31 (noting that a pamphlet published by the defendant recommended Mictine
for use in “diuretic therapy in cases of hypertension, congestive heart failure, glomerulo-nephritis,
pyelonephritis and nephrosis”).
154. Id. at 732–33. Because the products treated different conditions, physicians or
pharmacists would not prescribe one drug in place of another. Id. at 732 (“Neither from the
evidence presented in this case, nor by way of judicial notice, can this Court reasonably find that
a physician would prescribe or a pharmacist dispense the product of one of the parties for the
treatment of a condition for which the product of the other party is indicated.”).
155. Morgenstern, 253 F.2d at 394.
156. Id.
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Throughout the 1950s, 1960s,157 1970s,158 1980s,159 1990s,160
157. “[W]here ethical goods are sold and careless use is dangerous, greater care should be
taken in the use and registration of trademarks to assure that no harmful confusion results.”
Sterling Drug Inc. v. Merritt Corp., 119 U.S.P.Q. (BNA) 444 (T.T.A.B. 1958), 1958 WL 6047, at
*1 (quoting Campbell Prods., Inc. v. John Wyeth & Bro., Inc., 143 F.2d 977, 979 (C.C.P.A.
1944)), aff’d, 277 F.2d 956 (C.C.P.A. 1960); see Morgenstern, 253 F.2d at 393; Dietene Co. v.
Dietrim Co., 225 F.2d 239, 243 (8th Cir. 1955); see also Merritt, 277 F.2d at 956–57 (sustaining
opposition for SUPERIN as a trademark for an aspirin suppository on the grounds that it is
confusingly similar to SUPRARENIN as a trademark for “synthetic epinephrine” to coagulate
blood during operations because both medications could be confused in emergency situations);
cf. Clifton v. Plough, Inc., 341 F.2d 934, 934–36 (C.C.P.A. 1965) (finding NUMOL “for a
pharmaceutical product for the relief of coughs, colds and bronchial irritations” confusingly
similar to NUJOL “for mineral oil for chemical, medicinal and pharmaceutical uses other than the
treatment of constipation” and other medicinal purposes); Chi. Pharmacal Co. v. Am. Home
Prods. Corp., 280 F.2d 148, 150 (C.C.P.A. 1960) (sustaining opposition and affirming the
Trademark Trial and Appeal Board’s decision on the grounds that, because the products were
available by prescription, the public would be “protected from purchaser confusion” but that drugs
may be sold over-the-counter in the future and neither endorsing nor rejecting the idea that doctors
should be treated as sophisticated consumers).
158. See, e.g., Pennwalt Corp. v. Ctr. Labs., Inc., 524 F.2d 235, 235–37 (C.C.P.A. 1975)
(sustaining opposition against ALLERSET for a prescription allergy hyposensitization injection
as confusingly similar to ALLEREST for an over-the-counter allergy medication and sinus relief
and finding that “[p]hysicians, especially those who happen to be allergy sufferers, are also
consumers” but discounting heightened sophistication of physicians and finding likelihood of
confusion as to source in the minds of consumers (emphasis omitted)); Glenwood Labs., Inc. v.
Am. Home Prods. Corp., 455 F.2d 1384, 1384–86 (C.C.P.A. 1972) (sustaining opposition on the
grounds that MYOCHOLINE for “a medicinal preparation for treatment of dysphagia, abdominal
distention, gastric retention, and urinary retention” was confusingly similar to MYSOLINE, an
anti-convulsant) (affirming the higher standard applied by the board, while citing Campbell and
Clifton); Geigy Chem. Corp. v. Atlas Chem. Indus., Inc., 438 F.2d 1005, 1006–08 (C.C.P.A. 1971)
(sustaining opposition and finding that HYDRONOL for a diuretic was confusingly similar to
HYGROTON for an investigational diuretic because a physician “not prescribing diuretics to his
diverse patients every day, on encountering the other product a week or two later or searching his
memory or the index of the ‘Physicians’ Desk Reference’ (PDR)” might make a mistake and
prescribe one meaning to prescribe the other); Am. Cyanamid Co. v. Connaught Labs., Inc., 231
U.S.P.Q. 126, No. 86 Civ. 3533 (RO), 1986 WL 6155, at *2 (S.D.N.Y. May 29, 1986) (issuing a
preliminary injunction against the defendant’s use of Hib-VAX on vaccinations based on the
plaintiff’s registration of the HIB-IMUNE mark for vaccinations and applying Morgenstern for
support), rev’d sub nom. Am. Cyanamid Corp. v. Connaught Labs., Inc., 800 F.2d 306 (2d Cir.
1986); Nu-Dent Porcelain Studio, Inc. v. Hue-Dent, Inc., 184 U.S.P.Q. (BNA) 298, No. 70-C550, 1974 WL 20230, at *2–4 (E.D.N.Y. Sept. 4, 1974) (sustaining opposition for HUE-DENT
as confusingly similar to NU-DENT for dental services and citing cases like Syntex and
Morgenstern); In re Merck & Co., Inc., 189 U.S.P.Q. 355 (T.T.A.B. 1975), 1975 WL 20942, at
*1 (sustaining opposition against M-M-VAX as confusingly similar to M-VAC). But see Geigy
Chem. Corp., 438 F.2d at 1008 (Baldwin, J., dissenting).
159. Fisons Ltd. v. UAD Labs., Inc., 219 U.S.P.Q. (BNA) 661 (T.T.A.B. 1983), 1983 WL
50164, at *1–2 (sustaining opposition against ENDAL, a “pharmaceutical for coughs; post-nasal
drip of chronic sinusitis, bronchitis; upper respiratory infections; chronic rhinitis; allergic rhinitis;
[and] asthma,” as confusingly similar to INTAL, a pharmaceutical for asthma, on the grounds that
a prescribing mistake might cause consumers to use the wrong medication despite their different
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2000s,161 and even the 2010s,162 a number of courts reached similar
results for similar reasons.163 Often they cited for support one or more of
the decisions mentioned above.164 A few decisions, however, are worth
noting for their discussion of confusion and harm.165 One is Syntex
Laboratories, Inc. v. Norwich Pharmacal Co.,166 where, in 1971, the U.S.
Court of Appeals for the Second Circuit followed Morgenstern.167 In this
methods of administration (quoting U.S. Trademark Application Serial No. 200,274 (filed Jan.
16, 1979))); Merck & Co., Inc. v. Abbott Labs., 210 U.S.P.Q. (BNA) 605 (T.T.A.B. 1981), 1981
WL 40432, at *1, *4 (sustaining opposition of A-HYDROCORT “as a trademark for an antiinflammatory product” as confusingly similar to HYDROCORTONE, which was “previously
used and registered by opposer for a hormonal substance of use in the treatment of collagen,
allergic and other diseases”); see also Littelfuse, Inc. v. Parker-Hannifin Corp., 230 U.S.P.Q.
(BNA) 654, No. 85 C 7490, 1986 WL 13640, at *10 (N.D. Ill. May 19, 1986) (citing Syntex for
support to enjoin the defendant from using the plaintiff’s trademark on low-quality fuses that pose
a safety risk); In re Istituto Sieroterapico E Vaccinogeno Toscano “SCLAVO” SpA, 226 U.S.P.Q.
(BNA) 1035 (T.T.A.B. 1985), 1985 WL 72097, at *2 (declining to apply a “higher standard of
care” in the medical equipment context because there was “no possibility of confusion of the
products in their use” (emphasis added)).
160. E.g., Genderm Corp. v. Biozone Labs., No. 92 C 2533, 1992 WL 220638, at *16–17
(N.D. Ill. Sept. 3, 1992); see also Blansett Pharmacal Co. v. Carmrick Labs. Inc., 25 U.S.P.Q.2d
(BNA) 1473 (T.T.A.B. 1992), 1992 WL 430462, at *1, *4–5 (sustaining cancellation of NOLEX
on grounds of confusing similarity to NALEX).
161. See, e.g., Kos Pharm., Inc. v. Andrx Corp., 369 F.3d 700, 716 (3d Cir. 2004) (noting
that medical expertise is not likely to mitigate confusion); Sanofi-Aventis v. Advancis Pharm.
Corp., 453 F. Supp. 2d 834, 851 (D. Del. 2006) (finding the doctrine “somewhat applicable” to
“house marks” and noting that “the sophistication of doctors and nurses may be outweighed by
the need for heightened care when it comes to protecting patients”); Alfacell Corp. v. Anticancer,
Inc., 71 U.S.P.Q.2d (BNA) 1301 (T.T.A.B. 2004), 2004 WL 1631116, at *4–6 (granting the
petition to cancel ONCONASE, for cancer-treating drugs, on grounds of confusing similarity to
ONCASE, for the same class of drugs, and noting that even if the products are sold to pharmacies
and hospitals, patients might experience confusion in use and there had been cases of drug mixups where the drugs had similar names); see also VisionQuest Indus., Inc. v. SurgiTech, Inc.,
2008 WL 4233881, at *4, *8 (T.T.A.B. 2008) (declining to find infringement, but noting that
where cases “involv[e] medical products, greater care should be taken in the use and registration
of trademarks to assure that no harmful confusion results” because “it is proper to require a lesser
quantum of proof than for nonmedical products”).
162. In re Alvogen IP Co. S.a.r.l., 2012 WL 423816, at *1–3 (T.T.A.B. 2012) (refusing to
register a design).
163. The doctrine is still applicable in the context of “pharmaceuticals or medicinal products
for human use.” U.S. PATENT & TRADEMARK OFFICE, supra note 7, § 1207.01(d)(xii).
164. See, e.g., Clifton v. Plough, Inc., 341 F.2d 934, 936 (C.C.P.A. 1965) (holding that
NUMOL for mineral oil was confusingly similar to NUJOL (the plaintiff’s mark) for over-thecounter medications despite the disparate uses).
165. Here, confusion refers to confusion in both the infringement and registration contexts.
166. 437 F.2d 566 (2d Cir. 1971).
167. Id. at 568–69 (“Moreover, the cases cited by [the defendant] never dealt with the
problem raised here, for the only relevant confusion there was source-of-origin confusion among
purchasers. Hence their statements about what is the ‘keystone’ of a trademark infringement
action can be seen as focusing on the fact of likelihood of confusion, not on the fact that the
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case, there was some risk that a consumer might apply VAGESTROL
(the defendant’s mark), a form of estrogen used to treat atrophic vaginitis,
instead of VAGITROL (the plaintiff’s mark), a cream to treat vaginal
infections.168 Just like in Strasenburgh and Morgenstern, the consumer
in Syntex was not confused at all.169 When she arrived home, she applied
the product that was prescribed.170 The mistake occurred among
intermediaries, likely by the physician who prescribed the product.171
And this mistake, the court found, was perfectly acceptable to the
confusion analysis.172 Part of the reason it found no difficulty in doing so
was because the Lanham Act had been amended in 1962 to eliminate the
requirement that confusion must occur among “purchasers as to the
source of origin of . . . goods or services.”173 Without this limiting
language, the court had little trouble finding that what it called product
confusion—as opposed to consumer confusion as to source of origin—
was actionable under the Lanham Act.174
So it was with many cases moving forward. The amendment to the
Lanham Act allowed courts to find actionable confusion in a variety of
confusion went to source of origin. In a case such as the one at bar, where product confusion could
have dire effects on public health, looking to such confusion, in addition to source-of-origin
confusion, in determining whether there has been trademark infringement, is entirely in accord
with public policy, as well as with the Lanham Act.” (footnote omitted)).
168. Id. at 568 n.1.
169. See Syntex Labs., Inc. v. Norwich Phamacal Co., 315 F. Supp. 45, 49 (S.D.N.Y. 1970).
170. See id.
171. Id.
172. Id. at 568.
173. Id. at 568 (emphasis added) (quoting 15 U.S.C. § 1114(1)(a) (1958)).
174. Id. (“Judge Mansfield did look primarily to product confusion among physicians and
pharmacists, rather than to source-of-origin confusion among purchasers. But contrary to
Norwich’s assertions, that standard is quite correct. Although Norwich cites several cases for the
proposition that confusion among purchasers as to source of origin is the ‘keystone’ of a trademark
infringement action under the Lanham Act, the Act itself does not contain such a limitation.”
(citations omitted)). Most courts interpreted the 1962 amendment as opening the door to new
kinds of actionable confusion, such as post-sale and initial interest confusion. See, e.g.,
Checkpoint Sys., Inc. v. Check Point Software Techs., Inc., 269 F.3d 270, 295 (3d Cir. 2001)
(holding initial interest confusion actionable because “Congress recognized the relevance of initial
interest confusion and its effect on a company’s goodwill when it amended the Lanham Act in
1962”); Ferrari SPA Esercizio v. Roberts, 944 F.2d 1235, 1244–45 (6th Cir. 1991) (holding postsale confusion actionable because, “[s]ince Congress intended to protect the reputation of the
manufacturer as well as to protect purchasers, the Act’s protection is not limited to confusion at
the point of sale” but erroneously pegging the amendment year as 1967 and not 1962); J.G.
Wentworth, SSC v. Settlement Funding, LLC, No. 06-0597, 2007 WL 30115, at *7 (E.D. Pa. Jan.
4, 2007) (noting that, “[e]ssentially, initial interest protection has extended the Lanham Act’s
applicability to pre-sale confusion as well as post-sale confusion” as a result of the 1962
amendment); see also 1 MCCARTHY, supra note 1, § 5:6 (“This [1962 amendment] has been
viewed as expanding the range of actions that can constitute infringement of a trademark by not
limiting it to confusion of purchasers and not limiting it to confusion as to the source of goods.”).
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cases that would otherwise have been difficult to justify under the original
statute. Many, however, have criticized the expansion of actionable
confusion that accompanied this development.175
Yet this freedom to look at other types of confusion also meant courts
could look to confusion after the sale of a product. Although so-called
post-sale confusion developed mainly to protect luxury brands,176 there
are at least two examples where courts used this kind of confusion to
prevent physical harm.177 One occurred in American Home Products
Corp. v. USV Pharmaceutical Corp.,178 where the applicant applied for
the mark PRESAMINE as to prescription antidepressants.179 The opposer
had a registered mark, PREMARIN, for the “treatment of ovarian
deficiencies and for pharmaceutical preparations containing
estrogens.”180 The Trademark Trial and Appeal Board (TTAB) voiced the
concerns that by this time had become standard: harm from taking one
medication when the other was prescribed and taking a medication that
was contraindicated for a certain population.181 There was, however, a
different risk—a risk of post-sale confusion.182 Patients, after all, might
have “both products . . . . placed side-by-side in [their] . . . medicine
cabinet[s].”183 Confusion here might cause patients to take one
medication instead of the other or to take them at different dosages,
perhaps on a consistent basis. Although the TTAB did not address these
latter concerns, it was particularly worried that “accidental substitution
of one product for the other could have potentially harmful effects on a
patient.”184
The nature and form of “post-sale” confusion in American Home
Products is different from the post-sale confusion courts have recognized
175. See supra note 84 and accompanying text.
176. See Sheff, supra note 14, at 790–93.
177. Am. Home Prods. Corp. v. USV Pharm. Corp., 190 U.S.P.Q. (BNA) 357 (T.T.A.B.
1976), 1976 WL 20937, at *3–4; see also Byk-Gulden, Inc. v. Trimen Labs., Inc., 211 U.S.P.Q.
(BNA) 364 (T.T.A.B. 1981), 1981 WL 40488, at *7–9 (Kera, Member, concurring in part and
dissenting in part) (dissenting from the opposition dismissal and arguing that the relevant
confusion would occur at home, after the consumer had purchased VIOPAN-T (pharmaceutical
high-potency vitamins) or RIOPAN (an antacid)).
178. 190 U.S.P.Q. (BNA) 357 (T.T.A.B. 1976), 1976 WL 20937.
179. Id. at *2.
180. Id. at *1 (footnote omitted).
181. See id. at *3. The PRESAMINE antidepressant, for example, was contraindicated in
patients with “cardiovascular ailments.” Id.
182. This kind of post-sale confusion is not the kind that courts regularly recognize. In
traditional post-sale confusion, it is not the consumer of the purchased product who is confused.
See Sheff, supra note 14, at 772–73.
183. Am. Home Prods., 1976 WL 20937, at *3.
184. Id.

https://scholarship.law.ufl.edu/flr/vol72/iss5/5

34

Simon: Trademark Law & Consumer Safety

2020]

TRADEMARK LAW & CONSUMER SAFETY

707

repeatedly.185 Here the rationale for invoking a form of post-sale
confusion related to public safety.186 Confusion after the sale may present
a risk to the purchaser of the product. Modern post-sale confusion
doctrine, by contrast, seeks to prevent consumers from misrepresenting
their ability to buy prestige goods and, hence, status.187 Even potential
purchasers need not be confused. Although the focus on physical harm
distinguishes American Home Products from modern post-sale
confusion, physical harm also links American Home Products to the other
cases discussed in this Section. As we saw, courts used the public safety
rationale to help justify decisions of trademark infringement. Sometimes
this meant finding liability or sometimes refusing registration. American
Home Products was one example of this.
Despite many courts’ willingness to use trademark law to protect
consumers, not all did so.188 Developments at the FDA support some
recent court decisions rejecting the rationales proffered in cases like
Morgenstern. The next Section explains why.
C. Pushback to the Doctrine of Greater Care
Cases where confusingly similar trademarks presented a risk of
physical harm have not been decided all in one direction. A handful of
courts have been skeptical of the so-called Doctrine of Greater Care.
Sometimes it was because the facts allowed courts to find confusion
without assessing the risk of physical harm.189 Other times it was because
185. See Mastercrafters Clock & Radio Co. v. Vacheron & Constantin-LeCoultre Watches,
Inc., 221 F.2d 464, 466–67 (2d Cir. 1955).
186. Am. Home Prods., 1976 WL 20937, at *3–4.
187. Mastercrafters, 221 F.2d at 466–67; see Sheff, supra note 14, at 790–94 (discussing
“status confusion,” which is a concern about free riding on the luxury status of the mark). Sheff
identifies other forms of post-sale confusion, some of which are more defensible than others. But
he assesses the persuasiveness of each in reference to economic justifications of trademark law.
Indeed, the two harms Sheff identifies from traditional post-sale confusion are (1) harm to the
customer when the scarcity of luxury goods is called into question and (2) confusion of the public
about who holds the status in virtue of the scarce goods. Sheff, supra note 14, at 792.
188. Callmann is only partially correct when he concludes that the so-called Doctrine of
Greater Care has been extended to health-related services. See CALLMANN, supra note 1, § 21:5.
In one of the cases he cites, the court did not apply a lower standard of confusion; it applied a
higher standard because of the purported sophistication of the consumers. Id. § 21:5 n.29.
Callmann is correct that the doctrine has been extended to other product areas. E.g., Medtronic,
Inc. v. Med. Devices, Inc., 204 U.S.P.Q. (BNA) 317 (T.T.A.B. 1979), 1979 WL 24889, at *9
(noting that “de minimis” harm should be avoided even in the case of medical devices).
189. Sterling Drug Inc. v. Lincoln Labs., Inc., 322 F.2d 968, 971, 973 (7th Cir. 1963) (finding
DYPRIN confusingly similar to DIAPRARENE for products used to treat diaper rash because the
products had the same ingredients, were used by the same purchasers, and were marketed to the
same classes of purchasers (including doctors), and not finding it necessary to discount consumer
sophistication to hold that doctors might think both products bearing different marks emanated
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of a different risk tolerance.190 In American Cyanamid Corp. v.
Connaught Laboratories,191 for example, the Second Circuit was asked
to determine whether HIB-IMUNE (the plaintiff’s mark) and HibVAX
(the defendant’s mark) were confusingly similar as applied to chemically
identical influenza vaccines.192 Although chemically identical, the
administration of each was different, though both required mixing active
ingredients.193 Because mistakes—failed inoculation—could be made
only through “spectacular incompetence,” the risk was not worth
worrying about.194 Other courts have reached the same conclusion.195
While some courts have sidestepped the issue of physical harm, others
have rejected it outright. In 1960, the CCPA expressed reservations about
the doctrine precisely for the reasons it later embraced a different version
of it: the drugs at issue were marketed “entirely to physicians and

from the same source); Carter Prods., Inc. v. Fleetwood Co., Inc., No. 61 C 156, 1963 WL 8053,
at *1, *4 (N.D. Ill. Jan. 3, 1963) (finding that WALLACE SUPER DIETARY MEALZ for a
dietary food supplement was not an infringement of WALLACE for prescription drugs, including
“tranquilizers, anti-depressants, appetite suppressants, and estrogens”), aff’d, 333 F.2d 464 (7th
Cir. 1964).
190. See, e.g., Eli Lilly & Co. v. Nat. Answers, Inc., 233 F.3d 456, 464, 466 (7th Cir. 2000)
(noting that there was no real risk that consumers would take HERBROZAC thinking it was
PROZAC® but stating that this did not address consumers’ potential to think the plaintiff
sponsored or endorsed the defendant’s product and that this was sufficient to affirm the district
court’s grant of a preliminary injunction); Am. Cyanamid Corp. v. Connaught Labs., Inc., 800
F.2d 306, 310 (2d Cir. 1986) (finding that a mix-up in administering a flu vaccine would require
“spectacular incompetence”); Reedco, Inc. v. Hoffman-La Roche, Inc., 667 F. Supp. 1072, 1079
(D.N.J. 1987) (finding only a “remote possibility of confusion” for two different prescription
medications, TEGRIN (the plaintiff’s mark for a topical medication for psoriasis) and TEGISON
(the defendant’s mark for an oral medication to treat extreme cases of psoriasis), one of which
had very serious side effects only in very limited circumstances that the court contrived, and that
no one would confuse the drugs); Schering Corp. v. Thompson Med. Co., 209 U.S.P.Q (BNA)
72, No. 76 Civ 3417, 1979 WL 24976, at *1, *5, *6 (S.D.N.Y. May 14, 1979) (denying an
injunction and entering judgement for the defendant) (finding that “the likelihood of” a consumer
purchasing the defendant’s over-the-counter product instead of the plaintiff’s prescription drug
“is, in this court’s view, exceedingly remote” even though the possibility existed and the drugs
produced opposite effects and were contraindicated in certain patients, which ordinarily would
“suggest . . . that under Syntex and Morgenstern, an injunction should issue”).
191. 800 F.2d 306 (2d Cir. 1986).
192. Id. at 307.
193. Id.
194. See id. at 310 (“Such a mix-up could occur, however, only through the spectacular
incompetence of the physician or nurse who administered the injection. Even a marginally
incompetent medical professional would not combine the contents of two bottles bearing different
colored labels and different brand names solely because one bottle carried the trademark HibVAX
and the other the trademark HIB-IMUNE.”).
195. Nat. Answers, Inc., 233 F.3d at 463–65 (rejecting the district court’s conclusion that
there was a real possibility of initial interest confusion).
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pharmacists—a highly intelligent and discriminating public.”196 Though,
it should be noted, that same reason was only partially influential to the
CCPA years later in 1975.197 Even in the Third Circuit (which decided
Morgenstern), at least one district court has rejected the Doctrine of
Greater Care because, among other reasons, “[t]here is no basis in the
Lanham Act to draw any distinction in the substantive standard based on
the nature of the products at issue.”198 This is, however, simply false,199
both as a matter of historical record and doctrine.200
The hostility to the doctrine is not always, as one court attempted to
suggest, because Morgenstern had distinguishing features that current
disputes lack.201 It was not, in other words, simply because Morgenstern
involved a common law claim and subsequent cases involved federal
trademark infringement actions. Nor was it because a previous district
court had found Morgenstern bad law.202 What drove the changes were
regulatory developments at the FDA.
Prior to 2007, the FDA had no formal policy or practice with respect
to the proprietary naming of pharmaceuticals (what I will call Rx marks)
196. Warner-Hudnut, Inc. v. Wander Co., 280 F.2d 435, 436 (C.C.P.A. 1960); see id. at 435–
36 (finding that the defendant’s mark WANDER, which appeared on a medication for
tuberculosis, and the plaintiff’s mark WARNER, which appeared on a “wide range of
pharmaceuticals,” were different because the latter is a surname and the former is a verb and
because, curiously, “they do not sound alike”).
197. See Pennwalt Corp. v. Ctr. Labs., Inc., 524 F.2d 235, 236–37 (C.C.P.A. 1975) (noting
that physicians were also consumers of the products at issue and avoiding confusion in this context
was more important than any supposed sophistication of physicians). But see id. at 237 (Miller,
J., dissenting) (noting that the “professional training and experience” of medical doctors would
make confusion less likely, rather than more likely).
198. Pharmacia Corp. v. Alcon Labs., Inc., 201 F. Supp. 2d 335, 371 (D.N.J. 2002); see also
id. at 340, 371, 386 (denying a preliminary injunction) (finding that the plaintiff was unlikely to
succeed on the merits (post-eBay) as to confusing similarity (and dilution) between its mark,
XALATAN, and the defendant’s mark, TRAVATAN, for medications to treat glaucoma)
(rejecting Morgenstern by claiming that there was precedent for doing so and that Morgenstern
was a common law unfair competition claim, rather than a federal trademark action).
199. One district court in the Third Circuit reached the opposite conclusion a few years later.
See Sanofi-Aventis v. Advancis Pharm. Corp., 453 F. Supp. 2d 834, 851 (D. Del. 2006).
200. In reality, the standard is the same for state and federal trademark claims. MCCARTHY,
supra note 1, § 23:1.50. Morgenstern concerned a state, common law trademark claim.
Morgenstern Chem. Co. v. G.D. Searle & Co., 253 F.2d 390, 394 (3d Cir. 1958).
201. See Pharmacia Corp., 201 F. Supp. 2d at 371 (arguing that Morgenstern was decided
on state unfair competition grounds, which distinguished it from the present federal trademark
infringement action).
202. Interestingly, the Reedco court noted that the risk posed in Morgenstern did not arise in
the instant case. Reedco, Inc. v. Hoffman-La Roche, Inc., 667 F. Supp. 1072, 1080 (D.N.J. 1987)
(criticizing Morgenstern and noting how the Third Circuit has refused to subsequently apply the
test laid out in Morgenstern). “The only harm at stake,” the court wrote, “is the remote possibility
that plaintiffs will suffer typical trademark-infringement harms, such as lost sales.” Id.
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it approved for use and sale.203 The topic of confusion of Rx marks
resulting in medication errors, however, was not new.204 Partly in
response to the early concerns about confusion with pharmaceuticals,205
in 1963 the FDA promulgated rules governing the advertisement and
labeling of prescription and over-the-counter drugs.206 But those rules
203. See FOOD & DRUG ADMIN., U.S. DEP’T OF HEALTH & HUMAN SERVS., GUIDANCE FOR
INDUSTRY: BEST PRACTICES IN DEVELOPING PROPRIETARY NAMES FOR DRUGS 3 (2014),
https://www.fda.gov/files/drugs/published/Best-Practices-in-Developing-Proprietary-Names-for
-Drugs.pdf [https://perma.cc/NL94-UYN8]. As discussed below, the FDA did regulate the
labeling and advertisement of a drug. Some of its more recent policy guidance is based on parts
of regulations promulgated in 1963 and updated several times, significantly in 1975. See 21 C.F.R.
§ 201.10(c)(3) (2019) (stating that drug labeling may be misleading when “[t]he employment of
a fanciful proprietary name for a drug or ingredient in such a manner as to imply that the drug or
ingredient has some unique effectiveness or composition when, in fact, the drug or ingredient is a
common substance, the limitations of which are readily recognized when the drug or ingredient
is listed by its established name”); id. § 201.10(c)(5) (stating that drug labeling may be misleading
when a trademark is confusingly similar to an existing Rx mark or the established name of a
different drug or ingredient); id. § 201.10(g) (providing requirements that the established name of
any drug or ingredient be displayed alongside the trademark); id. § 202.1(a)(3) (“The
advertisement shall not employ a fanciful proprietary name for the drug or any ingredient in such
a manner as to imply that the drug or ingredient has some unique effectiveness or composition,
when, in fact, the drug or ingredient is a common substance, the limitations of which are readily
recognized when the drug or ingredient is listed by its established name.”); id. § 201.6(b) (“The
labeling of a drug which contains two or more ingredients may be misleading by reason, among
other reasons, of the designation of such drug in such labeling by a name which includes or
suggests the name of one or more but not all such ingredients, even though the names of all such
ingredients are stated elsewhere in the labeling.”); id. § 202.1(a)(5) (prohibiting the use of
confusingly similar Rx marks or ingredients).
204. See Benjamin Teplitsky, Confusing Names of Drugs, 207 JAMA 2440 (1969)
(describing ten examples of confusion of Rx marks resulting in medication errors and suggesting
that there may be hundreds of additional instances).
205. The first comprehensive drug labeling legislation was passed as part of the Federal Food
and Drugs Act of 1906, Ch. 3915, 34 Stat. 768, repealed by Federal Food, Drug, and Cosmetic
Act, ch. 675, 52 Stat. 1040 (1938). The concerns over drug labeling were not new, but increasing
attention was paid to drug names as drugs became more ubiquitous.
206. Congress amended the Federal Food, Drug, and Cosmetic Act in 1962, transferring drug
regulation to the FDA in 1962. See Drug Amendments of 1962, Pub. L. No. 87-781, 76 Stat. 780.
The FDA promulgated its first regulations the following year. See Regulations for the
Enforcement of the Federal Food, Drug, and Cosmetic Act, 28 Fed. Reg. 6375 (June 20, 1963).
This provision of the Code of Federal Regulations has been updated on many occasions since that
amendment. See supra note 203 and accompanying text. The FDA derives its authority to regulate
drugs from various subsections of Title 21 and Title 42 of the U.S. Code. See 21 U.S.C. §§ 321,
331, 351, 352, 353, 355, 358, 360, 360b, 360hh–360pp, 360rr, 360ss, 371, 374, 379e (2018); 42
U.S.C. §§ 216, 241, 262, 264 (2012). Labeling regulations are promulgated in 21 C.F.R. §§ 201.1–
.328 (2019). The labeling and naming of drugs specifically has been regulated in a more limited
fashion. See 21 U.S.C. § 352(a) (prohibiting false or misleading labels, requiring a specific form
and contents of the label, and designating certain uses of the drug name). These regulations were
promulgated in concert with the expansion of the FDA’s authority in the Drug Amendments of
1962. Wallace F. Janssen, The U.S. Food and Drug Law: How It Came; How It Works, 35 FOOD
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remained largely unchanged until 2002,207 when the FDA promulgated
rules to implement portions of the Food and Drug Administration
Modernization Act of 1997.208 These changes came only a few years after
the FDA began allowing DTC advertising in 1999.209 And as consumers
became more familiar with drugs as a result of DTC advertising, the FDA
became increasingly aware of the role trademarks might play in confusing
not only consumers but also doctors, pharmacists, nurses, and other
medical providers. In 2003, one year after updating its regulations on
advertising and labeling, the FDA held two meetings to discuss the issue
of Rx marks.210 Neither meeting resulted in further FDA action until after
2007,211 which is the year Congress reauthorized and expanded the
Prescription Drug User Fee Amendments of 2007 (PDUFA IV).212 In
updating the legislation, Congress expanded the power and scope of the
FDA’s authority.213 The FDA used its new revenue stream, in part, “to
reduce medication errors related to look-alike and sound-alike
proprietary names”—i.e., trademarks in both prescription and over-thecounter drugs.214
Spending money, as it turns out, takes time. In 2008, the FDA issued
a concept paper that proposed a voluntary pilot program to reduce
medication errors, which included a process for reviewing Rx marks
submitted by drug companies.215 The proposal was comprehensive and
focused on all “components and processes” of the system in which
DRUG COSM. L.J. 132, 137 (1980).
207. Amendment of Regulations Regarding Certain Label Statements on Prescription Drugs,
46 Fed. Reg. 4904–4907 (Feb. 1, 2002).
208. FDA Modernization Act of 1997, Pub. L. No. 105-115, 111 Stat. 2296 (1997).
209. See FOOD & DRUG ADMIN., U.S. DEP’T OF HEALTH & HUMAN SERVS., GUIDANCE FOR
INDUSTRY: CONSUMER-DIRECTED BROADCAST ADVERTISEMENTS 1–2 (1999), https://www.fda
.gov/media/75406/download [https://perma.cc/8N5V-2MV3]; Tamar V. Terzian, Note, Direct-toConsumer Prescription Drug Advertising, 25 AM. J.L. & MED. 149, 150 (1999).
210. FOOD & DRUG ADMIN., U.S. DEP’T OF HEALTH & HUMAN SERVS., PDUFA PILOT
PROJECT: PROPRIETARY NAME REVIEW 4–5 (2008). One meeting was public with stakeholders and
the other only with members of the Drug Safety and Risk Management Advisory Committee. Id.
211. See id. at 6–32 (explaining the PDUFA Pilot Project started by the FDA).
212. Pub. L. No. 110-85, 121 Stat. 825 (2007) (codified as amended in scattered sections of
21 U.S.C. (2018)).
213. See id.; see also FOOD & DRUG ADMIN., U.S. DEP’T OF HEALTH & HUMAN SERVS., supra
note 210, at 1 (“[PDUFA IV] significantly broadens and strengthens the Food and Drug
Administration’s (FDA) drug safety program, facilitating more efficient development of safe and
effective new medications for the American public.”).
214. FOOD & DRUG ADMIN., U.S. DEP’T OF HEALTH & HUMAN SERVS., CONTENTS OF A
COMPLETE SUBMISSION FOR THE EVALUATION OF PROPRIETARY NAMES: GUIDANCE FOR INDUSTRY
2 (2016).
215. FOOD & DRUG ADMIN., U.S. DEP’T OF HEALTH & HUMAN SERVS., supra note 214, at 6–
32; see also id. at 24–25 (explaining the process for over-the-counter drugs’ marks).
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medications were advertised, purchased, prescribed, etc.216 Although the
FDA’s process included extensive review and evaluation, the applicant
bore the burden of determining whether an applied-for name would likely
result in medication errors.217 The FDA would simply review and, where
appropriate, conduct its own studies of the proposed name.218 Over the
next eight years, the FDA issued two critical, nonbinding guidance
papers, one in 2013219 and the other in 2016.220 After nearly a decade of
running the pilot program, the FDA reaffirmed most of the advice
previously provided in its 2008 concept paper, with additional nuances
about the name-approval process.221
Greater oversight of Rx marks by the FDA, for some courts, reduced
the imperative underlying trademark law’s Doctrine of Greater Care. If
the FDA is tasked with preventing medication errors, there is less need
for trademark law to police the same risk. The FDA, after all, has greater
institutional competence and resources to evaluate the risk of confusingly
similar drug names. Given the FDA’s more prominent role, one could
easily conclude, as have some courts, that trademark law no longer needs
the Doctrine of Greater Care or should defer to the FDA’s expertise.222
This conclusion is a mistake. It supposes that the rationale for the
doctrine is context specific. When the context is no longer present, the
thought goes, so is the need for the doctrine. Although the context in
which this concern for physical harm may be less likely to occur, it does
not follow that the rationale for the doctrine is irrelevant or cannot be
applied in other contexts.223 Indeed, there are other contexts where
concern for physical harm is the appropriate domain of trademark law.
By extending this rationale to the doctrine of deceptive marks, trademark
law could enhance public safety and keep advertisers a little more honest.
Id. at 5.
See id. at 30.
See id.
See generally FOOD & DRUG ADMIN., U.S. DEP’T OF HEALTH & HUMAN SERVS.,
GUIDANCE FOR INDUSTRY: PRODUCT NAME PLACEMENT, SIZE, AND PROMINENCE IN ADVERTISING
AND PROMOTIONAL LABELING (2013) (providing a draft guide for Rx marks).
220. See generally FOOD & DRUG ADMIN., U.S. DEP’T OF HEALTH & HUMAN SERVS., supra
note 214 (providing a draft guide for Rx marks).
221. See generally id. (providing guidance on the name-approval process for Rx marks).
222. Similar deference occurs in the false advertising context. See, e.g., Apotex Inc. v.
Acorda Therapeutics, Inc., 823 F.3d 51, 64 (2d Cir. 2016) (finding that the FDA deserves
deference in its decisions to approve drug labeling and “hold[ing] that representations
commensurate with information in an FDA label generally cannot form the basis for Lanham Act
liability”).
223. There may be cases where this policy does not adequately police this risk. Because the
policy’s standard differs from the PTO’s likelihood of confusion test, it is possible that the FDA
approves an Rx mark but the mark is still confusingly similar to an existing mark—and a court
might want to make that finding on the basis of the risk of public harm.
216.
217.
218.
219.
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II. DECEPTION AND DESCRIPTION IN TRADEMARK LAW
The Doctrine of Greater Care is not trademark law’s only protective
mechanism; trademark law has other doctrinal means for preventing
economic harm. When, for example, marks mislead the public about the
characteristics of the good or service on which the mark is affixed,
trademark law either refuses—or imposes additional requirements to
gain—federal registration.224 The main justification for this
“deceptiveness” rule is to prevent economic harm: the consumer either
will think that a product has certain features it does not or may purchase
the product as a result of thinking a product has certain features it does
not.
This Part suggests that the deceptive marks doctrine can, as part of a
larger framework, protect consumers from physical harm. The suggestion
builds on the analysis of Part I, which showed that trademark law has
concerned itself with public safety when the law both creates, and
provides the means for mitigating, the risk of physical harm. The same
rationale applies to deceptive marks that present a risk of physical harm.
But applying this rationale to the doctrine of deceptive marks reveals an
important deficiency of the doctrine itself: it does not apply to suggestive
marks. At the same time, trademark law encourages the use of suggestive
marks by rewarding them with instant trademark protection—and a
variety of legal goodies upon registration.225 This Part distinguishes
224. See infra Section II.A.
225. See 15 U.S.C. § 1065 (2018) (allowing for incontestability); id. § 1072 (providing for
constructive notice); id. § 1115 (providing for presumptive validity and exclusive right to use);
id. § 1117 (allowing for damages to include the defendant’s profits, costs of the action (including
attorneys’ fees), and the plaintiff’s damages); id. § 1118 (allowing for destruction of infringing
articles); id. § 1124 (allowing for injunction against importation of infringing articles); 28 U.S.C.
§ 1338(a) (2012) (allowing for federal jurisdiction with no amount-in-controversy requirement);
id. § 1338(b) (allowing for joinder of unfair competition claims to trademark actions); 3
MCCARTHY, supra note 1, § 19:9 (“For registrations resulting from applications filed after
November 16, 1989, the registrant is entitled to a ‘constructive use date,’ nationwide in effect, as
of the filing date of the application, except as to a defined class of persons.”). As McCarthy notes:
In addition, [registration] . . . has been read by the courts to include prima facie
evidence of the following important benefits: prima facie evidence of the
continual use of the mark from the date of filing of a use-based application on
which the registration is based[;] prima facie evidence that the mark is not
confusingly similar to other registered marks[;] prima facie evidence that the
mark is inherently distinctive[;] prima facie evidence that, if registered under §
2(f), the mark has acquired secondary meaning[;] prima facie evidence that the
mark has been used in interstate commerce prior to registration[;] prima facie
evidence that the registrant is the owner of the mark[;] prima facie evidence that
the mark is not a generic name[;] prima facie evidence that the mark is not invalid
as a functional design.
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between three types of deceptive marks—explicit, implicit, and latent.226
It shows that each type of mark poses a different level of risk to
consumers. Each level of risk can be factored into the deception analysis.
Here trademark law sets itself up for failure in precisely the way the
Doctrine of Greater Care was designed to address. A feature of trademark
law (protection of suggestive marks) leads, in some cases, to marks that
pose a risk of physical harm to the consumer (e.g., healthcare and dietary
supplements). When trademark law principles conflict with consumer
safety, consumer safety should win out. To accomplish this, we need to
adjust the test for deception the same way courts and the PTO altered the
test for likelihood of confusion. In particular, this Part suggests that the
law should evaluate the risk posed by the product category and use this
evaluation to assess the deceptiveness inquiry. When the risk is high,
courts should make two adjustments. First, courts should be more flexible
in what counts as “misdescription” (Section II.B). Suggestive and
potentially even fanciful marks should, in some cases, be found to be
“misdescriptive.” Second, courts should lower the materiality
requirement when products pose a high risk to the public (Section II.C).
These changes alone, however, will only bar registration of deceptive
marks. Producers might still be able to use those marks as trademarks
protected by common law.227 To prevent this, the law should also bar
from protection deceptive marks. This change, unlike those suggested for
the deceptiveness standard, has already been hinted at—if not outright
endorsed—by courts. In cases dating back to the 1900s, courts have held
that a plaintiff with “unclean hands” is barred from asserting trademark
claims in certain circumstances.228 At common law, trademark owners
could dirty their hands by deceiving the public, either in advertising or in
the use of the mark itself.229 Modern courts have suggested that this
equitable bar to protection should extend to deceptive marks.230 I agree.
3 MCCARTHY, supra note 1, § 19:9.
226. I thank Richard Levy for helping me to articulate this point.
227. See 2 MCCARTHY, supra note 1, § 16:1 (“At common law, ownership of trademark or
trade dress rights in the United States is obtained by actual use of a symbol to identify the goods
or services of one seller and distinguish them from those offered by others.”).
228. Worthington v. Anderson, 386 F.3d 1314, 1320 (10th Cir. 2004) (“Historically, courts
have recognized two types of ‘related conduct’ that will permit application of the unclean hands
doctrine in a trademark case.”).
229. Worden v. Cal. Fig Syrup Co., 187 U.S. 516, 528–33 (1903) (reviewing common law
cases).
230. See, e.g., Healthpoint, Ltd. v. Ethex Corp., 273 F. Supp. 2d 817, 848 (W.D. Tex. 2001)
(“Equity denies relief ‘where the plaintiff is misrepresenting to the public the nature of his product
either by the trademark itself or by his label.’ Unclean hands is a defense to a Lanham Act claims
[sic] such as trademark infringement and unfair competition.” (footnote omitted) (quoting Morton
Salt Co. v. G.S. Suppiger Co., 314 U.S. 488, 494 (1942), abrogated by Ill. Tool Works, Inc. v.
Indep. Ink, Inc., 547 U.S. 28 (2006))).
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And Section II.D articulates why. Before doing this, however, Section
II.A briefly explains what deceptive marks are.
A. Deceptive Marks
When a producer uses a trademark that purports to describe some
feature of a good, trademark law tries to keep him honest. A consumer
may think, for example, that the mark describes a product feature or
quality it does not in fact have. If that occurs, the Lanham Act treats the
mark as “deceptively misdescriptive.”231 Importantly, the misdescription
cannot be material to the consumer’s decision to purchase the product.232
If it is not, these marks are disfavored but allowable in some cases:
Section 2(e)(1) of the Lanham Act bars deceptively misdescriptive marks
from registration233 unless the mark owner can demonstrate the mark has
acquired secondary meaning.234 An arbitrary mark that describes a good
or service different from the one to which it applies, for example, is
misdescriptive. But if consumers are unlikely to believe the
misdescription, it will not be deceptively misdescriptive. RADIO
FREQUENCY MACHINE applied to a panini maker, for example,
would be both arbitrary and misdescriptive. It would not, however, be
deceptively misdescriptive because consumers are unlikely to think that
a panini maker uses radio frequencies. The same mark as applied to an
ultrasound machine, by contrast, may be deceptively misdescriptive but
could be registered as a trademark upon a showing of secondary meaning
if consumers did not purchase the product because they thought it
produced radio frequency—in other words, the misdescription was not
material.235 Deceptively misdescriptive marks therefore have an odd
231. 15 U.S.C. § 1052(e) (allowing for the refusal of a trademark where it “[c]onsists of a
mark which . . . when used on or in connection with the goods of the applicant is merely
descriptive or deceptively misdescriptive of them”).
232. U.S. PATENT & TRADEMARK OFFICE, supra note 7, § 1209.04.
233. 15 U.S.C. § 1052(e). The mark may still be registerable on the supplemental register.
See id. § 1091.
234. U.S. PATENT & TRADEMARK OFFICE, supra note 7, § 1209.04 (“Marks that have been
refused registration pursuant to §2(e)(1) on the ground of deceptive misdescriptiveness may be
registrable under §2(f) upon a showing of acquired distinctiveness, or on the Supplemental
Register if appropriate.”).
235. The same is true for common law marks. With regards to these marks, the Restatement
states that:
A designation that is likely to be perceived by prospective purchasers as merely
descriptive of the nature, qualities, or other characteristics of the goods, services,
or business with which it is used, or as merely geographically descriptive of their
origin or location, or as the personal name of a person connected with the goods,
services, or business, is not inherently distinctive under the rule stated in § 13(a).
Such a designation is distinctive only if it has acquired secondary meaning under
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feature. To gain protection, the mark must mislead the public in a
nonmaterial way for a sufficient period of time.
When the mark’s deceptiveness influences purchasing decisions (i.e.,
when it is material), however, the mark is categorically barred from
registration under Section 2(a) of the Lanham Act as “deceptive.”236 Both
marks misdescribe, but only one affects a consumer’s decision to
purchase that good: deceptively misdescriptive marks do not; deceptive
marks do. The test for both kinds of marks starts with the same two
questions: “(1) Is the term misdescriptive of the character, quality,
function, composition or use of the goods? (2) If so, are prospective
purchasers likely to believe that the misdescription actually describes the
goods?”237
Affirmative answers to questions one and two render a mark
deceptively misdescriptive.238 To be deceptive, however, a third question
must be answered affirmatively239: “(3) If so, is the misdescription likely
to affect [a significant portion of the relevant consumers’] . . . decision to
purchase?”240
Called “materiality,” this last prong of the deceptiveness test is vital
because it “shows that the misdescription deceived the consumer.”241 The
burden to show these elements is on the PTO (or the opposer).242 Once it
satisfies them, the burden shifts to the applicant (registrant) to rebut
them.243
Deceptive marks come in variety. So long as they satisfy the threepart test, they may be a single term or part of a mark that includes
nondeceptive terms.244 They may include or be design elements of a
the rule stated in § 13(b).
RESTATEMENT (THIRD) OF UNFAIR COMPETITION § 14 (AM. LAW INST. 1995).
236. 15 U.S.C. § 1052(a) (barring any mark that “[c]onsists of or comprises . . . deceptive . .
. matter”), invalidated by Matal v. Tam, 137 S. Ct. 1744 (2017), and Iancu v. Brunetti, 139 S. Ct.
2294 (2019).
237. In re Budge Mfg. Co., 857 F.2d 773, 775 (Fed. Cir. 1988); U.S. PATENT & TRADEMARK
OFFICE, supra note 7, § 1203.02(b).
238. U.S. PATENT & TRADEMARK OFFICE, supra note 7, § 1203.02(c).
239. Id.
240. In re Budge, 857 F.2d at 775; U.S. PATENT & TRADEMARK OFFICE, supra note 7,
§ 1203.02(b). The standard in false advertising law is similar. See Cashmere & Camel Hair Mfrs.
Inst. v. Saks Fifth Ave., 284 F.3d 302, 313 (1st Cir. 2002) (“The next element of a false advertising
claim under the Lanham Act requires plaintiffs to demonstrate that the alleged misrepresentation
deceived a substantial portion of the consuming public.”).
241. In re Cal. Innovations, Inc., 329 F.3d 1334, 1337 (Fed. Cir. 2003).
242. In re Budge, 857 F.2d at 775.
243. Id. at 776.
244. U.S. PATENT & TRADEMARK OFFICE, supra note 7, § 1203.02(a) (“A deceptive mark
may be comprised of: (1) a single deceptive term; (2) a deceptive term embedded in a composite
mark that includes additional non-deceptive wording and/or design elements; (3) a term or a
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mark.245 Examples of marks typically trotted out as deceptive include
“LOVEE LAMB for ‘automobile seat covers’” not made from
lambskin,246 DURA-HYDE for shoe material not made from leather,247
WULIZED for material not made from wool,248 SILKEASE for women’s
clothing made from polyester,249 and SUPER SILK for clothing not made
from silk.250 There are, of course, examples in the other direction:
FAWNSKIN for clothing material made from a variety of different
fabrics,251 COPY CALF for nonleather “wallets and billfolds,”252 and
THE FIRST NAME IN FLOORCARE for vacuum cleaners253 all were
held not deceptively misdescriptive or deceptive under the Lanham Act.
The rationale for barring registration of deceptive marks (and
deceptively misdescriptive marks without secondary meaning) is simple:
consumers should not be misled about the character, quality, function,
composition, or use of the goods or services. Requiring marks to correctly
identify for consumers the products on which they appear, or even the
ingredients in the products, protects consumers from buying the wrong
product or buying a product believing it contains something it does not.
This is a form of consumer protection.254

portion of a term that alludes to a deceptive quality, characteristic, function, composition, or use;
(4) the phonetic equivalent of a deceptive term; or (5) the foreign equivalent of any of the above.”
(citations omitted)).
245. Id. (“Although there is no published Board or Federal Circuit decision regarding
whether a mark consisting solely of a design can be deceptive, if there is evidence to support such
a refusal, it should be issued.”).
246. In re Budge, 857 F.2d at 777 (quoting U.S. Trademark Application Serial No. 507,974
(filed Nov. 8, 1984)); U.S. PATENT & TRADEMARK OFFICE, supra note 7, § 1209.04.
247. R. Neumann & Co. v. Overseas Shipments, Inc., 326 F.2d 786, 787, 791 (C.C.P.A.
1964); see also id. at 789 (finding persuasive the FTC’s repeated condemnation of “trademarks
which include the term ‘hide’ or ‘hyde’ for nonleather products”).
248. Ex parte Puritan Piece Dye Works, 69 U.S.P.Q. (BNA) 257 (Comm’r Pat. &
Trademarks 1946), 1946 WL 2980, at *1.
249. In re Shapely, Inc., 231 U.S.P.Q. (BNA) 72 (T.T.A.B. 1986), 1986 WL 83693, at *1
(affirming the examiner’s refusal to register the mark as deceptive).
250. In re Phillips-Van Heusen Corp., 63 U.S.P.Q.2d (BNA) 1047 (T.T.A.B. 2002), 2002
WL 523343, at *1 (refusing registration based on Sections 2(a) and 2(e)(1) of the Lanham Act).
251. Steinberg Bros. v. J. P. Stevens & Co., 156 U.S.P.Q. (BNA) 574 (T.T.A.B. 1967), 1967
WL 7441, at *10 (finding the mark not deceptive or deceptively misdescriptive).
252. A. F. Gallun & Sons Corp. v. Aristocrat Leather Prods., Inc., 135 U.S.P.Q. (BNA) 459
(T.T.A.B. 1962), 1962 WL 8685, at *3 (finding the mark not deceptive or deceptively
misdescriptive).
253. Hoover Co. v. Royal Appliance Mfg. Co., 238 F.3d 1357, 1359, 1361 (Fed. Cir. 2001)
(affirming the TTAB’s dismissal of the opposition to the applicant’s mark).
254. It may also be competitive and moral, among other things.

Published by UF Law Scholarship Repository,

45

Florida Law Review, Vol. 72, Iss. 5 [], Art. 5

718

FLORIDA LAW REVIEW

[Vol. 72

B. Suggestive Marks as Deceptive
Some marks, of course, do not describe any aspect of the good or
service but instead suggest the good or service possesses some feature.
These marks, which by definition cannot be deceptive,255 are given
automatic protection as inherently distinctive.256 The same is true for
arbitrary and fanciful marks.257 Every producer appreciates instant
gratification; it therefore has an incentive to use anything but a
descriptive mark to increase its legal protection.
What is good for business, however, is not always good for
consumers. Suggestive marks, by their nature, do something descriptive
marks—if one can, for a moment, suspend judgment about the rigidity of
the categories—do not. They suggest all kinds of things about the product
without actually describing the product itself.258 At least that is the
thought. Differences between suggestive and descriptive marks,
however, are often a matter of perspective and degree.259 Although not
255. In re Phillips-Van Heusen Corp., 2002 WL 523343, at *5 (“[W]e observe that in order
for a term to misdescribe goods or services, the term must be merely descriptive, rather than
suggestive, of a significant aspect of the goods or services which the goods or services plausibly
possess but in fact do not.”); see Hako-Med USA, Inc. v. Axiom Worldwide, Inc., No.
8:06CV1790 T27EAJ, 2006 WL 3760416, at *1 (M.D. Fla. Dec. 19, 2006) (“The Court agrees
that the mark ‘VASOPULSE’ is suggestive rather than descriptive because it does not describe
what the machine actually does, nor is there evidence that the term ‘vasopulse’ is used by third
parties or that another seller would naturally use the term ‘vasopulse’ in marketing and selling an
electrotherapy machine.” (footnote omitted)); see also Hoover, 238 F.3d at 1361 (explaining that
“[a] mark may be ‘deceptively misdescriptive’ under § 2(e) if it misrepresents any fact concerning
the goods that may materially induce a purchaser’s decision to buy” and finding that the mark,
“The First Name in Floorcare,” does not do so (quoting 2 MCCARTHY, supra note 1, § 11:56)).
256. Two Pesos, Inc. v. Taco Cabana, Inc., 505 U.S. 763, 768 (1992) (stating that suggestive
marks are inherently distinctive and therefore require no showing of secondary meaning to gain
protection).
257. Id.
258. Jake Linford, The False Dichotomy Between Suggestive and Descriptive Trademarks,
76 OHIO ST. L.J. 1367, 1383 tbl.2 (2015).
259. 2 MCCARTHY, supra note 1, § 11:66 (“The descriptive-suggestive borderline is hardly
a clear one. Its exact location in any given situation is hazy and only subjectively definable. The
descriptive category almost imperceptibly shades over at its fringe into the suggestive domain.”);
see also Linford, supra note 258, at 1415 (arguing that the line between suggestive and descriptive
marks is difficult to draw). The PTO likes to think that “a suggestive term differs from a
descriptive term, which immediately tells something about the goods or services.” U.S. PATENT
& TRADEMARK OFFICE, supra note 7, § 1209.01(a). But even the cases cited in the PTO Manual
are not obviously illustrative. Case law reveals a similarly complex and obtuse picture. See id.
Compare 2 MCCARTHY, supra note 1, § 11:72 (giving an illustrative list of marks held to be
nondescriptive and merely suggestive), with Zobmondo Entm’t, LLC v. Falls Media, LLC, 602
F.3d 1108, 1116–21 (9th Cir. 2010) (finding that the lower court erred in finding that “WOULD
YOU RATHER . . . ?” is descriptive under the “imagination test” and refusing to grant summary
judgment for the same term under the “competitors’ needs” test), and Pizzeria Uno Corp. v.
Temple, 747 F.2d 1522, 1528, 1533–34 (4th Cir. 1984) (reversing the lower court’s finding that
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typically understood this way, the same is true for the difference between
suggestive and fanciful marks.260 It is a problem the law recognizes but,
like every good legal fiction, often chooses to do little about.261
Ordinarily, we might be willing to live with the suggestive nature of
otherwise benign trademarks. YOLK262 may suggest that a restaurant
provides only egg-based meals even though it serves a wide range of
breakfast foods and drinks.263 Perhaps this suggestion even serves useful
economic functions. Differentiating the product with a suggestive name
lowers search costs twice over. Consumers can identify the product more
readily and, because the name suggests the product, use fewer cognitive
resources to do so.
We may even tolerate some mildly misleading suggestive marks on
the theory that, in today’s marketplace, trademarks are the least of the
problems with advertising.264 There are, however, two complications with
that approach. First, it discounts the power of trademarks.265 Trademarks
can be a company’s most valuable asset.266 And companies spend large
PIZZERIA UNO (and the dominant word UNO of the composite mark) is descriptive rather than
suggestive and noting how difficult it is to draw lines between suggestive and descriptive), and
20th Century Wear, Inc. v. Sanmark-Stardust Inc., 747 F.2d 81, 87 (2d Cir. 1984) (“We hold that
‘Cozy Warm ENERGY–SAVERS’ is a descriptive term.”), and Macia v. Microsoft Corp., 327 F.
Supp. 2d 278, 285 (D. Vt. 2003) (finding that whether POCKETMONEY was suggestive of
financial-management app software is a triable issue of fact). For a glimpse of how courts struggle
to translate foreign words, Pizzeria Uno is a must read. Pizzeria Uno Corp., 747 F.2d at 1533–34.
260. See generally Jake Linford, Are Trademarks Ever Fanciful, 105 GEO. L.J. 731, 760
(2017) (arguing that many fanciful marks have sound symbolism, making them more like
suggestive or descriptive marks, and that courts should account for this when determining the
scope of a mark’s protection).
261. See, e.g., Union Nat’l Bank of Tex. v. Union Nat’l Bank of Tex., 909 F.2d 839, 845 (5th
Cir. 1990) (“Finally, arbitrary and fanciful terms or phrases are those which are either coined
words or words which are not suggestive of the product or service.”); Abercrombie & Fitch Co.
v. Hunting World, Inc., 537 F.2d 4, 10 (2d Cir. 1976) (“The category of ‘suggestive’ marks was
spawned by the felt need to accord protection to marks that were neither exactly descriptive on
the one hand nor truly fanciful on the other . . . .”).
262. U.S. Trademark Application Serial No. 88/263,030 (filed Jan. 15, 2019); see also
YOLKED, Registration No. 5,770,771 (denoting “restaurant services featuring breakfast food”).
263. See YOLK, https://www.eatyolk.com/ [https://perma.cc/27ZU-A3GK].
264. See Alex Weidner, Examining the Impact of In re Brunetti on § 2(a) of the Lanham Act,
83 MO. L. REV. 1153, 1168 (2018) (suggesting that consumers are more likely to “see through the
false connection” in suggestive marks as compared to descriptive marks).
265. See, e.g., DEBORAH E. BOUCHOUX, PROTECTING YOUR COMPANY’S INTELLECTUAL
PROPERTY 3 (2001) (“[T]he Coca-Cola Company estimates the value of its portfolio of trademarks
at more than $30 billion.”); GORDON V. SMITH & SUSAN M. RICHEY, TRADEMARK VALUATION
MANAGEMENT 76 (2d ed. 2013). See generally Michael J. Freno, Trademark Valuation:
Preserving Brand Equity, 97 TRADEMARK REP. 1055 (2007) (explaining how to value trademarks,
the value-added they can provide, and the lost value from infringement).
266. BOUCHOUX, supra note 265, at 3.
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quantities of cash “building” and “protecting” them.267 The idea that
trademarks are not a significant part of the problem belies the Benjamins.
Second, in some cases, suggestive marks may do more than economic
damage;268 they may pose a risk of physical harm. BABY SAFE (for pool
fencing),269 BREATHABLE BABY SAFE FOR SLEEP (for baby
sleepwear),270 and BRAINSTRONG (for dietary supplements)271 all raise
risks not posed by SPEEDI BAKE (for frozen dough),272
FRANKWURST (for wieners),273 and TINT TONE (for hair coloring).274
A consumer who buys a pool fence that purports to keep his child from
drowning faces a risk different from the one who buys dough hoping it
will rise quickly.
Here it is helpful to distinguish between the different types of risk
posed by a falsely suggestive trademark: explicit, implicit, and latent
risks. A risk is explicit when the trademark suggests a safety feature of a
product that the product does not have (or for which there is no evidence).
BABY SAFE pool fencing is one example. An implicit risk arises where
the trademark suggests a product is safe for some purpose and, although
the product can in fact be used for that purpose, it is (1) not safe to do so
or (2) there is no evidence it is safe to use the product in the manner
suggested). ROCK-N’-PLAY SLEEPER is one example. It suggests that
parents can use the product as a sleeping device for their children, but
doing so puts an infant at risk of death.275 Finally, a trademark can pose
267. Freno, supra note 265, at 1062.
268. In some cases, however, suggestive marks may frustrate the economic function of
trademarks. If a mark suggests a product feature the product does not have, consumer search costs
will increase. Marks that suggest that a product contains particular features may draw the
consumer to the mark because of this suggestion. But if the consumer discovers the product does
not contain the suggested feature, she will continue searching for one that does. Consumers, in
other words, will spend more time searching for products that have the feature they desire.
269. See supra note 22 and accompanying text.
270. U.S. Trademark Application Serial No. 88/514,892 (filed July 15, 2019).
271. BRAINSTRONG, Registration No. 4,352,302.
272. In re George Weston Ltd., 228 U.S.P.Q. (BNA) 57 (T.T.A.B. 1985), 1985 WL 71959,
at *1.
273. FRANKWURST, Registration No. 847,093.
274. In re John H. Breck, Inc., 150 U.S.P.Q. (BNA) 397 (T.T.A.B. 1966), 1966 WL 7270,
at *1.
275. The United States and Canada recently recalled the product because infants died when
using the product for sleeping. See Fisher-Price Recalls Rock ‘n Play Sleepers Due to Reports of
Deaths, U.S. CONSUMER PRODUCT SAFETY COMMISSION (Apr. 12, 2019), https://www.cpsc.gov/
Recalls/2019/fisher-price-recalls-rock-n-play-sleepers-due-to-reports-of-deaths [https://perma
.cc/3FYH-32F5]. The story of the ROCK-‘N-PLAY SLEEPER, of course, is more complicated
and involves a variety of lobbying efforts to create an exemption for an unsafe product. See Rachel
Rabkin Peachman, While They Were Sleeping: How a Product Tied to 73 Infant Deaths Came to
Market and Stayed for a Decade, as Government and Industry Knew the Risks, CONSUMER REP.
(Dec. 30, 2019), https://www.consumerreports.org/child-safety/while-they-were-sleeping/
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a latent risk by suggesting that a product has some quality, function,
feature, or effect that it does not have (or there is no evidence for the
suggestion) but that suggestion is not what makes the product unsafe; it
is the nature of the product itself that is unsafe. The false suggestion
simply makes it more likely that a consumer will be deceived into buying
the product, and therefore more likely the consumer will suffer some kind
of harm. A latent risk is qualitatively different from explicit and implicit
risks because the trademark’s suggestion might not be linked to the risk
in the same way. Supplements, for example, often pose risks to
consumers independent of the trademarks used to sell them. Falsely
suggestive marks here, though, still mislead consumers into thinking the
product will have some effect that it does not in fact have (or there is no
evidence for). But not having the effect just means the supplement fails
to work; yet the suggestion that it will work makes consumers more likely
to buy a product that could harm them physically. BRAINSTRONG is a
good example of this type of risk. It suggests, I think falsely, that it will
improve your brain function. That suggestion alone is not likely to harm
the consumer physically—but taking the supplement might.
Suggestive marks, then, may in some cases pose a heightened risk of
physical harm to consumers. If a mark falsely suggests or implies
features, characteristics, functions, qualities, or effects that the consumer
may rely on when purchasing the product, we should be concerned. And
if those suggestions come baked in with risks of physical harm that the
mark does not suggest, then there is reason for trademark law to be
skeptical about their value. Deceptiveness, after all, is about ensuring
consumers are not misled. And, as we learned from the case law in Part
I, trademark law is willing to account for the risk of physical harm in its
confusion analysis. Yet suggestive marks are immune from a finding of
deceptiveness simply because they are not descriptive. Although this rule
makes sense in the ordinary case, it is less defensible where a product
poses a risk of physical harm to consumers. The point is underscored by
the already blurry line between descriptive and suggestive marks.276 Why
[https://perma.cc/ZJ5Y-XHT6]. Importantly, authorities in Canada allowed the product to be sold
only as a ROCK-‘N-PLAY SOOTHING SEAT, “rather than [as] a sleeper.” See id. No deaths
have been reported in Canada. Fisher-Price Newborn Rock ‘n Play Sleeper Recalled Due to
Reports of Deaths in the United States, RECALLS & SAFETY ALERTS (May 15, 2019),
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69912r-eng.php [https://perma
.cc/747Y-SAF4]. The trademark ROCK-‘N-PLAY was registered without the suffix
“SLEEPER,” but the company could potentially claim a common law mark in ROCK-‘N-PLAY
SLEEPER as a composite mark. See ROCK-‘N-PLAY, Registration No. 2,007,053 (registering
the mark ROCK-‘N-PLAY but subsequently cancelling the registration).
276. From a linguistic perspective, the line between descriptive and suggestive marks may
well be a mistake, because those marks are likely to influence consumers in similar ways. Linford,
supra note 258, at 1400, 1409–12, 1420.
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should trademark law err on the side of protection when it could easily
err on the side of consumer safety? So when a trademark poses risk of
physical harm, we have a good reason to eliminate the arbitrary linedrawing in favor of consumer protection.
The deceptiveness inquiry should do the same when there is an
increased risk of physical harm. This does not require any technical
training or special competence. Just as courts did in the context of
confusion,277 they should use common sense when evaluating whether
products pose a risk of physical harm. This is, in fact, more or less what
courts do all the time. Certain products and services—dietary
supplements, prescription medications, car components, weight-loss
programs, and medical care—carry heightened risks. Courts should be
able to identify these product categories without special training. And, as
stated below, the PTO already conducts a highly sophisticated analysis of
trademarks; asking whether those marks relate to a product that might
cause physical harm seems rather tame by comparison.
Once either the PTO or courts identify this risk, they should adapt the
first two elements of the deceptiveness test to account for it. This requires
them to ask, first, whether the product suggests, rather than misdescribes,
characteristics, qualities, functions, compositions, effects, or use of the
goods or services. Second, they should ask whether consumers believe
this suggestion. The modified parts of the test look like this:
(1) Does the term falsely suggest or imply a characteristic,
quality, function, composition, effect, or use of the goods?
(2) If so, are prospective purchasers likely to believe the
suggestion or implication?
This test expands the kinds of marks that can be considered
deceptive.278 But it does so in a limited, calculated way—in the same way
277. See, e.g., A&H Sportswear, Inc. v. Victoria’s Secret Stores, Inc., 237 F.3d 198, 214 (3d
Cir. 2000).
278. This approach is, in some ways, an end run around thorny First Amendment issues. In
the false advertising context, what this Article may be advocating for is a more stringent “puffery”
standard where the claims could cause a risk of harm. “Puffery” is protected from being false
advertising because it is deemed “so obviously exaggerated that even credulous consumers cannot
be misled.” Pernod Ricard USA, LLC v. Bacardi USA, Inc., 653 F.3d 241, 254 n.17 (3d Cir.
2011); see also id. at 253 (“Under these circumstances, a district court can properly disregard
survey evidence as immaterial, because, by definition, § 43(a)(1) does not forbid language that
reasonable people would have to acknowledge is not false or misleading.”); David A. Hoffman,
The Best Puffery Article Ever, 91 IOWA L. REV. 1395, 1399 (2006) (arguing for a more expansive
scope of puffery). This Article, however, focuses on the Abercrombie spectrum as a means for
tweaking the deceptiveness doctrine. Its hope is to avoid the complicated questions implicated by
the First Amendment’s commercial speech doctrine. See Cent. Hudson Gas & Elec. Corp. v. Pub.
Serv. Comm’n, 447 U.S. 557, 563 (1980). Even if forced to confront those issues, however, this
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courts accounted for the risk of physical harm in the confusion context.
It recognizes a risk exists because of the nature and use of the product
then adjusts the relevant legal standard (deception) to better account for
this risk.
Not all suggestive marks, of course, present a risk of physical harm.
In the standard case, we can leave in place the existing test for
deceptiveness. Misdescriptive, and not suggestive, marks will remain the
only ones vulnerable to the deception test.279 When a risk of harm is
present, and when there is a close call, the proposed adjustments are
designed to capture any doubts about the category (descriptive or
suggestive) into which the marks fall. Whether a mark poses a risk of
harm will depend on the kind of product to which it is affixed.
SLEEPWELL for mattresses280 or sleepwear281 may be misleading, but
there is no obvious risk of physical harm. As applied to botanical
extracts282 for pharmaceutical purposes, however, SLEEP WELL does
present a risk of physical harm. So the altered standard of deceptiveness
would apply only in the latter case.
Risk profiles—explicit, implicit, and latent—should also be used to
evaluate the deceptiveness of a mark. In general, marks that make explicit
safety suggestions should be given the least amount of leeway; latent the
most. But the analysis is not rigid. The nature of the product can influence
the stringency of the deceptiveness inquiry. So a trademark that poses a
latent risk—one involving a potentially life-threatening supplement—
could be subject to greater scrutiny than a trademark that poses an explicit
risk where the potential for physical harm is low.
Article’s approach would likely pass constitutional muster. Notably, it might be difficult to apply
the “puffery” framework to suggestive and, in particular, fanciful marks. Whether consumers are
so credulous to believe a suggestion or implication of a mark is a question related to the legal
question raised by puffery but not identical to it. For an analysis of trademarks in the context of
the First Amendment, see generally Rebecca Tushnet, The First Amendment Walks into a Bar:
Trademark Registration and Free Speech, 92 NOTRE DAME L. REV. 381 (2016). This Article also
has no desire to import false advertising law’s requirement of consumer surveys to prove
implicitly false claims. Tushnet, supra note 89, at 1337–41. The PTO, for one, has no resources
to conduct surveys, and trademark law does fine without requiring them in every case.
279. As suggested below, the same line of reasoning could be applied to certain health
products more generally. SLEEPSAFE for medical use, for instance, suggests to consumers that
the product will provide them with safe sleep, even if the product is not actually designed to have
that feature. See SLEEPSAFE, Registration No. 3,685,416.
280. U.S. Trademark Application Serial No. 88/193,789 (filed Nov. 14, 2018) (seeking
registration for online retail store services featuring mattresses); SLEEPWELL, Registration No.
1,319,398 (providing registration of a typed drawing for mattresses, box springs, and
foundations).
281. SLEEPWELL, Registration No. 5,687,433.
282. U.S. Trademark Application Serial No. 77/519,419 (filed July 10, 2008) (abandoning,
after filing, an intent-to-use application and failing to file an affidavit within one year).
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Including suggestive marks within the ambit of deceptiveness—and
weighing them according to risk profile—will make decisions easier.
Consider the following examples. SLEEP WELL BY MEDIBLES283
somewhat obviously describes what the product is designed to do.284
ZZZZ INFUSED E-LIQUID285 clearly suggests that the product will help
you sleep. COGNITEX286 supplements imply that they will help with
cognition, even if the mark does not outright describe the product.
BRAINSTRONG suggests to the consumer that the supplements will
improve brain performance. All of these products, given their nature (i.e.,
e-cigarettes and dietary supplements) pose a risk of physical harm and
should be evaluated as potentially deceptive. This is true even though the
risks presented by the marks are latent. Because the products themselves
pose a significant risk of physical harm, their latency should be evaluated
in relation to their potential to cause harm. The more potential for harm a
product poses, the greater weight courts should allocate to the false
suggestion in the deceptiveness inquiry.
Since courts do not have to decide whether the mark is descriptive or
suggestive, they can focus on whether the mark falsely suggests
information about the product that is material to the consumer. Here it is
useful to remember the TTAB is constantly making decisions about
whether marks are generic,287 descriptive,288 suggestive, arbitrary, or
fanciful. Allowing both the PTO and courts to make deceptiveness
findings when marks are suggestive will reduce the burden on the PTO—
it will no longer be forced to parse the differences between descriptive
and suggestive marks, which is far from clear.289
283. SLEEP WELL BY MEDIBLES, Registration No. 4,374,796.
284. In a PTO action, registration of SLEEP WELL BY MEDIBLES was subsequently
denied because the mark was found to be confusingly similar to SLEEP SO WELL. See Patent &
Trademark Office, Office Action (Official Letter) About Applicant’s Trademark Application
Serial No. 85/683,608 (Nov. 23, 2012); see also U.S. Trademark Application Serial No.
85/683,608 (filed July 22, 2012) (applying for registration of the mark SLEEP WELL, which also
provides some indication of what the product is designed to do).
285. U.S. Trademark Application Serial No. 88/218,684 (filed Dec. 5, 2018).
286. COGNITEX, Registration No. 3,810,855.
287. See, e.g., Shammas v. Rea, 978 F. Supp. 2d 599, 614−15 (E.D. Va. 2013) (affirming the
TTAB’s finding that PROBITOIC was generic for fertilizer).
288. See, e.g., Timex Grp. USA, Inc. v. Focarino, No. 1:12–CV–1080, 2013 WL 6713119,
at *11 (E.D. Va. Dec. 17, 2013) (overruling the TTAB’s decision that INTELLIGENT QUARTZ
was descriptive and finding it suggestive), supplemented by 993 F. Supp. 2d 606 (E.D. Va. 2014).
289. Other, more fanciful marks may pose a similar, if not subtler, problem. NEURIVA
draws on both “nerve” and “viva” to imply, if not outright suggest, that the supplement will
enhance brain performance. See NEURIVA, Registration No. 5,782,353. Since these latter marks
are suggestive or fanciful, they cannot be deceptive. Yet they may pose real safety risks, even if
the precise risks posed by any given product are not uniform. Lars Noah & Barbara A. Noah, A
Drug by Any Other Name . . . ?: Paradoxes in Dietary Supplement Risk Regulation, 17 STAN. L.
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In making decisions about what may mislead consumers, the PTO
should have significant leeway, which courts have recognized.290 Often
this will mean relying “on sources of publicly-available information
likely to reflect such perceptions and, of course, common sense.”291
Frequently this will require the PTO to make decisions about what
consumers are likely to believe in light of both the mark and the context
in which they encounter it.292 There is no reason to think the PTO will be
any worse at this task than the others it frequently undertakes.
C. Loosening Materiality
Expanding the deceptiveness test to include suggestive marks will not
necessarily be enough to bar the marks from registration. The third
element of the deceptiveness test requires that the misdescription (or
misleading suggestion) is “likely to affect a significant portion of the
relevant consumers’ decision to purchase.”293 Immediately one wonders,
what evidence satisfies this test?
The answer in trademark law is not well-developed. The cases
specifically examining the materiality component of deceptiveness under
Section 2(a) of the Lanham Act are not numerous. Most of them are
focused on a subset of deceptiveness cases involving geographical
indications.294 Many of the decisions on deceptiveness suggest that
& POL’Y REV. 165, 173–74 (2006) (noting that the risks supplements pose “lie on a continuum”).
More evidence about the risks and nature of the marks would need to be marshaled in these cases
before the marks could be found deceptive.
290. See, e.g., In re Budge Mfg. Co., 857 F.2d 773, 775 (Fed. Cir. 1988).
291. Glendale Int’l Corp. v. USPTO, 374 F. Supp. 2d 479, 486 (E.D. Va. 2005).
292. In re Juleigh Jeans Sportswear Inc., 24 U.S.P.Q.2d (BNA) 1694 (T.T.A.B. 1992), 1992
WL 340751, at *4 (finding that consumers would be likely to think the mark LONDON LONDON
primarily indicates the location where the applicant’s goods were made).
293. U.S. PATENT & TRADEMARK OFFICE, supra note 7, § 1203.02(b). The standard in false
advertising law is similar. See Cashmere & Camel Hair Mfrs. Inst. v. Saks Fifth Ave., 284 F.3d
302, 313 (1st Cir. 2002) (noting that one “element of a false advertising claim under the Lanham
Act requires plaintiffs to demonstrate that the alleged misrepresentation deceived a substantial
portion of the consuming public”).
294. See, e.g., In re Les Halles De Paris JV, 334 F.3d 1371, 1372, 1375 (Fed. Cir. 2003)
(finding that “the record,” which included the TTAB’s references to travel brochures and
statements from articles regarding the region in question, did “not show that a material reason for
the diner’s choice of this restaurant in New York City was its identity with the region in Paris”);
Institut Nat‘l Des Appellations D’Origine v. Vintners Int’l Co., 958 F.2d 1574, 1581 (Fed. Cir.
1992) (noting that the opposer to the registration of CHABLIS WITH A TWIST on the grounds
that it was geographically deceptively misdescriptive did “not establish what would and what
would not be a material factor in the decisions of consumers to purchase the product”); Daesang
Corp. v. Rhee Bros., No. Civ. AMD 03–551, 2005 WL 1163142, at *12 (D. Md. May 13, 2005)
(finding that “consumers are likely to be misled by the deceptive use of Soon Change on Rhee
Bros.’ labels for gochujang, and that deception is likely to affect the purchasing decisions of
consumers” based on the region’s reputation for producing high-quality gochujang).
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proving consumers are likely to believe a misdescription is more difficult
than proving materiality.295 And even those that do address the issue
specifically as to deceptive marks are not always clear.296 Some decisions
find sufficient support in a review of consumer publications and
inferences that could reasonably be drawn from them.297 Common sense,
in other words, may be enough to find materiality.298
For guidance, we might look to trademark law’s cousin, false
advertising law. Here, materiality is baked into all claims.299 And, like
trademark law, false advertising law has a rather common sense way of
295. See, e.g., Hako-Med USA, Inc. v. Axiom Worldwide, Inc., No. 8:06CV1790 T27EAJ,
2006 WL 3760416, at *2 (M.D. Fla. Dec. 19, 2006) (“Defendants have not introduced evidence
showing that a prospective purchaser, such as a medical doctor or other health care professional,
is likely to believe that the term VASOPULSE actually describes the function of Plaintiffs’
machine or that the name VASOPULSE would affect their decision to purchase Plaintiffs’
machine.”); In re Juleigh Jeans Sportswear Inc., 24 U.S.P.Q.2d (BNA) at 1699, 1992 WL 340751,
at *6 (“Because, in fact, no such connection exists with respect to applicant’s goods, and since
the favorable reputation of London for clothing is a material factor influencing the decision to
purchase an item therefrom, we conclude that applicant's mark is geographically deceptive within
the meaning of Section 2(a).”).
296. See, e.g., In re Phillips-Van Heusen Corp., 63 U.S.P.Q.2d (BNA) 1047 (T.T.A.B. 2002),
2002 WL 523343, at *8–9.
297. See, e.g., Glendale Int’l Corp. v. USPTO, 374 F. Supp. 2d 479, 486–87 (E.D. Va. 2005)
(finding that the examiner had made out a prima facie case of deceptiveness against the
registrant’s mark, TITANIUM, by reviewing automotive publications that referenced titanium as
a component in automotive manufacturing and drawing an inference that this would affect
purchasing decisions).
298. Cases here run the gamut. For an example of where common sense lost out, see In re
One Minute Washer Co., 95 F.2d 517 (C.C.P.A. 1938), which reversed the Commissioner of
Patents’s decision and held not deceptive the trademark, ONEMINUTE, for a washing machine
that took eleven minutes to operate because it was “intriguing, and, although it may suggest a
desirable characteristic of the goods on which it is used, is, in our opinion, purely fanciful and
arbitrary.” Id. 518, 520. There has been somewhat more discussion of materiality in the context
of geographically deceptively misdescriptive marks. See 15 U.S.C. § 1052(e)(3) (2018); In re
Spirits Int’l, NV, 563 F.3d 1347, 1353 (Fed. Cir. 2009).
299. 5 MCCARTHY, supra note 1, § 27:35 (“Plaintiff must make some showing that the
defendant’s misrepresentation was ‘material’ in the sense that it would have some effect on
consumers’ purchasing decisions.”). Interestingly, materiality might not have been an included
element of the test but for a fateful decision by the U.S. District Court for the Northern District of
Illinois. Vincent N. Palladino, Lanham Act “False Advertising” Claims: What Is a Plaintiff to
Do?, 101 TRADEMARK REP. 1601, 1601, 1604–05 (2011) (noting that the current standard for false
advertising was drawn from Skil Corp. v. Rockwell International Corp., which copied “almost
verbatim” a standard first proposed, without citing authority, by scholar Gilbert H. Weil in his
article, Protectability of Trademark Values Against Competitive Advertising, and not the
competing standard, where no materiality was required, in Potato Chip Institute v. General Mills,
Inc. (first citing Skil Corp. v. Rockwell International Corp., 375 F. Supp. 777, 783 (N.D. Ill. 1974);
then citing Gilbert H. Weil, Protectability of Trademark Values Against Competitive Advertising,
44 CALIF. L. REV. 527 (1956); and then citing Potato Chip Inst. v. General Mills, Inc., 333 F.
Supp. 173, 179 (D. Neb. 1971), aff’d, 461 F.2d 1088 (8th Cir. 1972) (per curiam))).
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dealing with materiality.300 The standard may or may not be identical to
the query in In re Budge Manufacturing Co.301 (i.e., whether the
misdescription is “likely to affect a significant portion of the relevant
consumers’ decision to purchase”).302 But materiality does imply that
some nontrivial portion (usually a “substantial portion”) of consumers be
influenced by the deception.303 So perhaps the difference between the two
is immaterial.
Some courts, such as the U.S. Courts of Appeals for the First and
Second Circuits, even have developed shortcuts to materiality,304 asking
300. See Tushnet, supra note 89, at 1344–52.
301. 857 F.2d 773 (Fed. Cir. 1988).
302. See supra note 290 and accompanying text.
303. The Federal Circuit and the Restatement both state this is a required element. Compare
In re Spirits, 563 F.3d at 1356 (“Though varying linguistic formulations have been used, the wide
consensus of the courts of appeals is consistent with the conclusion of the Third Circuit in Johnson
& Johnson-Merck that the mark or advertising must deceive a substantial portion of the relevant
consumers.” (citing Johnson & Johnson v. Smithkline Beecham Corp., 960 F.2d 294, 298 (2d Cir.
1992))), with RESTATEMENT (THIRD) OF UNFAIR COMPETITION § 2 reporters’ note, cmt. d (AM.
LAW INST. 1995) (“A frequently quoted statement of the elements of a cause of action for
deceptive advertising under § 43(a) requires that the representations ‘actually deceived or have
the tendency to deceive a substantial segment of their audience.’” (quoting Skil Corp., 375 F.
Supp. at 783)). The Second Circuit has, perhaps inadvertently, formulated this test in a somewhat
misleading way to suggest the deception must affect just purchasing decisions and not necessarily
the purchasing decisions of a substantial segment of the audience that is deceived or tends to be
deceived by the statement in question. See NBA v. Motorola, Inc., 105 F.3d 841, 855 (2d Cir.
1997) (citing precedents from the U.S. Courts of Appeals for the Third and Fifth Circuits defining
materiality as, respectively, when “the deception is material in that it is likely to influence
purchasing decisions” and “is likely to influence the purchasing decision” (first quoting AT&T
Co. v. Winback & Conserve Program, Inc., 42 F.3d 1421, 1428 n.9 (3d Cir. 1994); and then
quoting Taquino v. Teledyne Monarch Rubber, 893 F.2d 1488, 1500 (5th Cir. 1990))). The cases
cited actually follow Skil, which implied that the deception must relate to the portion of the
audience that the statement deceives or tends to deceive. Taquino, for example, explained that the
“statements deceived or had the capacity to deceive a substantial segment of potential consumers.”
Taquino, 893 F.2d at 1500. The text quoted by NBA, therefore, linked materiality back to “a
substantial segment.” Tushnet, however, has formulated the test in a different way. See Tushnet,
supra note 89, at 1344 (“To be actionable under section 43(a)(1)(B), a falsehood must be
‘material’: it must be likely to affect a reasonable consumer’s purchasing decision.”). Both
formulations can be correct at the same time. The “reasonable consumer” just means the
substantial portion of the public that is likely to find the statement both deceptive and material.
For an illustration of how the formulations can be simultaneously applicable, see Am. Rockwool,
Inc. v. Owens-Corning Fiberglas Corp., 640 F. Supp. 1411, 1443 (E.D.N.C. 1986). “To establish
a right to damages, a plaintiff must prove the falsity of the statement in question and also that the
statement actually deceived a portion of the buying public.” Id.
304. Whether this is a shortcut to materiality, a restatement of the materiality requirement,
or a separate materiality requirement altogether is not clear. See Church & Dwight Co. v. SPD
Swiss Precision Diagnostics, GmbH, 843 F.3d 48, 70 & n.10 (2d Cir. 2016) (stating that “the
essential elements of the materiality standard indeed appear to be somewhat unsettled in our
circuit” and noting that NBA defined materiality as “an inherent quality or characteristic” and that

Published by UF Law Scholarship Repository,

55

Florida Law Review, Vol. 72, Iss. 5 [], Art. 5

728

FLORIDA LAW REVIEW

[Vol. 72

whether “the defendant[] ‘misrepresented an “inherent quality or
characteristic”’ of the product.”305 What counts as “inherent” is another
definitional problem unto itself. Sometimes “inherent” means the
statement in question relates to what the product actually is. So “it seems
obvious [to the First Circuit] that cashmere is a basic ingredient of a
cashmere-blend garment; without it, the product could not be deemed a
cashmere-blend garment or compete in the cashmere-blend market.”306
But, other times, the “inherentness” inquiry is no better than the one
into materiality more generally. Take, for example, National Basketball
Ass’n v. Motorola, Inc.307 There, the defendant sold a “handheld
pager . . . [that] display[ed] updated information of professional
basketball games in progress.”308 In a press release, the defendant claimed
that its pager “‘updated game information direct from each arena’ which
‘originate[s] from the press table in each arena.’”309 The retail box in
which the pager was sold also stated that the device provided “‘game
updates from the arena.’”310 Because the pager actually collected
information from “television and radio broadcast[s],”311 the plaintiff
argued the statements were false: the information was derived from a
third party, not from the area “directly.”312 But the Second Circuit thought
this argument focused on the wrong question. The real issue was whether
the statements concerned an inherent quality or characteristic of the
product—whether they were material.313 The Second Circuit did not think
post-NBA cases “do not mention this ‘likely to influence purchasing decision’ feature of the
standard” and instead focus on the test just stated (quoting NBA, 105 F.3d at 855)).
305. NBA, 105 F.3d at 855 (quoting Nat’l Ass’n of Pharm. Mfrs. v. Ayerst Labs., 850 F.2d
904, 917 (2d Cir. 1988)); accord Cashmere & Camel Hair Mfrs. Inst. v. Saks Fifth Ave., 284 F.3d
302, 311–12 (1st Cir. 2002) (“One method of establishing materiality involves showing that the
false or misleading statement relates to an ‘inherent quality or characteristic’ of the product.”
(quoting NBA, 105 F.3d at 855)).
306. Cashmere, 284 F.3d at 312. The First Circuit also suggested that a producer’s emphasis
on certain product features or attributes could render the feature “inherent.” See id. (“Moreover,
defendants prominently labeled their garments as ‘Cashmere and Wool,’ ‘A Luxurious Blend of
Cashmere and Wool,’ ‘Cashmere Blend,’ or ‘Wool and Cashmere,’ and their garments were
conspicuously advertised in stores and catalogues as ‘Cashmere Blazers.’ It seems reasonable to
infer from defendants’ aggressive marketing strategy highlighting the ‘cashmere’ nature of the
blazers that defendants themselves believed cashmere to be an inherent and important
characteristic of the blazers.”).
307. 105 F.3d 841, 843 (2d Cir. 1997).
308. Id.
309. NBA, 105 F.3d at 855 (providing a direct quote of the information included in a
Motorola press release regarding SportsTrax).
310. Id.
311. Id.
312. Id.
313. NBA, 105 F.3d at 855.
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they were.314 Consumers, according to the court, cared only that they
received (accurate) information, not whether the information they
received was “taken from broadcasts instead of being observed firsthand.”315 In explaining when these statements might satisfy this test, the
Second Circuit confirmed that its test of “inherency” was simply a more
general judgment about what was material.316
Applying the First and Second Circuits’ formulation, then, may not
help courts resolve the materiality inquiry in any meaningful way.
Perhaps expanding what counts as “inherent” when products pose a high
risk of physical harm might help ameliorate this problem.317 But it would
also threaten to collapse the entire deceptiveness inquiry into the first two
elements—materiality would be irrelevant or at least assumed. That may
be a desirable conclusion given the importance attached to the first two
elements of the deceptiveness test and the difficulty in using more than
common sense to assess materiality. But it would require a break from
established precedent. This makes it an unlikely solution.
Although historically courts have “taken materiality for
granted . . . when a [false advertising] claim . . . relates to health or
safety,”318 the “common sense [idea] that consumers care about health
[and] safety . . . is no longer enough to guarantee a victory . . . though it
will often suffice.”319 Trademark law would benefit from retaining the
common sense assumptions both it and false advertising law have relied
upon for materiality.320 But when the goods or services at issue risk
physical harm, common sense suggests that the standard for materiality
should be easier to meet. What constitutes a “substantial” number of
“relevant” consumers, in other words, should be both smaller in number
and broader in reach. If the suggestion might be material to even a handful
of consumers who could suffer serious physical harm from using the
product, courts should err on the side of consumer safety and find the
314. Id. (“[T]he complained-of statements are not material and do not misrepresent an
inherent quality or characteristic of the product.”).
315. Id.
316. See id. (“[I]f the NBA were in the future to market a rival pager with a direct datafeed
from the arenas—perhaps with quicker updates than SportsTrax and official statistics—then
Motorola's statements regarding source might well be materially misleading.”).
317. Cf. Palladino, supra note 299, at 1621–25 (arguing that the “inherent quality or
characteristic” requirement should be eliminated because it is unduly limiting and courts
frequently wrongly equate it with materiality).
318. Tushnet, supra note 89, at 1348.
319. Id. at 1350.
320. Compare supra notes 296, 298 and accompanying text (explaining false advertising
law’s common sense approach), with Tushnet, supra note 89, at 1347 (“In general, courts have
evaluated materiality by inquiring whether, as a matter of common sense and the intended uses of
the product or service, a claim is likely to be relevant to a purchasing decision.”).
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deception material. This would further the goal of protecting consumers
from deception—and not just the kind that might decimate their wallets,
but also the kind that might wreak havoc on their bodies.
This is, in some sense, a suggestion to recast what a “reasonable
consumer”321 would find deceptive or material. Accounting for the risk
of harm by reducing “the sophistication” of the consumer is not without
precedent.322 Doing the same in the context of deceptiveness may provide
a better shortcut to materiality than the Second Circuit’s query into the
“inherent quality or characteristic” of a product.323 If the reasonable
consumer is the one most likely to be hurt by a product, courts would
have more flexibility in determining materiality.324 Products marketed to
children, the elderly, or the sick,325 for instance, would require a lower
quantum of evidence to satisfy this element.
321. Williams v. Gerber Prods. Co., 552 F.3d 934, 938 (9th Cir. 2008) (“Under the
reasonable consumer standard, Appellants must ‘show that “members of the public are likely to
be deceived.”’” (quoting Freeman v. Time, Inc., 68 F.3d 285, 289 (9th Cir. 1995))); Nelson v.
MillerCoors, LLC, 246 F. Supp. 3d 666, 674 (E.D.N.Y. 2017) (“The reasonable consumer
standard applies to section 349 and 350 claims [of the N.Y. Gen. Bus. Law], meaning challenged
conduct must be ‘materially deceptive or misleading “to a reasonable consumer acting reasonably
under the circumstances.”’” (quoting Dash v. Seagate Tech. (U.S.) Holdings, Inc. (Dash I), 27 F.
Supp. 3d 357, 360 (E.D.N.Y. 2014))). The standard is also discussed when evaluating whether a
false statement is deceptive or mere puffery. See Pizza Hut, Inc. v. Papa John’s Int’l, Inc., 227
F.3d 489, 495 n.5 (5th Cir. 2000) (“Context will often help to determine whether the statement at
issue is so overblown and exaggerated that no reasonable consumer would likely rely upon it.”).
322. See discussion supra Section I.B. Tort law does, in limited circumstances, make similar
adjustments. See RESTATEMENT (SECOND) OF TORTS § 283A (AM. LAW INST. 1965) (“If the actor
is a child, the standard of conduct to which he must conform to avoid being negligent is that of a
reasonable person of like age, intelligence, and experience under like circumstances.”); cf. id.
§ 283B (“Unless the actor is a child, his insanity or other mental deficiency does not relieve the
actor from liability for conduct which does not conform to the standard of a reasonable man under
like circumstances.”). The analogy to torts is inexact. In torts, the “reasonable person” standard is
the standard for assessing the conduct (and liability) of the defendant. In the context of trademark
law, one assesses the conduct of the consumer to determine either liability or confusion questions.
323. For an explanation of the current standard’s inflexibility, see Laura A. Heymann, The
Reasonable Person in Trademark Law, 52 ST. LOUIS U. L.J. 781, 783 (2008). The inquiry might
be simpler if, instead of asking about substantiality in materiality, it simply asks, just as with
deception itself, whether the deception is material to “the person[s] to whom the advertisement is
addressed.” Johnson & Johnson v. Smithkline Beecham Corp., 960 F.2d 294, 297–98 (2d Cir.
1992) (emphasis omitted) (quoting Am. Home Prods. Corp. v. Johnson & Johnson, 577 F.2d 160,
166 (2d Cir. 1978)); see William H. Morris Co. v. Grp. W, Inc., 66 F.3d 255, 258 (9th Cir.)
(“Where a statement is not literally false and is only misleading in context, however, proof that
the advertising actually conveyed the implied message and thereby deceived a significant portion
of the recipients becomes critical.”), supplemented by 67 F.3d 310 (9th Cir. 1995) (unpublished
table decision).
324. Injunctions require only the likelihood of deception; damages require actual deception.
5 MCCARTHY, supra note 1, §§ 27:36, :41.
325. Although being “sick” does not reduce one’s mental capacity, it may increase one’s
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Although the PTO commonly makes materiality determinations
without much difficulty, it would not be left totally to its own devices. It
can, and it should, take cues from the FDA and FTC.326 If either agency
has found barred or found deceptive a word or phrase in connection with
a good or service that poses a risk of physical harm, the PTO should count
that as good evidence that the same word or phrase will be deceptive as
applied to trademarks. Not only will this ease the evidentiary burden on
the PTO, but it will also relieve it of the analytical burden. With a finding
of deceptiveness in hand, the PTO will not always need to analyze in
detail a mark’s classification along the Abercrombie spectrum.
D. Barring Deceptive Marks from Protection
If courts alter their deception analysis as suggested, they still need to
confront another issue: do deceptive marks deserve protection? This
Section suggests that they do not and that there are good reasons to think
courts will reach the same conclusion. The primary reason is because, at
common law, courts held deceptive marks unenforceable. In a world of
federal trademark legislation, however, there is still a question about
whether this common law rule applies.
For almost the entire nineteenth century,327 trademarks were entirely
creatures of state law.328 Even as federal trademark law expanded,
common law trademarks persisted. To this day, courts routinely read
Section 43(a) of the Lanham Act as providing a federal infringement
action that is identical to state law.329 Federal trademark law is, in
essence, “largely a codification of the common law.”330 This means that
state courts draw on federal precedent when deciding state trademark law
susceptibility to suggestions, either out of desperation or out of hope. This suggestion would be a
move toward recognizing the social context and psychological factors that influence consumer
behavior.
326. See R. Neumann & Co. v. Overseas Shipments, Inc., 326 F.2d 786, 789 (C.C.P.A. 1964)
(“While not controlling here, we deem it proper to take cognizance of the fact that the Federal
Trade Commission, which functions under a statute prohibiting ‘deceptive acts or practices in
commerce,’ repeatedly has condemned trademarks which include the term ‘hide’ or ‘hyde’ for
nonleather products.” (footnote omitted) (quoting 15 U.S.C. § 45 (1964))).
327. Congress enacted trademark legislation in 1870. Trade-Mark Cases, 100 U.S. 82, 92
(1879). In 1879, however, the U.S. Supreme Court struck down the law. See id. at 99. The Court
held that Congress did not have the constitutional authority to enact a trademark statute. See id.
328. Congress enacted additional trademark legislation in 1881 and again in 1905. See Act
of Feb. 20, 1905, ch. 592, 33 Stat. 724 (repealed 1946) (“An Act To authorize the registration of
trade-marks used in commerce with foreign nations or among the several States or with Indian
tribes, and to protect the same.”); Act of Mar. 3, 1881, ch. 138, 21 Stat. 502 (repealed 1946).
329. See 4 MCCARTHY, supra note 1, §§ 23:1, :1.50.
330. RESTATEMENT (THIRD) OF UNFAIR COMPETITION ch. 3, intro. note (AM. LAW INST.
1995).
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or unfair competition claims.331 Federal courts likewise sometimes draw
on common law to inform their understanding of federal trademark
infringement actions.332
At common law, the equitable doctrine of “unclean hands” barred
trademark owners from enforcing their trademarks when the plaintiff
deceived the public either by using the particular mark at issue or by
making false representations about the product on which it appeared.333
So long as the deception related to the right the plaintiff attempted to
assert, equity would not intervene on the plaintiff’s behalf.334 The
doctrine’s purpose, the U.S. Supreme Court noted in 1883, “is founded
in honesty and good sense; it rebukes fraud and encourages fair dealing
with the public.”335 The most commonly cited formulation of this
doctrine is stated in Clinton E. Worden & Co. v. California Fig Syrup
Co.336:
[W]hen the owner of a trade mark applies for an injunction
to restrain the defendant from injuring his property by
making false representations to the public, it is essential that
the plaintiff should not in his trade mark, or in his
advertisements and business, be himself guilty of any false
or misleading representation, that if the plaintiff makes any
material false statement in connection with the property
which he seeks to protect, he loses his right to claim the
assistance of a court of equity, that where any symbol or
label claimed as a trade mark is so constructed or worded as
to make or contain a distinct assertion which is false, no

331. See 1 MCCARTHY, supra note 1, § 1:19.
332. See 1 CALLMANN, supra note 1, § 3:4 (“According to some authorities, 43(a) creates a
new, ‘sui generis’ federal tort which is within federal subject matter jurisdiction; an action for
unfair competition based upon infringement of a common-law trademark can now be brought in
federal court.” (footnotes omitted)); see also 1 MCCARTHY, supra note 1, § 1:19.50 (noting that
federal decisions holding that Section 43(a) could form the basis for a complaint diminished the
role of state unfair competition law).
333. RESTATEMENT (THIRD) OF UNFAIR COMPETITION § 32 cmt. a; see infra note 337.
334. See infra note 337. Modern cases are equally clear on this causal-nexus requirement.
See, e.g., Fuddruckers, Inc. v. Doc’s B.R. Others, Inc., 826 F.2d 837, 847 (9th Cir. 1987)
(“[E]quity requires that those seeking its protection shall have acted fairly and without fraud or
deceit as to the controversy in issue.” (alteration in original) (emphasis added) (quoting Ellenburg
v. Brockway, Inc., 763 F.2d 1091, 1097 (9th Cir. 1985))); Alpo Petfoods, Inc. v. Ralston Purina
Co., 720 F. Supp. 194, 214 (D.D.C. 1989) (“The doctrine requires that the conduct which is said
to be unclean hands must relate to the ‘very matter in controversy.’ In an action for false
advertising, the unclean hands conduct of the plaintiff must relate to the same product a defendant
has falsely advertised.”).
335. Manhattan Med. Co. v. Wood, 108 U.S. 218, 227 (1883).
336. 187 U.S. 516 (1903).

https://scholarship.law.ufl.edu/flr/vol72/iss5/5

60

Simon: Trademark Law & Consumer Safety

2020]

TRADEMARK LAW & CONSUMER SAFETY

733

property can be claimed on it, or, in other words, the right to
the exclusive use of it cannot be maintained.337
What kinds of “false or misleading representation[s]” did the Court
have in mind?
Historically, these run the gamut, including express and demonstrably
false statements made about a product to trademarks that suggested

337. Id. at 528. The Worden Court based its decision on a line of U.S. common law and
English decisions dating back to 1837. Id. at 527–34; see Manhattan Med. Co., 108 U.S. at 222;
Krauss v. Joseph R. Peebles’ Sons Co., 58 F. 585, 594 (C.C.S.D. Ohio 1893) (holding that “[a]
court of equity cannot protect property in a trade-mark thus fraudulently used” and refusing to
enforce a trademark for “Jas. E. Pepper & Co.” whiskey where the mark and packaging misled
consumers into thinking the whiskey contained in the bottles to which the trademark was affixed
was made entirely “by Jas. E. Pepper & Co., unadulterated by mixture with it of anything else,”
when in fact it contained a mixture of whiskeys, much of which was not made by Jas. E. Pepper
& Co.); Clotworthy v. Schepp, 42 F. 62, 62–63 (C.C.S.D.N.Y. 1890) (barring a plaintiff’s
trademark action for Vanilla Rose Puddine because the plaintiff also “call[ed] his preparation
‘fruit’ puddine” in various places on the label but a chemical analysis by the defendant showed
that “it contain[ed] no fruit in any form”); Connell v. Reed, 128 Mass. 477, 477 (1880) (dismissing
an action in equity to enforce the mark EAST INDIAN used for medicines because the mark
misled the public into believing “that the medicines were used in the East Indies, and that the
formula for them was obtained there, neither of which is the fact”); Siegert v. Abbott, 61 Md. 276,
284–87 (1884) (noting that “[i]t is a general rule of law . . . that courts of equity will not interfere
by injunction . . . where there is any misrepresentation in his trade-mark or labels” and holding
that equity prevented the plaintiff from enforcing “Aromatic Bitters, or Angostura Bitters,
prepared by Dr. Siegert, at Angostura, now Port of Spain, Trinidad,” against the defendant because
Dr. Siegert had died, never lived in Spain, and never manufactured the product in Angostura, and
that these facts, along with the change of ownership (from Dr. Siegert to the business’s
successors), were misrepresented by the label) (holding that the geographic nature of the
misrepresentation was the least important among them); Alden v. Gross, 25 Mo. App. 123, 130–
32 (1887) (holding that the word “fruit” as applied to vinegar misdescribed a vinegar not made
from fruit and, because it was deceptive, the court (in equity) would not enforce it, and also
holding that the plaintiff had no exclusive right “to . . . use . . . the word ‘fruit,’ as applied to
vinegar”); Prince Mfg. Co. v. Prince’s Metallic Paint Co., 31 N.E. 990, 992–94 (N.Y. 1892)
(holding that the plaintiff’s mark, PRINCE’S METALLIC PAINT, could not be enforced because
“[t]he party who comes into a court of equity for relief against fraud must himself be free from
fraud in the matter of which he complains, or, as is frequently said, he must come with ‘clean
hands’”) (noting that the plaintiff’s mark represented, and had acquired a meaning of, paint made
using ore from a specific mine; that half of the plaintiff’s paint sold under this mark used ore from
other mines; and that this fact “was a material circumstance, because it was one of the essential
grounds of the credit which [the plaintiff] . . . had acquired in the market, and contributed to its
sale”; therefore, the mark deceived purchasers); Leather Cloth Co. v. Am. Leather Cloth Co.
(1863), 46 Eng. Rep. 868, 870–71; 4 De G.J. & S. 136, 142–44 (holding, in an opinion by Lord
Chancellor Westbury, that the plaintiff cannot enforce a trademark if used in a way as to deceive
the public by material false representation and that materiality would be presumed if the statement
was willfully false); Pidding v. How (1837), 59 Eng. Rep. 190, 191; 8 Sim. 477, 479–80 (holding
that equity barred the claim of a plaintiff selling teas under the mark “Howqua’s Mixture” because
the plaintiff had falsely represented the nature of the teas and how they were procured).
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products had certain features they did not in fact have.338 Worden was
about the latter.339 The plaintiff in Worden manufactured and sold a
constipation remedy called Syrup of Figs, which it used on its bottles,
packages, and products.340 When first manufactured, the product
contained some fig extract, but later this was eliminated.341 The defendant
sold what the plaintiff alleged was “a worthless production”—namely, a
liquid laxative—under the name “Fig Syrup” and “Syrup of Figs.”342 This
was, in short, a classic passing-off case. When the plaintiff brought a
claim, however, the defendant asserted that the law barred the plaintiff
from relief.343 Why? Because the plaintiff deceived the public by using a
mark that did not accurately describe the product (which did not contain
fig syrup) or the active ingredient (which was senna, not figs).344
The Court agreed.345 In holding that the common law barred the
plaintiff’s claim, the Court found both kinds of misdescriptions
important.346 Because the product did not contain fig syrup, the mark
could not “properly designate or describe” the plaintiff’s product.347 That
misdescription notwithstanding, the Court held another form of deception
material: the mark “Syrup of Figs” misled consumers into thinking the
main active ingredient of the product was fig syrup, when in fact it was
senna.348 The mark itself, in other words, deceived the public into
338. In one case, a New York ice-cream maker sued for trademark infringement of its
“marketing theme.” Häagen-Dazs, Inc. v. Frusen Glädjé Ltd., 493 F. Supp. 73, 74, 76 (S.D.N.Y.
1980) (“On the contrary, since plaintiff itself has attempted to package its product in such a way
as to give the impression that it is of Scandinavian origin, although it too is, in fact, of domestic
origin, it is guilty of the same deceptive trade practices of which it accuses defendants. In short,
since plaintiff’s hands are similarly unclean, they may not secure equitable relief simply because
defendants’ hands may be a shade or two less clean.”). Despite its claim being an abject failure,
the court added insult to injury by finding the plaintiff’s claim barred by dirty hands. Id. at 76.
The reason? The plaintiff packaged its product in a way to suggest “it [was] of Scandinavian
origin[] although it . . . [was] of domestic origin.” Id.
339. See supra note 337 and accompanying text.
340. Worden, 187 U.S. at 517.
341. Id. at 523–24.
342. Id. at 518.
343. Id. at 527.
344. Id. at 527–28, 533.
345. Id. at 537, 540.
346. Id. at 539–40.
347. Id. at 539. Technically, the plaintiff used fig syrup when it first began manufacturing
but subsequently discontinued its use of fig syrup. Id. at 536–37 (“Even if it were true that, at the
time the medicine in question was first made and put upon the market, the juice of figs was so
largely used as one of the ingredients, as to have warranted the adoption of the name ‘Syrup of
Figs’ as descriptive of the nature of the medicine, that would be no justification for continuing the
use of the term after the manufacturers and vendors of the medicine ceased to use fig juice as a
material ingredient.”).
348. See id. at 537. Senna is an herb known to be a laxative. See Senna (Oral Route), MAYO
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thinking the plaintiff’s product was made of, and derived its medicinal
benefits from, figs. If the plaintiff’s success depended upon deception, it
could hardly complain to be the victim of deceit.
When the U.S. Supreme Court decided Worden in 1903, Congress had
not yet fully enacted a comprehensive federal trademark law.349 Even
after Congress passed federal trademark legislation,350 courts continued
to rely on Worden when invoking the doctrine of unclean hands.351 One
relatively recent source, the Restatement (Third) of Unfair Competition,
categorizes the doctrine of unclean hands as a defense when the plaintiff
uses a “deceptive designation.”352 In support of this proposition it cites,
among other cases, Worden.353 The most recent case cited in the
Restatement (within Reporters’ Note, Comment b) is one from 1985.354
The majority of cases, however, predate the Lanham Act. 355 And none
conclusively hold that a finding of deceptiveness under Section 2(a) of
the Lanham Act effectively dirties the registrant’s hands at common law.
Section 2(a), it may seem, remains simply a bar to registration and not to
protection.
That is not to say modern courts have ignored the doctrine. In 2009,
the U.S. Court of Appeals for the Federal Circuit opined that “[b]efore
the Lanham Act, deceptive common law trademarks were unenforceable”
on the theory of unclean hands articulated in Worden.356 “The same
common law requirement,” the court held, “continues to this day.”357
Because the Lanham Act “codif[ied] . . . the common law . . . by
CLINIC, https://www.mayoclinic.org/drugs-supplements/senna-oral-route/side-effects/drg-20406
012?p=1 [https://perma.cc/X6PM-CYUP].
349. Congress made a second attempt at federal registration after its first was thwarted. But
its second attempt limited the scope of the federal law. See supra notes 327–28 and accompanying
text.
350. See supra note 328and accompanying text.
351. See infra note 367 and accompanying text.
352. RESTATEMENT (THIRD) OF UNFAIR COMPETITION § 32 cmt. b (AM. LAW INST. 1995) (“If
a designation used as a trademark, trade name, collective mark, or certification mark misdescribes
the goods, services, or business with which it is used in a manner likely to influence the purchasing
decisions of a significant number of prospective purchasers, the designation is deceptive. Thus,
the doctrine of unclean hands is applicable against a plaintiff’s assertion of rights in designations
that materially misrepresent the ingredients or other characteristics of the plaintiff’s goods or
services, the nature of the plaintiff’s business, or the geographic origin of its products.” (citation
omitted)).
353. Id. reporters’ note, cmt. b. It also adapts Worden and uses it as an “Illustration” of what
counts as unclean hands. See id. cmt. d, illus. 1 (Other Related Misconduct).
354. See id. reporters’ note, cmt. b. (citing Rick v. Buchansky, 609 F. Supp. 1522 (S.D.N.Y.
1985), appeal dismissed, 770 F.2d 157 (2d Cir. 1985) (mem.)).
355. See id. (citing several cases decided before 1946).
356. In re Spirits Int’l, NV, 563 F.3d 1347, 1354 (Fed. Cir. 2009) (citing Clinton E. Worden
& Co. v. Cal. Fig Syrup Co., 187 U.S. 516, 528 (1903)).
357. Id. at 1355.
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prohibiting the registration of deceptive marks,”358 it seems to follow that
deceptive marks refused registration should also be barred from
enforcement.
As recently as 2015, the Federal Circuit seemed to suggest that all
Section 2(a) bars to registration may also be bars to protection.359 But its
reason for doing so had nothing to do with unclean hands. Reading the
1964 Model State Trademark Act, the court noted that “mark” at common
law may mean only those marks “entitled to registration.”360 One could,
by this logic, read Section 2(a) of the Lanham Act as not only barring a
federal registration but also barring state common law rights in the mark.
This meant that “[w]hether a user of an unregistrable, disparaging mark
has any enforceable common law rights is at best unclear.”361
Outside the Federal Circuit, courts have not, generally speaking,
suggested such broad interpretations.362 But on the point of unclean
hands, courts seem perfectly willing to consider the defense applicable to
actions brought under the Lanham Act.363 So stated a district court as
recently as 2001 in Healthpoint, Ltd. v. Ethex Corp.364 And it provided
plenty of authority for its pronouncement.365 Without leaving doubt about
358. Id. at 1354.
359. See In re Tam, 808 F.3d 1321, 1340–41 (Fed. Cir. 2015) (noting that “it has been widely
recognized that federal trademark registration bestows truly significant and financially valuable
benefits upon markholders” and that “[d]enial of these benefits creates a serious disincentive to
adopt a mark” (emphasis omitted)), as corrected (Feb. 11, 2016), aff’d sub nom. Matal v. Tam,
137 S. Ct. 1744 (2017).
360. Id. at 1344.
361. Id.
362. One court, following Shapely, found a trademark geographically deceptively
misdescriptive under Section 2(a) and, on that basis, concluded it was barred from protection.
Daesang Corp. v. Rhee Bros., No. Civ. AMD 03-551, 2005 WL 1163142, at *12 (D. Md. May
13, 2005) (citing Clinton E. Worden & Co. v. Cal. Fig Syrup Co., 187 U.S. 516, 528 (1903))
(stating that, because the mark was barred from registration under Section 2(a), the plaintiff “is
not entitled to trademark protection for the term ‘Soon Change’”).
363. This includes both trademark infringement and false advertising claims.
364. 273 F. Supp. 2d 817 (W.D. Tex. 2001).
365. Id. at 848 (“Unclean hands is a defense to a Lanham Act claims [sic] such as trademark
infringement and unfair competition.”). The court noted that “[o]ther courts have rejected the
unclean hands defense as applied to Lanham Act cases.” Id. at 849. This quote is ambiguous. If
the court meant that other courts rejected unclean hands as a defense to the Lanham Act, then the
quote is erroneous. The quote is correct if, instead, the court meant that other judges found the
defenses not applicable because the defendant could not make out the elements of the defense.
Each court cited found that the defendant failed to prove the elements of the unclean hands
defense, not that the defense did not apply in Lanham Act cases. See Levi Strauss & Co. v. Shilon,
121 F.3d 1309, 1313 (9th Cir. 1997) (finding that the defendant failed to show it was “entrapped”
by the plaintiff); Fuddruckers, Inc. v. Doc’s B.R. Others, Inc., 826 F.2d 837, 847 (9th Cir. 1987)
(“Unclean hands is a defense to a Lanham Act infringement suit.”); Healthpoint, 273 F. Supp. 2d
at 849–50; Inmuno Vital, Inc. v. Golden Sun, Inc., 49 F. Supp. 2d 1344, 1359 (S.D. Fla. 1997)
(rejecting the unclean hands defense because the alleged misconduct related to violations
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whether this defense could apply to the trademark itself, the judge in
Healthpoint quoted the U.S. Supreme Court: “Equity denies relief ‘where
the plaintiff is misrepresenting to the public the nature of his product
either by the trademark itself or by his label.’”366
Earlier cases, usually citing Worden, openly endorse the defense of
unclean hands in actions brought under the Lanham Act.367 Some
specifically note the doctrine applies in trademark cases.368 Not all cases,
however, require the defendant to prove exactly the same elements—and
there are circumstances where the defense will not apply.369 Nevertheless,
some common features emerge: a misrepresentation by the plaintiff,
materiality, and a causal nexus between the misrepresentation and the
plaintiff’s current claim.
In general terms, then, the elements for the defense of unclean hands
as to a trademark infringement action are similar, but not identical, to the
elements of a deceptiveness claim under Section 2(a) of the Lanham
Act.370 Both require that the mark itself deceives the public as to the
nature of the product. Courts discussing misrepresentations and deception
at common law, in fact, call to mind Section 2(a)’s definition of
enforceable only by a federal agency, not by an individual); Alpo Petfoods, Inc. v. Ralston Purina
Co., 720 F. Supp. 194, 214 (D.D.C. 1989) (“The defense of unclean hands is available in an action
brought under the Lanham Act seeking equitable and monetary relief.”), aff’d in part, rev’d in
part, 913 F.2d 958 (D.C. Cir. 1990); see also Innovation Ventures, LLC v. Pittsburg Wholesale
Grocers, Inc., No. C 12–05523 WHA, 2013 WL 4519805, at *1, *3 (N.D. Cal. Aug. 23, 2013)
(finding, in a counterfeiting action, that the unclean hands defense did not apply because the
plaintiff’s mark was neither “deceptive” nor “inherently misleading” and the plaintiff’s trade dress
was not deceptive; holding that Worden required a “distinct assertion which is false” and that an
unclean hands defense based on the plaintiff’s advertising did not have the requisite causal nexus
to the plaintiff’s claims (emphasis added) (quoting Worden, 187 U.S. at 528)).
366. Healthpoint, 273 F. Supp. 2d at 848 (quoting Morton Salt Co. v. G.S. Suppiger Co., 314
U.S. 488, 494 (1942), abrogated by Ill. Tool Works Inc. v. Indep. Ink, Inc., 547 U.S. 28 (2006)).
367. Inmuno Vital, 49 F. Supp. 2d at 1357–58 (mentioning Worden in a favorable light); see
also cases cited supra note 365.
368. See Fuddruckers, 826 F.2d at 847 (“Worden recently has been interpreted to mean that
‘a court should not protect the exclusive right to use a name or mark which is misleading to the
public.’” (quoting Shatel Corp. v. Mao Ta Lumber & Yacht Corp., 697 F.2d 1352, 1355 (11th Cir.
1983)); Shatel, 697 F.2d at 1355 (“The law on ‘unclean hands’ in a trademark case is well stated
in Worden . . . .”); see also Strey v. Devine’s, Inc., 217 F.2d 187, 190 (7th Cir. 1954) (“It is well
established that a court of equity may deny relief for infringement of a trade-mark where plaintiff
misrepresents the nature of his product.”).
369. See cases cited supra note 365.
370. Cf. Immuno Vital, 49 F. Supp. 2d at 1358 (stating that the defendant in the U.S. Court
of Appeals for the Eleventh Circuit must prove a causal nexus and that “it was personally injured
by the plaintiff’s conduct”). Some of the unclean hands cases relate to what are now called
geographical indications, which fall within a separate category of deceptive marks: geographically
deceptive marks. See Daesang Corp. v. Rhee Bros., No. Civ. AMD 03-551, 2005 WL 1163142,
at *12 (D. Md. May 13, 2005).
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“misdescription.”371 They also require the deception to be “material”; the
deception must make a difference to purchasing decisions of a nontrivial
number of consumers.372
Despite these similarities, differences remain. Some courts require the
defendant to show that it suffered harm373—an element not required in a
registration (but required in an opposition or cancellation proceeding).374
Unclean hands, moreover, is a defense to infringement asserted by a
defendant in a lawsuit. Section 2(a) bars are used by the PTO to deny
registration.
Given the similarities between the two, however, courts could use
Section 2(a) refusals as prima facie evidence, perhaps conclusive
evidence, that a mark is unenforceable on a theory of unclean hands. That
is, in fact, exactly what they should do. There is ample case law showing
that courts will apply the doctrine in cases where trademarks are
deceptive. And the grounds for doing so are effectively the same as the
Lanham Act’s bar to registration: to prevent public deception. Since all
trademark infringement actions involving deceptive marks will have the
requisite causal nexus, courts should adopt a general rule that deceptive
trademarks are unenforceable. This rule would merely restate the doctrine
of unclean hands as a rule of federal trademark law. It would also be in
line with the Lanham Act’s desire to “codify” the common law, and it
would fit comfortably within the federal and state trademark regimes that
operate across the United States. Finally, unifying the two standards
would provide a double disincentive to use deceptive marks as
trademarks—not only would the user be deprived of the “truly significant
benefits” of registration, but she would also lose any trademark rights at
all.375 By making these changes, trademark law can do its part to help
371. Since not all of these cases involve trademarks, it is difficult to generalize from them.
Recall that Worden was a case about the trademark FIG SYRUP for a product that was not made
mostly from fig syrup but contained other active ingredients. See Worden, 187 U.S. at 537. Other
cases involve what would now be called geographical indications—and those cases match the
statute fairly well. See, e.g., Strey, 217 F.2d at 190.
372. See, e.g., Shatel, 697 F.2d at 1355 (requiring a “material misrepresentation” for unclean
hands); RESTATEMENT (THIRD) OF UNFAIR COMPETITION § 32 cmt. b (AM. LAW INST. 1995).
373. See Immuno Vital, 49 F. Supp. 2d at 1358 (requiring the defendant to “show that it was
personally injured by the plaintiff’s conduct”).
374. The Lanham Act provides that “[a]ny person who believes that he would be damaged”
may file an opposition and cancellation. 15 U.S.C. § 1063 (2018) (providing for the opposition to
registration); id. § 1064 (providing for the cancellation of registration).
375. Compare In re Tam, 808 F.3d 1321, 1340–41 (Fed. Cir. 2015) (noting that “federal
trademark registration bestows truly significant and financially valuable benefits upon
markholders” and that “[d]enial of these benefits creates a serious disincentive to adopt a mark
which” is barred by Section 2(a) of the Lanham Act; the marks in this case were offensive or
disparaging marks (emphasis omitted)), as corrected (Feb. 11, 2016), aff’d sub nom. Matal v.
Tam, 137 S. Ct. 1744 (2017), with Matal, 137 S. Ct. at 1753 (noting important benefits of federal
registration).
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reduce the risk of physical harm posed to consumers by deceptive
trademarks.
CONCLUSION
This Article argued trademark law should care more explicitly about
protecting consumers from physical harm. It showed that, historically,
there is some precedent for courts doing exactly that. Concern for
physical safety, however, extended only as far as confusion would allow.
Courts, in other words, did not pay much attention to how trademarks
might pose a risk of physical harm when the trademark at issue was not
confusing but deceptive. This Article argued that courts should take a
closer look at trademarks whose suggestions or implications present a risk
of physical harm to the consumer. Where the risk of physical harm is
higher, courts should relax their standards for evaluating whether a mark
is deceptive, just as they have in the confusion context. This means
expanding the kinds of marks that can be deceptive when they appear on
products with higher risk profiles. Misleadingly suggestive, as well as
descriptive, marks should be fair game for the deceptiveness inquiry in
these cases. To supplement this approach, this Article advocated lowering
the threshold for materiality. Doing so, it argued, would allow the PTO
and courts to recognize that what is material should depend, in part, on
the risk presented by the product or service to which the trademark is
affixed. Finally, to ensure there is a strong disincentive to use deceptive
marks that present a risk of physical harm, this Article argued that
trademark law should bar deceptive marks from protection. These
suggestions, if implemented, will not completely resolve the problem of
deceptive advertising, but they will ensure that trademark law, where it
can, discourages it.
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